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ABSTRACT 
 Arborviruses such as western equine encephalitis virus (WEEV) are capable of 
causing a wide range of diseases in humans.  The CDC and NIAID consider WEEV as a 
potential bioterrorism weapon due to several factors:  potential for aerosol transmission, 
lack of effective countermeasures, and ease of genetic manipulation to increase virulence 
and high levels of death.  A series of thieno[3,2-b]pyrrole-based inhibitors were 
discovered to be active against WEEV following a high-throughput screen (HTS).  This 
dissertation discusses the development of novel indole-2-carboxamide RNA replication 
inhibitors with improved in vitro and in vivo activity and the development of tag-free 
photoaffinity probes for target identification.  A first-generation indole, CCG 203926 
(12), with modestly improved potency and metabolic stability over the original screening 
lead CCG 32091, achieved efficacy in a preliminary in vivo study against neuroadapted 
Sindbis virus.  Second-generation inhibitor, CCG 205432 (50), was the first inhibitor 
with submicromolar activity and further improved half-life compared to CCG-203926.  In 
a WEEV-infected mouse model, in which CCG 203926 was inactive, it increased 
survival and decreased disease severity.  Even though a related third generation inhibitor, 
CCG 209023 (110), was less potent than 50, it had a significantly improved half-life, 
lower recognition by Pgp and equal efficacy to CCG-205432 at improving survival.  It 
was determined that 50 and related indole-2-carboxamide inhibitors have a wide range of 
activity against other RNA viruses and elicit their antiviral activity by targeting host 
factors instead of viral enzymatic proteins.  One of the two photoaffinity probes, 126, is 
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equipotent to lead indole 50 and is currently being used for preliminary target 
identification studies.  Compound 110 is also being studied as a combination therapy with 
neuroprotective agents.  The lack of clinical therapeutics against alphaviruses emphasizes 
the significance of this work, as there is a critical need to develop potent antivirals against 
these pathogens.  
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CHAPTER I.   INTRODUCTION 
Alphavirus transmission and infection 
 Arboviruses (arthropod-borne virus) are viruses that are transmitted through 
arthropod vectors such as mosquitoes, mites, and ticks.
1
   The viral family Togarividae is 
an example of such viruses.  Togarividae contains four genera:  Alphavirus, Rubuvirus, 
Pestivirus, and Arterivirus.
2
  Alphaviruses include Venezuelan, eastern, and western 
equine encephalitis viruses (VEEV, EEEV, and WEEV, respectively).  WEEV is 
considered as a recombinant virus where its structural glycoproteins are from the Sindbis 
virus (SV) and the rest of its genome is derived from EEEV.
3
  Virus propagation relies 
heavily on the continuous transmission cycle between host and vector.  Viruses with birds 
as their primary hosts, such as WEE, have wider distributions.
4
  However, once 
introduced, it becomes a localized strain and distinguishable from a virus at a different 
geographical area.
4, 5
  WEEV is enzootic to the western United States, Canada, and South 
America.
6
 WEEV utilizes rodents and passerine birds as hosts and Culex tarsalis as its 
vector mosquito.
7
 Epizootic events are due to the infection of a bridging mosquito and 
transmission of the disease to non-traditional hosts such as equines and humans.  Humans 
are considered “dead-end” hosts because the viremia is not prolonged or high-titered 
enough for efficient transmission to the mosquito vector.
8, 9
   
Encephalitic alphaviruses infect the central nervous system (CNS) and induce 
neuronal cell death via two pathways: direct viral infection or indirect excitotoxicity due 
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to an overactive glutamate pathway. 
10-12
  Glutamate stimulates AMPA (α-amino-3-
hydroxy-5-methyl-4-isoxazole propionic acid), NMDA (N-methyl-D-aspartate), and 
kainite receptors.
10
   Glutamate activation of these receptors results in the influx of Ca
+2
, 
Na
+
 and Zn
+2
 ions into the cell resulting in cell depolarization.  NMDA receptors are 
highly permeable to Ca
+2
 ions while AMPA is more resistant to Ca
+2
 influx.  However, 
during infection, AMPA receptors may have an increased permeability to Ca
+2
.
13, 14
  This 
excess Ca
+2
 ion due to glutamate receptor activation results in neuronal excitotoxicity.
10
   
Studies have shown that administration of NMDA or AMPA receptor antagonists during 
viral infection decreased neuronal death without affecting virus titers and levels of 
apoptosis.
10, 15
  However, in Sindbis virus models, only AMPA antagonists protected 
mice from severe paralysis.
10, 16
  In addition, glial cells participate in removal of excess 
glutamate in the synapse.  Insufficient maintenance of glutamate levels results in 
excitotoxicity and triggers cell lysis of both infected and normal cells.
16
  Factors that 
determine the cells’ susceptibility include:  cellular maturity, levels of cellular regulatory 
systems, level of viral infection and neurovirulence.
16-18
  The dual pathway in which 
these viruses attack the CNS emphasizes the need for antivirals to prevent viral 
replication and neuroprotective agents to maintain neuronal homeostasis.
10, 19, 20
   
Pathology 
Because WEEV is transmitted through a mosquito bite, initial infection occurs 
outside of the CNS.  Pathogen release begins in the bloodstream and enters the CNS.
21-23
  
WEEV causes a wide range of ailments from minor rashes to encephalitis.  It has a short 
incubation period of 2-7 days, which may be asymptomatic.
8
  Between 1964 and 2005, 
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there have only been 639 confirmed human cases with a fatality rate of 3-7%.
8
  During 
epidemics, the case fatality rate may reach 15%.
2
  Death is higher among children and the 
elderly.
24-26
 Survivors may experience severe neurological sequelae that may last weeks 
or a lifetime.
27
   
Neuroadaptive Sindbis virus (NSV), a representative alphavirus, showed that 
neuronal injury was prominent in the hippocampus, brainstem, cortex, and spinal cord.
10, 
28, 29
  After NSV infection, mice were shown to suffer from encephalomyelitis and 
hindlimb paralysis.
20, 30-32
  WEEV infections manifest themselves in the CNS as vasculitis 
and focal hemorrhages in the basal ganglia and thalamus.
33
  
Bioterrorism 
 Some arboviruses have been recognized by the National Institute for Allergy and 
Infectious Diseases (NIAID) and the Center for Disease Control (CDC) as potential 
biological weapons.
34, 35
  In the 1960s, the US military weaponized and stored VEEV.  
The viruses were later destroyed.
36, 37
  Even though alphaviruses are naturally transmitted 
through mosquitioes, the equine encephalitis viruses remain highly infectious in an 
aerosol form.
37, 38
  Several factors contribute to their consideration as a biological threat:  
stability in aerosol form, ease of large-scale production, lack of effective 
countermeasures, and possible genetic manipulation to increase virulence that may lead 
to high mortality rates.
37, 39, 40
         
Therapeutics 
A host’s immune response plays a critical role in minimizing and recovering from 
an alphavirus infection.  Early in the infection, the host’s innate immune response 
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triggers the production of interferon (IFN).
41, 42
  IFN may limit virus replication until the 
host’s adaptive immune system develops where antibody response aids in viral clearance 
and recovery.
43
  In addition, antibodies have been shown to confer protection against 
glycoproteins E1 and E2, both of which are necessary for virus infection.
42, 44
  When used 
therapeutically, synthetic IFN, such as interferon alfacon-1, showed protective qualities 
when administered before WEEV infection.
45
  However, interferon alfacon-1 has a short 
lifetime and requires multiple doses.
42
  Vaccines against the equine encephalitic viruses 
have been developed and approved for veterinary use.  Live, attenuated virus (TC-83) 
vaccine against VEEV has high reactogenicity, requires frequent booster shots, has low 
efficacy and is restricted to researchers.
37, 46-48
  Formalin-inactivated vaccines for EEEV 
and WEEV(PE-6 and CM-4884, respectively) are available to laboratory researchers; 
however, they have low efficacy.
42, 47, 49
  Currently, there are no effective clinical 
treatments available for alphavirus infections. 
Genomic Structure  
 
 
Figure 1:  Alphavirus genome 
SGp
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WEEV is an enveloped virus and its genome is expressed by a single strand, 
positive polarity RNA sequence that serves as a direct template for replication.  It 
contains a 5’-cap and a 3’-polyadenylated tail.  In addition, it has a subgenomic RNA 
sequence that encodes for structural proteins produced during viral RNA replication.  The 
genome also encodes non-structural proteins (nsP) with various enzymatic activities. 
Nonstructural protein 1 (nsP1) is required for initiating the synthesis of a negative 
strand RNA.  It caps both genomic and subgenomic RNA.
50
  It functions as a 
methyltransferase and a guanylyltransferase.
51, 52
  The second non-structural protein 
(nsP2) serves as both helicase and protease.  The C-terminal of nsP2 is a cysteine 
protease responsible for the processing of nonstructural polyprotein.
51, 53
  Elimination of 
the C-terminal domain resulted in a loss of enzymatic activity.
51
  The function of the nsP3 
is not well understood.  Nonstructural protein (nsP4) expresses the RNA dependent-RNA 
polymerase (RdRp).  This protein synthesizes both negative- and positive-strand RNAs.
7
      
Viral Replication 
Alphavirus infection begins with the attachment of the virus to the cell followed 
by internalization.  Membrane fusion between host and virus  is facilitated by the E1-E2 
heterodimer.
54
  The acidic environment in the endosomes initiates the exposure of E1 
fusion domain and the virus and endosomal membrane fuses.
55, 56
  During early infection, 
the association of the nucleocapsid with ribosomes triggers the disassembly of the viral 
core.
57
  However, newly generated nucleocapsids become stable during late stages of 
infection.  These differences in stability may be due to the different sizes between mature 
and new nucleocapsids.  Also, changes in the sodium and potassium ion concentrations 
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allow increased nucelocapsid stability and the low pH in the endosomes initiates capsid 
degradation.
51
  During infection, host protein synthesis stops shortly after infection.  It 
was previously shown that a decrease in potassium cations resulted in the decrease in 
translation of host mRNA; however, viral mRNA was insensitive to the change.
58, 59
   In 
addition, it may also be attributed to the viral mRNA having a higher affinity for 
initiation factors such as eIF-4B compared to host mRNA.
51
   Early in the infection, both 
plus-strand and minus-strand RNA are rapidly synthesized.  However, the synthesis of 
minus-strand RNA stops while plus-strand RNA synthesis continues throughout the 
infection.
51
   The minus-strand RNA serves as a template for both the synthesis of 
genomic RNA and a capped, polyadenylated subgenomic mRNA.  Translation of the 
subgenomic RNA results in the formation of a structural protein polypeptide (Figure 1).
49, 
60
  The nucleocapsid autocleaves itself from the nascent structural polypeptide.  Once the 
capsid is released, glycoprotein E3 binds to the membrane of the rough endoplasmic 
reticulum.  During the synthesis of E3 and E2 various oligosaccharides and fatty acids are 
added.
60
  Segments of E2 remain exposed to the cytoplasm after hydrophobic domains of 
E2 anchor the polypeptide to the endoplasmic reticulum.  A peptide sequence following 
the anchoring sequence in E2, referred to as 6K, signals the insertion of the glycoprotein 
E1 and is cleaved from E1 and E2.
61
  The polypeptide containing E2 and E3 translocates 
to the Golgi apparatus where it is further cleaved to the mature E2 and E1.  The 
glycoproteins are released from the Golgi apparatus.
62-64
  New virus packaging mainly 
occurs through budding from the host plasma membrane (Figure 2).
65
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High-throughput screen (HTS) 
The laboratory of David Miller and the University of Michigan Center for 
Chemical Genomics (CCG) collaborated to run a high-throughput screen of 55,000 
compounds.  A replicon (pWR-Luc) based primary screen utilized a modified WEEV 
plasmid transfected into BSR-T7/5 cells.  BSR-T7/5 cells are BHK cells that express a T7 
RNA polymerase.
66
  As previously discussed, viral replication may induce the production 
of type I interferons in order to combat infection.  BHK cells are incapable of producing 
IFN; therefore, reduction in replication may be due to the presence of inhibitors.
66-69
As 
seen in studies using SV replicon, translation of the subgenomic RNA is enhanced by the 
presence of a 27 nucleotide sequence preceding a characteristic hairpin structure.  
Alphaviruses do not necessarily have high homology, but they all have a 27-29 
 
 
Figure 2:  WEEV replication.   
(a) binding (b) endocytosis (c) fusion and RNA release (d) genomic RNA translation (e)  transcription 
(f) packaging and budding (g) cell lyse and virus release 
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nucleotide distance between the promoter and the hairpin structure.  Therefore, the first 
27 amino acids of the subgenomic RNA were preserved.
66, 70
  Since the structural genes 
encoded in the subgenomic region are unnecessary for genome replication, they were 
replaced with the firefly luciferase gene (Figure 3).
66, 71
  The hepatitis δ virus ribozyme 
δRz/T7T terminator was placed downstream of the polyadenylation region to ensure the 
proper formation of a 3’ end.66  Furthermore, because of the absence of structural 
nucleocapsids and envelope proteins (discussed in page 5), which are necessary for viral 
entry into host cells, secondary infections do not occur.
72, 73
  Therefore, these replicon 
systems can be handled in a lower safety level than those required by WEEV.  Because of 
the constitutive T7 promoter, the luciferase gene is expressed resulting in a baseline 
luminescent signal.  However, addition of an effective inhibitor decreased luminescence 
indicating that replication was interrupted.   
 
The compound testing funnel consisted of a battery of screens and validations 
(Table 1).  Potential inhibitors were tested at 10 µM and were chosen from the HTS if 
they showed greater than 90% activity compared to the positive control, Ribarivin or if 
they showed greater than two standard deviations compared to the vehicle (DMSO). 
Using the same replicon system, inhibitors were confirmed by dose response testing at 
 
Figure 3:  WEEV replicon plasmid.   
T7p (T7 polymerase promoter),  T7T (hepatitis δ virus ribozyme δRz/T7t terminator), SGP (subgenomic 
promoter), An (polyadenylated tail), U (untranslated region) .   
Image adapted from Ref. 66  
LuciferaseU
nsP1 nsP3nsP2 nsP4
U An δRz
T7P T7TSGP
Non-structural proteins Nucleocapsid proteinsEnvelope glycoproteins
Methyltransferase Helicase Protease RNA polymerase
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concentrations ranging from 100 µmol/L to 10 nmol/L.  In order to eliminate compounds 
that were potential luciferase inhibitors, compounds previously active on luciferase-based 
assays were eliminated.  Seventy seven out of 114 compounds from the previous category 
had an IC50 < 100 µM.  The compounds were taken into another replicon assay utilizing a 
construct that is derived from EEEV and VEEV.  Instead of having a firefly luciferase 
gene as an indicator, it utilizes a secreted alkaline phosphatase (SEAP) reporter gene.  
Similar to the luciferase replicon, the SEAP replicon monitors the level of genome 
replication within the cell.  The SEAP assay further eliminates any compounds that were 
luciferase inhibitors.  In addition, it indicated whether an inhibitor may have activity 
against other alphaviruses.
66
  Finally, active compounds were subjected to another dose-
response assay using the pWR-Luc replicon and an MTT assays to directly compare 
activity and toxicity, respectively.  Compounds with a selectivity index (CC50/IC50) of > 5 
were considered for further development (Table 1).  Four compounds were initially 
identified; however, CCG 32091 (1) exhibited a selectivity index of >20 and an IC50 of 
24 μM, which is comparable to ribavirin in the same assay with selectivity index of 19 
and an IC50 of 16 μM (Figure 4).
66
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Preliminary SAR 
Metabolic stability is an important aspect of drug discovery.  Metabolism occurs 
in two phases.  These two phases generate polar molecules that facilitate clearance of 
endogenous and exogenous compounds.  Molecules do not necessarily need to proceed 
through both phases of metabolism to be cleared from the body.   
Phase I involves oxidations, hydrolyses and dealkylations.  Phase II involves 
conjugations.
74
  Phase I metabolism occurs via oxidative enzymes such as the family of 
cytochrome P450 (CYP450) enzymes and flavin mono-oxygenase (FMO).
75
   CYP450 
enzymes are primarily responsible for the majority of the oxidative hydroxylations of 
compounds. 
74, 76, 77
  The mechanism proceeds through a heme-NAPDH mediated 
Table 1:  Inital HTS hit selection.   
 Experiment Criterion 
Number of 
Compounds 
 CCG chemical libary  51,028 
HTS 
pWR-Luc replicon & 
BSR-T7/5 cells 
(1) fLUC activity > 2 
SD/plate below 
negative control, 
DMSO OR 
(2) > 90% per plate of 
level obtained by 
positive control, 
Ribavirin 
196 
HTS triage 
pWR-Luc replicon & 
BSR-T7/5 cells 
Inactive in previous CCG 
Luciferase based assays 
114 
HTS 
confirmation 
pWR-Luc replicon & 
BSR-T7/5 cells 
IC50
 
<100 µM
 
77 
Secondary 
screen 
EEEV/VEEV-SEAP 
replicon bearing BHK 
cells 
IC50
 
<100 µM 11 
Tertiary 
screen 
pWR-Luc replicon & 
BSR-T7/5 cells 
Selectivity index > 5 4 
Table source: Ref. 66; CCG:  University of Michigan Center for Chemical Genomics, IC50:  inhibitory 
concentration at 50%; CC50:  cytotoxicity  concentration at 50%; flUC:  firefly luciferase; Selectivity 
index:  CC50/IC50   
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oxygenation of molecules using molecular oxygen.
77
  If a molecule is sufficiently polar to 
be excreted, it can bypass Phase II metabolism.  If not, Phase II metabolism involves the 
additon of moeities such as glucuronic acid,sulfate, and glutathione.
74
  Even though the 
main objective of metabolism is to increase clearance rate of compounds from the body, 
this process can generate reactive species that may interact with macromolecules in cells 
(DNA, RNA, etc.).  These intermediates may lead to toxicity and other side effects.  In 
drug development, metabolism affects bioavailability, exposure and clearance.
78
  
Therefore, it is necessary that all active compounds be evaluated for metabolic stability 
before considering compounds for in vivo studies.      
Figure 4 shows key compounds that led to the transformation of the original 
thienopyrrole HTS hit (1) to the indole lead compound CCG 102516 (10).  Anticipating 
possible metabolic liabilities due to the thienopyrrole and the furanyl carboxamide via 
CYP450 oxidation,  the two functionalities were replaced with bioisosteres.  Bioisosteres 
are functional groups that have similar chemical and physical properties, but also elicit 
the same biological activity.
79, 80
  The thienopyrrole and furanyl carboxamide were 
replaced with the indole and the benzyl carboxamide, respectively.  A representative 
synthetic route, developed by Dr. Bryan Yestrepsky, used to generate thienopyrrole 
inhibitors is shown in Scheme 1.  Methyl 4H-thieno[3,2-b]pyrrole-5-carboxylate (150) 
was alkylated with 4-chlorobenzyl chloride in the presence of potassium carbonate.  
Subsequently, the resulting ester was saponified to carboxylic acid 151 using lithium 
hydroxide.  Amide bond formation followed by hydrolysis resulted in acid 152.  Peptide 
coupling with benzylamine resulted in inhibitor 3.     
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Replacement of the furanyl carboxamide in 1 with the benzyl carboxamide (2) 
resulted in equipotent compounds.  Exchanging the fluorine with a chlorine (3) improved 
potency.  Finally, replacing the thienopyrrole with an indole generated the first generation 
indole lead,  CCG 102516 (10).    The similar potencies of 1 and 10 indicated that both 
the benzyl carboxamide and indole were valid bioisosteric replacements for the furanyl 
carboxamide and thienopyrrole, respectively.
81
   
 
Scheme 1:  Representative synthesis for thienopyrrole synthesis 
*synthetic route developed by Dr. Bryan Yestrepsky 
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In order to evaluate the original metabolic liability hypothesis, a microsomal 
stability experiment was performed by Scott J. Barraza.  Inhibitors (1.0 µM in DMSO) 
were incubated in mouse liver microsomes (MLM) for 15 minutes.  The percentage of the 
parent compound was measured over time via LC/MS.
81
  Compounds 3 and 10 had a half 
lives of approximately 1.7 and  7.3 minutes, respectively.   This experiment demonstrated 
an increase in metabolic stability, validating the indole and benzyl carboxamide as 
bioisosteric replacements.    
 
Figure 4:  Key preliminary SAR 
# synthesized by Dr. Bryan Yestrepsky, * synthesized by Dr. Kyle Buldoc 
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CHAPTER II.    FIRST GENERATION INDOLE-2-CARBOXAMIDE 
DERIVATIVES 
Rationale 
SAR development around compound 10 focused on optimizing potency while 
minimizing toxicity in order to achieve in vivo activity.  Figure 5B identifies the three 
points of diversifications that were pursued in the SAR studies.  Concurrently, the general 
characteristics of a successful CNS drug had to be taken into consideration for analog 
design since we were targeting a neurotropic alphavirus.  The calculated physical 
properties exhibited by marketed CNS drugs versus compound 10 are shown in Figure 
5A.
82, 83
  It is apparent from this comparison that during our SAR optimization we would 
need to reduce the molecular weight (MW) and/or topological polar surface area (TPSA) 
in order to maximize potential for CNS penetration.   
Because our lead was identified in a phenotypic replicon screen, we had no 
knowledge of the actual molecular target.  Thus, we also planned to use SAR to provide 
information regarding which areas of the molecule were interacting most strongly with 
the unknown target.  Molecular modifications leading to an increase or decrease in 
potency would suggest an important interaction between the functional groups being 
altered and the protein target.  On the contrary, changes that did not affect potency would 
imply that the functional group was in a position not interacting strongly with the binding 
site, possibly a solvent exposed portion of the molecule.  We considered that this 
15 
 
information would be important in designing effective affinity probes (Chapter VI) by 
identifying areas that could be modified without compromising activity along with areas 
of the molecule that were in close proximity to the binding site.    
 
Synthesis  
 
A Property 
Marketed 
CNS drugs  
Compound 10  B 
 
 MW (g/mol) 319 486  
 HBD & HBA 4.41 5  
 TPSA (Å) 40.5 52.6  
 cLogP 3.43 4.55  
 
Figure 5:  (A) Physical properties of marketed CNS drugs (B) Three points of diversity 
 
 
Scheme 2:  Benzylamide derivative synthesis 
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 Carboxamide derivatives were synthesized according to Scheme 2.  Ethyl 1H-
indole-2-carboxylate was alkylated with 4-chlorobenzyl chloride in the presence of 
potassium carbonate.  The resulting ester was hydrolyzed using lithium hydroxide to 
generate acid 156.  A peptide coupling with ethyl isonipecotate followed by another 
saponification resulted in compound 157.  Amide coupling with various amines generated 
carboxamide inhibitors 10 - 22.     
Carboxamide position and initial SAR 
 All new analogs were tested for activity in the WEEV replicon assay previously 
described in Chapter I.  Table 2 summarizes the WEEV replicon activity of the initial 
indole derivatives.  SAR indicated that replacement of benzyl carboxamide in 10 with a 
phenyl carboxamide 17 is detrimental to the activity.  In contrast, lengthening to a 
phenethyl carboxamide (56, Table 6) produced an inhibitor equipotent to 10.  This 
suggested the possibility of a potential hydrophobic binding pocket that might be 
exploited to increase activity due to a favorable - stacking interaction.  The position of 
the carboxamide in relation to the indole core was also examined.  The analogous 
piperidine-3-carboxamide (24) resulted in a diminishment of activity.  Therefore future 
indole inhibitors were designed to retain the piperidine-4-carboxamide substitution 
pattern.   
Increasing lipophilicity by adding a methyl or halogens to the benzyl aromatic 
ring (13-15) did not improve potency.  Interestingly, small aliphatic analogs (19, 20, 23) 
had similar potencies to 10, suggesting that the benzyl amide is not making optimum 
interactions with the binding site.  Addition of polarity such as a prolinol (18) or 4-
17 
 
methoxybenzyl (16) resulted in a reduction or complete loss of potency.  N-methylation 
of the benzylamide (21) resulted in an equipotent inhibitor. 
Significantly, replacement of the phenyl ring of 10 with pyridine (22) provided an 
improvement in potency (IC50 = 6.8 µM) without increasing cytotoxicity.  This finding 
was our first indication that a distal hydrogen bonding motif might be capable of 
interacting with the binding site.  This hypothesis was further investigated as described in 
Chapters III and IV.   
Chirality  
The thienopyrrole series mentioned in Chapter I demonstrated that chirality has a 
marked effect on activity (Figure 6).  Taking a similar approach, both the (S) and (R)-α-
methylbenzyl carboxamide (11 and 12) derivatives were synthesized for the indole series.  
Of the two enantiomers, only the R-isomer showed activity.  The high level of 
enantioselectivity signifies that the inhibitors are interacting with a chiral macromolecule 
instead of an achiral structure such as a cellular membrane.  We viewed this pair of 
enantiomers as ideal probes with which to establish that replicon activity is correlated 
with antiviral activity, both in vitro and in vivo.  The two analogs have identical physical 
properties except for their chirality, and thus any subsequent differences in their antiviral 
and in vivo activity could be directly correlated with the replicon assay, rather than any 
differences in their physicochemical properties.  
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Table 2:  Initial indole carboxamide analogs   
 
CCG 
Number 
NR1R4 
IC50 
(µM)
a
 
CC50 
(µM)
b
 
  10* 102516 
 
15.5 ± 5.6 >100 
11 203927 
 
>100 >100 
12 203926 
 
6.5 ± 1.5 89.9 
13 204042 
 
75.1 ± 43.8 >100 
14 206399 
 
>50 >50 
15 204043  15.3 ± 9.0 
>100 
16 204025  >50 
ND 
17 206334  >50 
ND
 
18 204021 
 
30.6 ± 4.5 98.9 
19 203928  9.2 ± 2.8 
51.7 
20 204022  10.5 ± 2.1 >100 
21 203930 
 
16.9 ± 4.4 87.0 
22 203929 
 
6.8 ± 1.7 >100 
23 102514 
 
22.2 ± 4.3 65.6 
  24
**
 205483  30.6 ± 7.3 
>100 
 
a
Inhibition of luciferase expression in WEEV replicon assay. Ribavirin as positive control has an IC50 in the 
assay of 16 µM. Values are mean of at least n=3 independent experiments + SE.  
b
Cell viability determined 
by inhibition of mitochondrial reduction of MTT. Values are mean of at least n=3 independent experiments.  
Provided by Dr. David Miller. *synthesized by Dr. Kyle Buldoc; **synthesized using ethyl nipecotate 
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Figure 6:  Chirality effect 
#synthesized by Dr. Bryan Yestrepsky 
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In Vitro antiviral activity 
 In order to determine whether the inhibitor activities in the replicon assay will 
translate to antiviral activity, the cytopathic effect (CPE) and viral titer reduction were 
measured.  CPE plaque assays measures the level of morphological changes caused by a 
virus infection.  These changes include: rounding of infected cells, fusion with adjacent 
cells, and pyknosis.
84
  It was previously shown that WEEV causes the rounding of cells 
and forms pyknotic cells.
85
  Post-infection viability was measured using an MTT assay, 
similar to that used in the HTS.  Human BE(2)-C neuronal cells were infected with either 
NSV or WEEV.  Due to the rapid rate of viral replication and production, both WEEV 
and NSV are highly virulent in cultured cells.  Cells were incubated with 25 µM of 
inhibitor for 24 hours before the viral titer and cellular viability were measured.
81
  The 
negative and positive controls were DMSO and ribavirin (Rib), respectively.  The initial 
experiment compared the thienopyrrole core (3), the achiral indole core (10) and (R) 
versus (S) enantiomers (12 and 11) for their different antiviral effects.    
Figure 7 shows that compounds that were active in the replicon assay (Rib, 3, 10, 
and 12) increased neuronal survival and decreased viral titer, while the inactive 
enantiomer (11) was unchanged from negative control DMSO in both assays.  These 
antiviral effects of the active analogs were observed regardless of the virus.  This 
experiment firmly established a correlation between the replicon assay and antiviral 
activity, suggesting that the observed antiviral effects may due to inhibition of RNA 
replication.   
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Neuroadaptive Sindbis virus (NSV) in vivo study 
Dr. David Irani and Pennelope Blakely conducted an in vivo study comparing 11 
and 12.  The experiment utilized NSV infection because of its lower biosafety level 
containment (BSL2) requirement than WEEV (BSL3).  Direct intracranial infection with 
NSV causes lethal infection in mice within 7-10 days.
31, 32
  It infects the brain and spinal 
cord leading to hind leg paralysis in weanling mice.
31, 32, 86
  The Irani lab utilized inbred 
C57BL/6 mice 5-6 weeks of age.  Mice were inoculated with 10
3
 plaque forming units 
(pfu) of NSV via direct intracranial injection.  Six groups of mice (5 mice/group) were 
treated via intraperitoneal injection with either 11 or 12 at 10 mg/kg or 30 mg/kg, vehicle 
or untreated.  Treatment started 12 hours post-infection until day seven.  Dosing was 
stopped at day 7 because viral titers peak in 7 days in the CNS.  After this point, viral 
 
Figure 7:  WEEV and NSV antiviral studies.       
Human BE(2)-C neuronal cells were infected with WEEV or NSV and incubated with inhibitors at 25 
µM.  Cell viability and viral titiers were measured 24 h post infection via MTT and plaque assays.  
Ribavirin(Rib) as positive control; DMSO negative.  P < 0.05 Graph courtesy of Dr. David Miller 
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titer decreases indicating that a full host immune response has been reached.  Each mouse 
was given a clinical score according to the following categories:  (1) normal (2) partial 
paralysis (some weakness in hind legs) (3) moderate paralysis (weakness in both hind 
legs) (4) severe paralysis (complete paralysis in hind legs) and (5) dead.
81
  Mice were 
observed for another seven days, at which point they were euthanized.  
 
 Figure 8 shows that the more active enantiomer (12) offered protection against the 
disease and increased survival compared to vehicle while the inactive enantiomer (11) 
was indistinguishable from vehicle.  The observed protection was also dose-dependent, 
with the higher dose achieving greater statistical significance.  It is worth noting that 
despite the increased survival, the mice were impacted severely by the infection.  This is 
also reflected in the pathology results described below.  
81
   
As previously described in Chapter I, alphavirus infection may also cause 
neuronal cell death through excitotixicty and microglial system.  This pathway affects 
both infected and normal cells.
10, 16
  Therefore, it is important for developed inhibitors to 
offer some neuroprotection.  In addition to the survival experiment, the Irani lab 
determined the extent to which neuronal cells were degenerating.  Degenerating cells can 
 
Figure 8:  NSV infection studies  CCG 203927 (11) and CCG 203926 (12).   
Six groups of C57BL/6 mice (n=5/group) infected with 10
3
 pfu/mL of NSV were treated with 11 or 12 
using 10 mg/kg or 30 mg/kg/dose, vehicle or left untreated.  Animals were treated via intraperitoneal 
injection every 12 hours beginning 12 hours after virus challenge until day 7.  (A) Disease severity (B) 
Survival Graph courtesy of Dr. David Irani and Pennelope Blakely 
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be identified with fluorojade staining.
87
  After the mice were sacrificed, tissue sections 
were harvested and labeled.  Figure 9, a representative staining slide identifies neuronal 
cells from the hippocampus, a prominent location in the CNS infected by NSV.
10
  The 
Nissl Red stain (red) labeled all neurons while fluorojade staining labeled only 
degenerating neurons (green with arrows).  The graph shows the percentage of neurons 
degenerated.  Once again, the active (R)-enantiomer conferred protection while its 
counterpart and the vehicle were ineffective. 
 
     Both the in vitro and in vivo experiments described above demonstrated that 
compound 12 was able to modulate both antiviral and neuroprotective activities,  
indicating the feasibility of eliciting a pharmacological response that increases survival 
and decreases disease severity.  However, it was imperative to explore other regions of 
the indole core in order to further improve potency, maintain minimal toxicity, and 
modify physicochemical properties to optimize potential for CNS activity (Figure 5).     
 
Figure 9:  Fluorojade staining of hippocampus neuronal cells post NSV infection 
Neuronal cells from the hippocampus, a site of heavy NSV infection, were chosen for further study.  
(A) Fluorojade staining of damaged hippocampal neurons in the brains of NSV-infected mice.  
NisslRed was first used to label neurons in sections through the hippocampus, while fluorojade staining 
(arrows) was then performed to identify those cells undergoing active degeneration.  (B) The proportion 
of fluorojade-positive hippocampal neurons was determined in quadruplicate slides prepared from 3 
mice in each group.  *p<0.05.  Figure provided by Dr. David Irani and Pennelope Blakely 
 
12 11Vehicle
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Physicochemical properties 
It has been estimated that more than 98% of drug candidates targeting the CNS do 
not make it into the market.
88, 89
  Neurotherapeutic candidates face both a structural and 
biochemical barrier.  The blood brain barrier (BBB) isolates the CNS from the circulatory 
system and maintains a microenvironment.
90
  Structurally, the BBB is composed of tight 
junctions (TJs) that limit the permeability of therapeutics and polar solutes into the 
brain.
91-93
  In addition, BBB has few pinocytotic vesicles and lacks fenestrations.
82
  This 
barrier limits the rate of diffusion from the periphery into the CNS.  In general small 
molecules enter the CNS through diffusion and it is inversely proportional to molecular 
weight, and directly proportional to lipophilicity.
92
  However, many molecules do not 
abide by these rules because there is another obstacle therapeutics encounter.  
Biochemically, macromolecules encounter the P-glycoprotein (Pgp) efflux transporter.  It 
is a transmembrane protein that has a broad range of substrates and is expressed in high 
population in the CNS.
94
  Even though CNS entry is aided with higher lipophilicity, it 
may be counter-productive.
95
  Pgp recognition generally increases with lipophilicity 
facilitating the efflux of lipophilic xenobiotics from the CNS.
91, 96
   
In order for our inhibitors to elicit the greatest efficacy, it is necessary for them to 
have high passive permeability, low Pgp recognition, and high metabolic stability.  The 
level to which Pgp interacts with these inhibitors was determined by measuring 
Rhodamine 123 (Rho 123) uptake into MDCK cells transfected with human Pgp (MDR1-
MDCKII).
97
 Rho 123 is a known Pgp substrate and is readily effluxed.
95
  In this assay, 
tariquidar, a known Pgp inhibitor, is included as a control.  This takes into account the 
natural variation of Pgp expression in the cells.  In the presence of a Pgp inhibitor or a 
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competitive substrate for Pgp, there will be an increase in intracellular concentration of 
Rho 123.
98
  The results for a test compound are expressed as a percent of the effect that 
tariquidar has on Rho123 uptake in the same assay.  A higher number indicates higher 
recognition by Pgp.  Results for selected compounds are presented in Figure 10. 
Another factor that determines CNS penetration is the passive permeability of 
these compounds through the BBB.  An in vitro experiment that estimates passive 
permeability across the BBB is parallel artificial membrane permeability assay 
(PAMPA).  Select inhibitors were tested using the PAMPA Explorer program from pION 
using a PAMPA-BBB lipid mixture.
99, 100
  PAMPA involves a “sandwich” of two 96-well 
plates.  This is formed by a donor plate and an acceptor plate separated by an artificial 
lipid membrane.  The donor plates contain a DMSO stock solution of inhibitors diluted 
with a proprietary pION, Inc. system solution.  Inhibitors passively diffuse through the 
artificial membrane into the acceptor plate.  The difference in UV absorbance after a 4 
hour incubation between the donor and acceptor plate determines the extent to which a 
molecule is permeable.
99-101
  Due to the low solubility of these compounds, a 20% 
acetonitrile co-solvent was used in the donor wells.
102
  In PAMPA-BBB experiments, a 
log Peff  > -4 are considered highly permeable while those that have a log Peff of ≤ -6.0 are 
considered to have low permeability.
99
     
  As shown by Figure 10, select compounds from the initial indole derivatives have 
medium to low passive permeability.  The active (R)-isomer (12) was recognized less by 
Pgp than the indole lead (10).  However, decreasing molecular weight and lipophilicity 
with the dimethyl carboxamide (20) and 4-pyridylmethyl carboxamide (22) did not aid in 
decreasing Pgp interaction compared to 12.   
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Even though it would be expected that an overall increase in lipophilicity in 
compound 12 (cLogP 5.07) compared to 10 (cLogP 4.75), which is known to increase 
metabolic susceptibility to CYP450 oxidation, would lead to reduced metabolic stability, 
the presence of an α-methylbenzyl carboxamide (MLM T½ = 31 min, 12) actually 
increased metabolic stability.
103
  This suggested that the addition of a methyl group 
blocks a major site of metabolism in 10 (MLM T½ = 7.3 min).          
27 
 
  
 
 
Figure 10:  MDR recognition and PAMPA-BBB measurements 
Rhodamine 123 (Rho 123) uptake was measured in MDR1-MDCKII cells utilizing Glomax Multi 
Detection System (Promega). ‘MDR1 recognition’ was assessed by measuring uptake in the presence of 
MDR inhibitor, tariquidar (5 µM), and either 30 µM of anti-viral or vehicle, and calculating: % Rho 
123eff = (Cav – Cveh)*100/(Ctar-Cveh), where Cav = concentration of Rho 123 in the presence of anti-viral, 
Cveh = concentration in the presence of vehicle, Ctar = concentration of Rho 123in the presence of 
tariquidar. In the presence of tariquidar, Rho 123uptake was 1123 ± 54% of vehicle controls (n=44) .   
MDR recognition provided by Dr. Richard Keep and Jianming Xiang 
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N1-indole derivatives synthesis and SAR development 
 
 Another region explored was the N1-indole position (R
2
, Figure 5).  The N1 
indole analogs were originally designed to contain the benzyl carboxamide seen in 
compound 10.   The synthetic route used to generate N1-indole inhibitors is shown in 
Scheme 3.  Ethyl-2-indole carboxylate was hydrolyzed in the presence of lithium 
hydroxide.  Subsequent EDCI coupling with ethyl isonipecotate provided ester 160.  
Compound 160 was saponified and coupled with either benzylamide or N-methylbenzyl 
amide resulting in advanced intermediates 161 or 90, respectively.   
The original synthetic route using intermediate 161 posed several synthetic 
difficulties due to the similar acidities of the N1-indole proton and the carboxamide 
 
Scheme 3:  N1 indole analog synthesis 
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proton (pKa = 12.3 and 15.5, respectively) present on 161.
104
  The use of strong bases 
such as potassium tert-butoxide and sodium hydride resulted in a mixture of N-alkylation 
products being obtained.  These included the desired N1-analogs, along with 
bisalkylation at the N-1 and carboxamide NH, and mono-alkylation at the carboxamide 
position N-H.  However, bases such as cesium carbonate resulted in decomposition 
possibly due to the required prolonged reaction times in the presence of heat.  
According to Table 2, the presence of an N-methylbenzyl carboxamide (21) did not 
compromise activity compared to 10; therefore, indicating that N-methyl benzylamine 
could serve as a valid substitute for benzylamine during our initial survey of N1-indole 
SAR.  Preparation of N1-indole inhibitors thus proceeded through advanced intermediate 
90.  Alkylation resulted in inhibitors 80-89 and 91 (Table 3).   
Table 3 shows that modifications on the N1-indole position resulted in minimal 
change or decreased activity.  Due to the lack of improvement in potency, both the first 
and second generation carboxamide analogs contained the original 4-chlorobenzyl motif 
at the N1-indole position.  Furthermore, this lack of SAR suggested that the indole 
substituent is not likely to be making strong interactions with the molecular target.  
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Table 3:  N1-indole derivatives 
 
 
CCG 
Number 
R2 
IC50 
(µM)
a
 
CC50 
(µM)
b
 
21 203930 
 
16.9 ± 4.4 87.0 
80 206332 
 
27.9 ± 3.6 58.2 
81 205477 
 
16.5 ± 0.8 99.2 
82 208789 
 
24.2 ± 3.6 80.3 
83 205404 
 
17.0 ± 1.1 64.8 
84 205484 
 
61.3 ± 35.5 >100 
85 208917 
 
35.1 ± 43.5 90.3 
86 206330 
 
95.9 ± 7.0 >100 
87 206333 
 
35.1 ± 43.5 90.3 
88 206331  >50 >50 
89 206401 
 
>50 >50 
90 205400 H 27.7 ± 3.9 >100 
91 205428 Me >50 >50 
a
Inhibition of luciferase expression in WEEV replicon assay. Ribavirin as positive control has an IC50 in the 
assay of 16 µM. Values are mean of at least n=3 independent experiments + SE.  
b
Cell viability determined 
by inhibition of mitochondrial reduction of MTT. Values are mean of at least n=3 independent experiments.  
Provided by Dr. David Miller and Craig Dobry.   
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5-hydroxy indole synthesis 
Another area we elected to explore was the 5-position of the indole ring, using an 
ether linker to facilitate diversity introduction (Figure 5B).  Scheme 4 shows the initial 
synthesis of the 5-hydroxy indole analogs.  The synthesis began with the peptide coupling 
between 5-methoxy-1H-indole-2-carboxylic acid and ethyl isonipecotate.  The N1-indole 
alkylation occurred in a two-step process.  It began with a Finkelstein reaction with 4-
chlorobenzyl chloride and sodium iodide.  The resulting iodide was used to alkylate the 
N1-indole position to generate intermediate 166.  Saponification using lithium hydroxide 
followed by another amide bond coupling using dimethyl amine resulted in 100.  
However, attempted O-demethylation using boron tribromide resulted in both 
demethylation and debenzylation of intermediate 100, giving low yield of inhibitor 105.  
 To avoid the lack of chemoselective demethylation, a second synthetic route 
towards the 5-hydroxy indole analogs was undertaken beginning with the Boc protection 
of ethyl isonipecotate followed by basic saponification to generate 170.  Peptide coupling 
with dimethyl amine and subsequent deprotection using hydrochloric acid resulted in 
synthon 171 (Scheme 5).  
In parallel, 5-methoxy-1H-indole-2-carboxylic acid was esterified in the presence 
of hydrochloric acid and ethanol.  Demethylation using boron tribromide resulted in 
172.
105
  The resulting phenol was protected with tert-butyldimethylsilyl chloride.
106
   
However, subsequent alkylation using 4-chlorobenzyl chloride provided the desired 
intermediate 173 along with bisalkylated product 174, indicating that premature 
desilylation of the 5-OH was occurring.  Compounds 173 and 174 were isolated in a 3:1 
ratio, respectively.  Bisalkylation may be due to the susceptibility of the TBS group to 
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cleavage by the newly generated chloride anion during the alkylation.  The inseperable 
mixture was taken directly to the next step.  Silyl deprotection using tetrabutylammonium 
fluoride allowed isolation of intermediate 175.  Alkylation with various alkyl bromide 
followed by hydrolysis resulted in intermediates176-178.  Subsequent amide coupling 
with synthon 171 resulted in analogs 102-104 (Scheme 6).   
 
 
Scheme 4:  Initial 5-hydroxy indole analogs 
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 Inhibitor 105 was then protected using tert-butyldiphenylsilyl chloride to generate 
compound 180.  The TBDPS ether was used instead of the TBS ether in an attempt to 
minimize the bisalkylation found with the TBS ether by slowing chloride-induced 
desilylation (Scheme 7).  Gratifyingly, alkylation using 4-chlorobenzyl iodide in the 
presence of a cesium carbonate resulted in intermediate 181.  Only trace amounts of the 
bisalkylated product were seen following the transition to the TBDPS ether.  Removal of 
the silyl protecting group was ultimately accomplished using tetrabutylammonium 
fluoride to generate 101.   
 
Scheme 5:  Synthesis of synthon 167 
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 We elected to explore the 5-hydroxy indole SAR with the dimethyl carboxamide 
in order to minimize molecular weight.  This replacement was considered a valid 
substitution because the original indole lead (10) and the dimethyl carboxamide (20) 
shown in Table 2 were equipotent compounds.  Larger lipophilic substituents on the 5-
OH group (103 and 104) resulted in similar potencies as 20.  On the contrary, smaller 
 
Scheme 6:  Synthesis of inhibitors 102, 103, and 104 
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substitutions (100-102) resulted in a decrease or complete loss of potency.  The 
contrasting activities between the sizes of the lipophilic groups may simply be due to an 
increase in cellular permeability.  When comparing inhibitors 101 and 105, the complete 
loss in potency in 105 indicated substitution at the N1-indole position is required for 
activity. 
Another hypothesis is that 20 has a different binding mode compared to 10.  
When considering a possible change in binding mode, it is possible that the larger, 
hydrophobic substituents found in 103, 104, and 20 are now interacting with the 
hydrophobic binding site that was previously occupied by the benzyl carboxamide 
functionality in 10.  The smaller, lipophilic substitutions such as the methyl (100) and the 
propargyl group (102) are not sufficient to make proper contact with the target resulting 
in the loss of potency.  
36 
 
 
  
 
Scheme 7:  Synthesis of compound 101 
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Table 4:  5-hydroxy indole SAR 
 
 
CCG 
Number 
R3
 IC50 
(µM)
a
 
CC50 
(µM)
b
 
100 211759 Me > 50 > 50 
101 222701 H 23.2 ± 8.0 >100 
102 212058 
 
> 50 > 50 
103 212151 Bn 8.1 ± 2.0 50.7 
104 212138 Pr 7.3 ± 4.7 15.1 
105
c
 212051 H > 50 > 50 
a
Inhibition of luciferase expression in WEEV replicon assay. Ribavirin as positive control has an IC50 in the 
assay of 16 µM. Values are mean of at least n=3 independent experiments + SE.  
b
Cell viability determined 
by inhibition of mitochondrial reduction of MTT. Values are mean of at least n=3 independent experiments.  
c
unalkylated N1-indole position.  Data provided by Dr. David Miller and Craig Dobry    
 
Conclusions 
Early SAR development demonstrated that derivatization of the carboxamide 
position in 10 modulates antiviral activity while the N1-indole and 5-hydroxy indole 
positions did not provide significant change in potency compared to 10.  Also, we 
discovered two enantiomeric compounds (11 and 12) with widely differing activity, 
indicating that our target of interest may have a chiral character, and evidence of a 
hydrogen bonding motif (22) in its binding site.  Furthermore, we have demonstrated that 
we are able to elicit in vivo activity against NSV through improvements in potency and 
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metabolic stability.  A key factor in improving metabolic stability was the transition from 
the thienopyrrole template to bioisosteric indole.  
39 
 
CHAPTER III.  SECOND GENERATION INDOLE-2-CARBOXAMIDE 
ANALOGS 
Rationale 
The SAR defined in Chapter II indicated that substituents on the terminal 
carboxamide position are able to modulate activity.  Both hydrophobic and hydrophilic 
modifications were effective to various degrees.  Of most significance was the increase in 
activity observed with a 4-pyridylmethyl carboxamide (22, IC50 = 6.8 μM) versus benzyl 
amide inhibitor 10 (IC50 = 15 μM), a modification that would be expected to decrease 
cell permeability and non-specific protein binding.  This result strongly suggested that a 
potential hydrogen bonding interaction between the target and ligand is available to 
increase potency further.  The following SAR focused on modulating the hydrogen 
bonding capability of the pyridylmethyl carboxamide.   
SAR development 
Inhibitors based on 22 were synthesized according to Scheme 2.  These analogs 
were made to probe hydrophilic interactions.  As illustrated by Table 5, substituents with 
increased basicity such as 35 and 38, significantly decreased potency compared to 
inhibitor 22.  However, a non-basic, saturated heterocycle such as a morpholine (39) 
resulted in an inhibitor with similar potency as the original lead indole 10.  Increasing the 
hydrogen bonding capability and altering ring size with an imidazole and a pyrazole (33 
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and 34) resulted in a drastic loss of activity, although the increase in TPSA with these 
two analogs (TPSA33, 34 = 68.25 vs. TPSA22 = 65.01) could have impeded cell 
permeability.
107
  Similarly, inhibitors capable of making multiple hydrogen bonds (36 
and 37) were inactive.  The position of the pyridine nitrogen also has an effect on 
potency.  Transitioning from the para-position (22) to the meta- position (30), in relation 
to the carboxamide, generated a less active inhibitor.  This loss in potency may be due to 
the incorrect directionality of the hydrogen bonding pair resulting in a weaker interaction 
between the target and inhibitor.
108
  Addition of a methylene resulted in our first 
submicromolar inhibitor (50) which has a 40-fold increase in potency compared to the 
indole lead 10.   
Chirality 
 Considering the target’s enantiospecificity and the previous success in increasing 
potency by adding chirality in both the thienopyrrole and indole series (Figure 6), it was 
hypothesized that adding chirality to 4-pyridyl carboxamide would increase potency.  The 
racemic α-methyl-4-pyridylmethyl amide (32) was more active than inhibitor 22.  Based 
on previous SAR, it was hypothesized that only the R-isomer (31) would show activity.  
In fact the R-isomer (31) was more active than the racemic α-methyl-pyridylmethyl 
amide (22) and the racemic α-methyl-4-pyridylmethyl amide (32), consistent with our 
previous SAR and indicative of retention of the overall binding mode.   
Antiviral activity 
 Due to the increased potency of 32 and 31, the antiviral activity of these two 
compounds was examined.  A related alphavirus, Fort Morgan virus (FMV) was used 
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because similar to NSV, FMV requires a lower biosafety level for safe handling 
compared to WEEV.  Antiviral activity was measured at 25 µM of inhibitor in human 
BE(2)-C neuronal cell line.  Figure 11 illustrates the significant decrease in viral titer 
compared to the standard ribavirin and previous lead 12.  Even though the enantiopure 
analog, 31, showed an improvement in potency compared to the racemate (32) in the 
replicon assay, it had a higher viral titer than 32 in an FMV infection study.  Compounds 
32 and 31 increased cellular viability compared to ribavirin and 12.  Racemate 32 
reduced viral titer and significantly increased cellular viability in WEEV infection.  
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Figure 11:  Viral Titer and Viability results for 32 and 31 
Human BE(2)-C neuronal cells were infected with WEEV or FMV and incubated with inhibitors at 25 
µM.  Cell viability and viral titiers were measured 24 h post infection via MTT and plaque assays.  
Ribavirin(Rib) as positive control; DMSO negative.  ND = not determined. P < 0.05* or 0.005**  
Graph courtesy of Dr. David Miller 
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Table 5:  CCG 203929 (22) analogs 
 
CCG 
Number 
NR1R4 
IC50 
(µM)
a
 
CC50 
(µM)
b
 
22 203929 
 
6.8 ± 1.7 >100 
30 205422 
 
14.4 ± 0.4 >100 
31 212090 
 
0.6 ± .3 92.3 
32 206329 
 
2.4 ± 0.8 90.1 
33 205455 
 
>50 >50 
34 205454 
 
76.9 ± 30.8 >100 
35 205429 
 
>50 >50 
36
δ
 211760 
 
>100  >100 
37 208787 
 
>50  >50 
38 204023 
 
31.4 ± 16.7 75.6 
39 204024 
 
12.8 ± 4.6 >100 
40 205430 
 
13.1 ± 2.0 63.3 
50 205432 
 
0.5 ± 0.2 49.9 
a
Inhibition of luciferase expression in WEEV replicon assay. Ribavirin as positive control has an IC50 in the 
assay of 16 µM. Values are mean of at least n=3 independent experiments + SE.  
b
Cell viability determined 
by inhibition of mitochondrial reduction of MTT. Values are mean of at least n=3 independent experiments.   
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Physicochemical properties 
 
As previously discussed, addition of the α-methyl substitution in 12 increased 
metabolic stability compared to lead inhibitor 10.  Figure 12 shows the metabolic stability 
of select compounds.  The figure above shows two half-lives for compound 12.  This is 
due to the two different batches of mouse liver microsomes used.  The two experiments 
are differentiated by the colors.  Transitioning to the α-methyl pyridyl carboxamide, the 
metabolic stability significantly increased compared to the corresponding α-methyl 
benzyl analog 12.  The increased metabolic stability may be due to the lowered 
lipophilicity.  The metabolic stability of the 4-pyridylmethyl carboxamide (22) was not 
measured because of the increased metabolic stability in 12 induced by the presence of an 
α-methyl group, we assumed the pyridyl analog lacking the α-methyl would be less 
stable.  This experiment emphasized the importance of having a known control when 
performing a metabolic stability experiment due to the potential for differences in activity 
between batches of microsomes.   
 
Figure 12:  Select metabolic stability 
a
Half-life in mouse liver microsome incubations. 
b
Blue and red indicates two different batches of MLM 
used to determine half-lives. Values are mean of ≥ 2 independent incubations.  Performed by Scott J. 
Barraza 
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Figure 10 (page 27) showed that the presence of 4-pyridylmethyl caboxamide 
substituents (22, 31, and 32) did not significantly change the passive permeability of the 
inhibitors.  However, these series of compounds had an increased Pgp recognition.  A 
third generation of carboxamide inhibitors based on 50 was subsequently pursued 
because of the dramatic 40-fold increase in potency compared to original indole lead 10. 
Conclusions 
This chapter further explored the interaction between the terminal carboxamide of our 
inhibitors and the hydrogen bonding motif hypothesized to be present in the binding site 
of our molecular target.  These modifications identified two compounds that have 
nanomolar activity (31 and 50) in the replicon assay, improved in vitro antiviral activity 
compared to indole lead 12, and significantly improved metabolic stability in MLM.   
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CHAPTER IV.    THIRD GENERATION INDOLE-2-CARBOXAMIDE 
ANALOGS 
Rationale 
Because of the significant increase in potency, a series of analogs were generated 
based on compound 4-pyridylethyl amide 50.  Similar to the strategy employed to 
derivatives based on 22, the analogs explored both hydrophobic and hydrophilic 
modifications.  In addition, they examined alternative hydrogen bonding motifs to 
explore the hypothesis that main chain amides of the molecular target were being 
engaged. 
SAR development 
 These third generation indole analogs were synthesized according to Scheme 2.  
Similar to the trend seen in the 4-pyridylmethyl carboxamide series (Table 5) the 
progressive movement of the pyridine nitrogen from para-position to the ortho-position 
(50, 53, and 57) resulted in a decrease in potency from 0.5 µM to 22.4 µM (Table 6).  
This result indicated that the pyridine nitrogen must be in the para-position in order to 
make an ideal interaction with the target.  The distance between the carboxamide and the 
pyridine motif was also examined.  The 4-pyridylpropyl carboxamide (63) analog was 
less active than 50.  Taken together with the previously observed activity of the shorter 
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single methylene analog 22, this indicates that the optimum distance between the 4-
pyridine and amide functionalities is two methylenes.   
 Additions of lipophilic motifs such as aliphatic groups or halogens can aid in 
increasing cellular permeability which results in an increase in intracellular concentration 
of inhibitors.  Lipophilic inhibitors (52, 56, 58, 59, and 62) showed lower activity than 
50.  These compounds suggest that even though the target is capable of making 
hydrophobic interactions, the protein of interest has a hydrophilic binding site that prefers 
to make hydrogen bonds with motifs such as the pyridine in 50.      
Conformationally restricting potential inhibitors can lead to increases in potency, 
mitigate metabolic instability, and alter Pgp recognition.  Restricting rotation about the 
ethylene linker of 50 was initially done by the sequential addition of methyl groups.  N-
methylation of 50 resulted in analog 51; however, this analog resulted in a slight decrease 
in potency.  This may be due to the different rotomers that 51 has and only one rotomer is 
in the right conformation to achieve the requisite hydrogen bond for increased potency.  
Monomethylation at the β-methylene of the 4-pyridylethyl  carboxamide (54) resulted in 
a compound of similar potency to 50.  This result suggests that 50 and 54 are able to 
achieve similar spatial conformation that allows them to bind to the target in a similar 
fashion.  However, greater conformational restriction by adding the gemdimethyl (55) 
restricts the molecule in a less than ideal three-dimensional shape limiting its capabilities 
to hydrogen bond to the target.  One can imagine that covalently restricting the 
movement of the ethylene linker with the dihydrofuran ring (64) may result in a decrease 
in potency; however, this analog had better potency than its gemdimethyl (55) 
counterpart.  This recovery in potency may be attributed to a better conformation than 55 
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or the presence of the oxygen in 64.  This oxygen may be participating in the same 
hydrogen bonding system that the pyridine nitrogen is involved in; however, it is not of 
the appropriate distance, orientation or strength of hydrogen bond resulting in a lower 
potency than 50.         
Hydrogen bonding substitutions 
Hydrogen bonds, which can influence interactions between drugs and their targets 
are integral interactions in drug discovery.
109
  They can have significant impact on 
potency, selectivity, permeability and solubility. 
110
  The relative strengths of these bonds 
are not only determined by the type of functionality, but also their shape and their local 
environment.  For example, lactams are better hydrogen bond acceptors than acyclic 
amides.  Also, electron donating or withdrawing functionalities affect the hydrogen 
bonding acceptor capabilities of aromatic systems.
110
  In addition, local environments 
influence the strength and significance of a hydrogen bond in a protein-drug interaction.  
Hydrogen bond networks can provide significant stability to an interaction.
110, 111
  Of 
particular interest, heteroaromatic rings are key components of most drugs.
112, 113
  They 
aid in determining molecular shape and recognition by proteins.
112, 114
  Aromatic 
heterocycles participates in hydrophobic, polar, hydrogen bonding, cation-π, amide-π, 
halogen-π, and π-stacking interactions.115-120      
Based on the key increase in potency observed with our lead inhibitor 50 upon 
introduction of the 4-pyridyl group, Dr. Paul Kirchoff performed a substructure search of 
the PDB for compounds that contained a pyridine in their bound ligands.  The database 
search primarily identified ATP competitive kinase inhibitors that interacted with the 
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protein backbone amides instead of the side chains.  Therefore, we hypothesized that our 
pyridyl amide might be interacting with main chain amides.  To test this hypothesis, we 
prepared analogs incorporating hydrogen bonding groups known to interact strongly with 
the hinge region of kinases.   
Hydrogen bonding substitution SAR development 
These derivatives explored other hydrogen bonding motifs as a possible 
replacement for the pyridine found in 50.  Bicyclic compounds 70 and 75 are 
regioisomeric indazoles and capable of making both - and hydrogen bond interactions 
with the target.  Even though these two compounds lost significant potency compared to 
50, they do highlight that structural changes not only affect potency but also cytotoxicity.  
The 4-indazolyl carboxamide (70) was significantly more cytotoxic than the 5-indazolyl 
(75).  Also, the 1-methylpyrazolyl carboxamide (76) is significantly more cytotoxic than 
its unmethylated counterpart (78).  Interestingly, tryptamine carboxamide (74) and 7-
azatryptamine carboxamide (71) showed that the two hydrogen bonding motifs in 71 
results in a more potent inhibitor than 74, which is what would have been predicted for an 
interaction with main chain amides.  The most active analog from this group was the 
simple N-unsubstituted pyrazole 78.  Increasing the distance between the amide and 
pyrazole motif did not improve potency (73 v. 78).  
3,4-dichlorophenethyl carboxamide (72) has the potential to establish an 
interaction referred to as halogen bonding.
117, 121, 122
 This interaction is seen to increase 
efficacy, potency, and selectivity in inhibitors for kinases such as CDK9.
121, 123-125
  C-X 
bonds where X is a halogen are capable of making interactions with electrophiles, 
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nucleophiles, and other halogens.
126
  Halogens, excluding fluorine, have an uneven 
distribution of electrons where a slight positive charge is found opposite of the C-X bond.  
This is called the σ-hole.109, 122  Similar to kinases where the carbonyl backbone acts as 
the primary hydrogen bond acceptor for the ATP site binding inhibitors, the carbonyl also 
functions as the primary halogen bond acceptor.
122
  Unfortunately, the 3,4-
dichlorophenylethyl amide (72) was not significantly more active than the simple 
phenethylamide (56,Table 6), suggesting that no productive halogen bonding with an 
amide backbone was realized.   
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Table 6:  Inhibitor 50 derivatives 
 
 
CCG 
Number 
NR1R4 
IC50 
(µM)
a
 
CC50 
(µM)
b
 
50 205432 
 
0.5 ± 0.2 49.9 
51 211761 
 
1.6 ± 0.8 47.9 
52 102518 
 
5.5 ± 2.2 75.2 
53 205433 
 
5.3 ± 1.1 39.4 
54 206580 
 
1.7 ± 1.2 98.2 
55 209022 
 
19.3 ± 21.0 43.6 
56 206397 
 
15.2 ± 9.3 62.2 
57 205456 
 
22.4 ± 10.0 86.2 
58 206400 
 
8.1 ± 1.1 40.4 
59 206396 
 
21.4 ± 18.8 18.6 
60 206398 
 
15.5 ± 14.6 11.3 
61 206395 
 
11.1 ± 3.8 >100 
 
 
 
 
 
 
 
 
 
 
 
 
52 
 
 
CCG 
Number 
NR1R4 
IC50 
(µM)
a
 
CC50 
(µM)
b
 
62 206461 
 
10.8 ± 3.3 27.2 
63 208788 
 
31.9 ± 37.9 71.5 
64 206581 
 
3.6 ± 1.7 75.8 
a
Inhibition of luciferase expression in WEEV replicon assay. Ribavirin as positive control has an IC50 in the 
assay of 16 µM. Values are mean of at least n=3 independent experiments + SE. 
b
Cell viability determined 
by inhibition of mitochondrial reduction of MTT. Values are mean of at least n=3 independent experiments.  
Provided by Dr. David Miller and Craig Dobry   
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Table 7:  CCG 205432 hydrogen bonding exploration 
 
 
CCG 
Number 
NR1R4 
IC50 
(µM)
a
 
CC50 
(µM)
b
 
50 205432 
 
0.5 ± 0.2 49.9 
70 215061 
 
14.0  ± 0.9 47.3 
71 222940 
 
3.40  ± 0.3 88.9 
72
 222720 
 
11.0   >100 
73 222760 
 
1.34  ± 0.8 45.5 
74 222900 
 
13.4  ± 0.9 98.0 
75 215060 
 
12.5 ± 2.6 >100 
76 215080 
 
2.33 ± 0.3 10.0 
77 206582 
 
4.9 ± 2.6 99.6 
78 215153 
 
1.0 ± .1 56.0 
a
Inhibition of luciferase expression in WEEV replicon assay. Ribavirin as positive control has an IC50 in the 
assay of 16 µM. Values are mean of at least n=3 independent experiments + SE. 
b
Cell viability determined 
by inhibition of mitochondrial reduction of MTT. Values are mean of at least n=3 independent experiments.  
Provided by Dr. David Miller and Craig Dobry    
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Physicochemical Properties  
 Metabolic stability was performed in a similar fashion as described in Chapter I. 
Studies indicated that 50 and 77 had longer half-lives than the first generation indole 
inhibitor 12 (MLM T½ = 2.1 min), but were both less stable than 31 (Figure 13).  This 
decrease in half life might be due to the reintroduction of an unsubstituted methylene 
group.  This site was shown (10 v 12, Chapter III) to be metabolically labile and addition 
of a methyl group decreased its susceptibility to metabolism.  Also, it is possible that 
having two methylenes allowed better binding of the pyridine in the CYP450 binding 
site, making it more prone to oxidation.   
 
 Pgp recognition and passive permeability were measured for select compounds.  
As shown by Figure 14, the N-methyled analog of 50 (51) led to increased recognition by 
Pgp.  However, unlike 51, methylation at the β-carbon (54) slightly decreased Pgp 
recognition relative to 50.  This result emphasizes that Pgp recognition is not only 
affected by changes in functional groups, but also molecular shape.  Regioisomers (50, 
53, 57) had similar Pgp recognition.  Extending the distance between the carboxamide 
 
 
Figure 13:  Select metabolic stability 
Half-life in mouse liver microsome incubations. Values are mean of ≥ 2 independent incubations. 
Performed by Scott J. Barraza 
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and pyridine (63) and conformationally restricting the ethylene linker (64) increased Pgp 
recognition compared to 50.  The more basic imidazolylethyl carboxamide (77) decreased 
Pgp recognition in comparison to 50.  In addition, its increased polarity resulted in a log 
reduction in passive permeability (Figure 14).   
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Figure 14:  Pgp  recogntition and passive permeability for pyridylethyl carboxamide analogs 
Rhodamine 123 (Rho 123) uptake was measured in MDR1-MDCKII cells utilizing Glomax Multi 
Detection System (Promega). ‘MDR1 recognition’ was assessed by measuring uptake in the presence of 
MDR inhibitor, tariquidar (5 µM), and either 30 µM of anti-viral or vehicle, and calculating: % Rho 
123eff = (Cav – Cveh)*100/(Ctar-Cveh), where Cav = concentration of Rho 123 in the presence of anti-viral, 
Cveh = concentration in the presence of vehicle, Ctar = concentration of Rho 123in the presence of 
tariquidar. In the presence of tariquidar, Rho 123uptake was 1123 ± 54% of vehicle controls (n=44) .   
MDR recognition provided by Dr. Richard Keep and Jianming Xiang 
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In vitro antiviral and viability studies 
 
 Similar to the previous studies, antiviral and viability studies were done at 25 µM 
inhibitor concentration in neuronal cells infected with FMV.  Figure 15 showed all the 
compounds were capable of reducing viral titer and increasing cellular viability compared 
to Ribavirin and 12.  Inhibitor 50 was efficacious in reducing viral titer to similar levels 
as 32 and 31.  The less potent β-monomethylated analog 54 did not reduce viral titer 
compared to 50.  However, both significantly increased viability to the same level 
compared to Ribavirin and 12.  These antiviral activities showed progress towards better 
antiviral and increased cellular viability. 
 
Figure 15:  FMV antiviral viral results for compound 50 analogs 
Human BE(2)-C neuronal cells were infected with FMV and incubated with inhibitors at 25 µM.  Cell 
viability and viral titiers were measured 24 h post infection via MTT and plaque assays.  Ribavirin(Rib) 
as positive control; DMSO negative.  P < 0.05* or 0.005** Data courtesy of Dr. David Miller and Craig 
Dobry  
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In vivo WEEV infection study 
Due to its increase in metabolic stability and 40-fold increase in potency, 50 was 
taken into a WEEV infection mice study.  Female C57BL/6 mice 5-6 weeks of age were 
infected with a highly virulent strain of WEEV, Cba-87.  Mice were infected 
subcutaneously with 10
3
 pfu of WEEV.  Treatment was administered via intraperitoneal 
injection at 30 mg/kg, twice daily starting the day of infection until day 7.  The mice were 
monitored until day 14, at which time they were euthanized.  Disease severity was scored 
according to the same scale described in Chapter II.  Figure 16 showed 50 decreased 
disease severity (clinical score) and increased survival compared to DMSO treated 
mice.
127
    
 
 
 
Figure 16:  In vivo WEEV infection treatment with compound 50  
Mice were infected with 10
3
 pfu/mL of WEEV and treated with 50 using 30 mg/kg/dose or vehicle. 
Animals were treated via IP injection every 12 hours beginning 12 hours after virus challenge. 
Composite of four independent experiments, where n=4-10 mice per group per experiment.  (A) 
Disease severity (B) Survival Graph courtesy of Dr. David Irani, Dr. David Miller, and Pennelope 
Blakely.  Figure adapted from Ref. 125 
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Conclusions 
This chapter explored in detail SAR at the terminal amide, reinforcing that the 4-
pyridylethyl amide (50)  was an optimal amide substitution pattern, leading to a 
nanomolar activity in the replicon assay, improved metabolic stability, and in vivo 
activity against WEEV.  In addition, modifications at the amide were able to modulate 
physicochemical properties identifying compounds with lower Pgp recognition and 
further increased metabolic stability.   
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CHAPTER V.    INDOLE SUBSTITUTION 
Rationale 
 The carboxamide position had been extensively probed, leading to the discovery 
of optimal inhibitor 50.  This compound is 40-fold more potent than the original indole 
lead (10).  In our early SAR studies, both the N1-indole and 5-hydroxy indole 
substitutions did not improve potency compared to 10, resulting in a majority of 
subsequent SAR being optimized for the 4-chlorobenzyl and 5-H indole scaffold.  It was 
on this scaffold that the 4-pyridylethyl carboxamide was found necessary to give the best 
potency.   We thus elected to revisit the role of the indole and its impact on activity, 
cytotoxicity and physicochemical properties in the presence of the optimal 4-pyridylethyl 
carboxamide.  Many of these analogs were also designed to further improve metabolic 
stability.  
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Synthesis 
 
 To streamline analog synthesis, the complete piperidine amide portion of 50 was 
first prepared.  Previously synthesized intermediate 170 was coupled with 2-(pyridine-4-
yl)ethan-1-amine.  Subsequent exposure to hydrochloric acid resulted in synthon 190 
(Scheme 8).   
6-fluoro-1H-indole-2-carboxylic acid and 1H-benzo[d]imidazole-2-carboxylic 
acid were coupled to ethyl isonipicotate and the resulting ester was alkylated with 4-
chlorobenzyl chloride to generate intermediate 193 and 194.  Saponification in the 
presence of lithium hydroxide followed by a second peptide coupling with 2-(pyridine-4-
yl)ethan-1-amine gave inhibitors 112 and 117 (Scheme 9).    
 
Scheme 8:  Synthesis of synthon 190 
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 The synthesis of compounds 110, 111, and 116 began with the alkylation of ethyl 
indole-2-carboxylate with the requisite benzyl halides.  Subsequent hydrolysis resulted in 
carboxylic acids 195, 196, and 220.  Coupling with synthon 190 resulted in inhibitors 
110, 111, and 116.  Ester 225 was alkylated with 4-chlorobenzyl chloride then 
hydrolyzed to give acid 230.  Coupling with 190 gave compound 113.  To generate 
inhibitor 114, ester 155 was hydrolyzed to give 235.  Coupling with synthon 190 gave the 
desired inhibitor (Scheme 10).   
  
 
Scheme 9:  Synthesis of analogs 112 and 117 
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Indole 155 was methylated in the presence of methyl iodide to generate ethyl 1-
methyl-1H-indole-2-carboxylate (Scheme 11).  Alkylation of ethyl 5-fluoro-1H-indole-2-
carboxylate (198) with 4-chlorobenzyl chloride generated ethyl 1-(4-chlorobenzyl)-5-
fluoro-1H-indole-2-carboxylate (200).  Both esters were hydrolyzed and the resulting 
carboxylic acids were coupled with ethyl isonipicotate using EDCI and HOBt to give 199 
and 200.  Esters 199 and 200 were hydrolyzed followed by a coupling with 2-(4-
pyridyl)ethylamine to give inhibitors 118 and 115.    
 
Scheme 10:  Synthesis of analog 110, 111, 113, 114, 116 
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SAR development 
Table 8 lists the various indole modification analogs synthesized.  The 4-
chlorobenzyl was replaced with a methyl and a hydrogen (118 and 114, respectively).  
These two analogs were completely inactive indicating a benzylic type motif is necessary 
for activity at the N1-indole position.  The 5-methoxy indole substitution (113) did not 
affect potency; however, it increased cytotoxicity.  Replacement of the indole with an 
electron deficient benzoimidazole (112) or 6-azaindole (143) resulted in about a 10-fold 
 
Scheme 11:  Synthesis of analog 115 and 118 
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loss of potency.  Both were intended to mitigate oxidative metabolism of the indole ring.  
The N1-benzyl substitution (110) showed slightly reduced potency to 50, indicating that 
the chlorine was contributing to potency, perhaps just through better cell permeability.  
Monocyclic analogs (140 and 141) were synthesized by Scott J. Barraza.  These 
compounds were intended to decrease the molecular weight in order to better coincide 
with the properties of marketed CNS drugs listed on page 15.  Compound 140 exhibited 
similar potency and better cytotoxicity than 50; however, in a preliminary in vivo study it 
caused severe neurotoxicity exhibited by seizures.  Imidazole analog (141) resulted in a 
total loss of potency.         
Several fluorine-containing inhibitors have been synthesized (111, 115, 117, and 
142).  Fluorine is a substituent in medicinal chemistry that is capable of modulating 
activity, cytotoxicity, physicochemical and pharmacokinetic properties.
128-130
  In addition, 
it adds lipophilicity to the compound and yet it is capable of generating hydrogen 
bonding interactions.
131
  For CNS drugs, it is capable of increasing BBB permeability due 
to its impact on lipophilicity.
130
  It is able to mitigate CYP450 metabolism.  Our 
fluorinated analogs were intended to improve metabolic stability.  Unfortunately, they did 
not improve potency.  However, the 4-fluoropyrrole inhibitor (142) resulted in a 
significant increase in toxicity.   
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Table 8:  Indole Substitution 
 
 
CCG 
Number 
X 
IC50 
(µM)
a
 
CC50 
(µM)
b
 
 
50 
 
205432 
 
0.5 ± 0.2 49.9 
110 209023 
 
1.6 ± 0.5 45.6 
111 209024 
 
1.3 ± 0.8 34.5 
112 206565 
 
4.1 ± 1.0 74.6 
113 209025 
 
0.47 ± 0.2 21.0 
114 212059 
 
>50 >50 
115 208919 
 
0.9 ± 0.8 52.5 
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a
Inhibition of luciferase expression in WEEV replicon assay. Ribavirin as positive control has an IC50 in the 
assay of 16 µM. Values are mean of at least n=3 independent experiments + SE.  
b
Cell viability determined 
by inhibition of mitochondrial reduction of MTT. Values are mean of at least n=3 independent experiments.  
Data provided by Dr. David Miller and Craig Dobry.  *Synthesized by Scott J. Barraza 
  
116 212150 
 
1.7 ± 0.2 53.3 
117 208918 
 
0.6 ± 0.7 43.1 
118 206484 
 
>50 >50 
 140* 206381 
 
0.7 ± 0.1 >100 
 141* 208916 
 
>50 >50 
 142* 209021 
 
0.9 ± 0.3 8.0 
 143* 211751 
 
4.4 ± 0.8 77.1 
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Antiviral activity 
Figure 17 shows the FMV antiviral results for selected indole modified analogs.  
These experiments used similar conditions as the previous antiviral experiments.  As 
shown, inhibitor 50 significantly decreased viral titer compared to its pyrrole analog 
inhibitor 140.  6-fluoroindole 117 reduced viral titer better than 50 but had similar effects 
on cellular viability.  Surprisingly, the less replicon-active benzoimidazole analog (112) 
showed a reduction in viral titer and an improvement in viability better than 140.  N-
benzyl indole 110 was slightly less potent than inhibitor 50; however, it reduced viral 
titer to similar levels as 50 and increased cellular viability better than 50 and ribavirin.  
Unexpectedly, 6-azaindole 143 did not reduce viral titer even though it was equipotent to 
benzoimidazole 112.  Compound 112 sufficiently decreased viral titer compared to 
Ribavirin.   
 
 
Figure 17:  Indole replacement antiviral results 
Human BE(2)-C neuronal cells were infected with FMV and incubated with inhibitors at 25 µM.  Cell 
viability and viral titiers were measured 24 h post infection via MTT and plaque assays.  Ribavirin(Rib) 
as positive control; DMSO negative.  P < 0.05* or 0.005** Data courtesy of Dr. David Miller and Craig 
Dobry 
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Physicochemical Properties 
Select compounds were subjected to metabolic stability in mouse liver 
microsomes.  These experiments were performed in a similar manner as those described 
in Chapter I.  Figure 18 showed that pyrrole 140 was very unstable to CYP450.  This 
indicated that the pyrrole is likely a major site of metabolism.  Generating electron 
deficient scaffolds, such as the benzoimidazole (112) and 6-azaindole (143), restored 
some metabolic stability, but surprisingly these were not much different than indole 50.  
The N1-benzyl derivative, 110, on the other hand showed a dramatic increase in stability.  
This result indicates that the N-benzylic substituent is not likely to be a metabolically 
labile group, and that the improvement in metabolic stability is rather due to an overall 
reduction in lipophilicity. 
These indole substitution analogs were unable to improve passive permeability 
compared to 50.  The fluorinated analogs (111, 115 and 117) were intended to reduce 
metabolic liabilities at the indole and benzyl positions; however, these inhibitors were 
unable to produce inhibitors with increased activities compared to 50 (Table 8).  
Similarly, they were also unable to improve Pgp recognition compared to 50 (Figure 19).  
The difference in Pgp recognition between 115 and 117, differing only in the position of 
a fluorine atom, demonstrates that small changes can have a large impact on Pgp 
recognition levels.  Electron deficient bicyclic inhibitors (112 and 143) markedly reduced 
recognition relative to indole 50.  Monocyclic inhibitors 140 and 141 eliminated Pgp 
recognition.  Reducing lipophilicity by removing the chlorine (110) reduced Pgp 
recognition (Figure 19).  Overall, these results indicate that Pgp recognition of this series 
of inhibitors can be attenuated by reducing lipophilicity, either by removal of halogens, 
70 
 
replacement of aromatic CH with N, or replacement of the bicyclic indole with 
monocyclic heteroaromatics.       
 
 
 
 
Figure 18:  Metabolic stability of indole substituents 
Half-life in mouse liver microsome incubations. Values are mean of ≥ 2 independent incubations. 
Performed by Scott J. Barraza 
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Figure 19:  MDR recognition and PAMPA-BBB measurements 
Rhodamine 123 (Rho 123) uptake was measured in MDR1-MDCKII cells utilizing Glomax Multi 
Detection System (Promega). ‘MDR1 recognition’ was assessed by measuring uptake in the presence of 
MDR inhibitor, tariquidar (5 µM), and either 30 µM of anti-viral or vehicle, and calculating: % Rho 
123eff = (Cav – Cveh)*100/(Ctar-Cveh), where Cav = concentration of Rho 123 in the presence of anti-viral, 
Cveh = concentration in the presence of vehicle, Ctar = concentration of Rho 123in the presence of 
tariquidar. In the presence of tariquidar, Rho 123uptake was 1123 ± 54% of vehicle controls (n=44).   
MDR recognition provided by Dr. Richard Keep and Jianming Xiang 
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WEEV in vivo infection study 
 Even though inhibitor 110 resulted in a slight decrease in potency compared to 50, 
it had a significant increase in metabolic stability and lower Pgp recognition.  Because of 
these two factors, inhibitor 110 was taken into a preliminary in vivo study.  The study was 
performed similarly to the in vivo experiment for 50 (Chapter IV).  Figure 20 showed that 
inhibitor 110 was capable of decreasing disease severity and increasing survival.  
Compared to 50 (page 58), 110 had survival rate of approximately 15% whereas 50 
increased survival to approximately 25% compared to DMSO at day 14.  In addition, at 
the end of the 14 days, the overall disease severity is lower when mice were treated with 
110.          
 
 
Figure 20:  In vivo WEEV infection treatment with compound 110 
Mice were infected with 10
3
 pfu/mL of WEEV and treated with 110 using 30 mg/kg/dose or vehicle. 
Animals were treated via IP injection every 12 hours beginning 12 hours after virus challenge. 
Composite of twor independent experiments, where n=5-10 mice per group per experiment  (A) Disease 
severity (B) Survival Graph courtesy of Dr. David Irani, Dr. David Miller, and Pennelope Blakely. P < 
0.05* and 0.005**.  Figure adapted from Ref. 125 
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Pharmacokinetic experiments 
 
 
Compound MLM T½ (min) %Rho efflux 
12 2.1 24.4 
50 11.5 30.9 
140 2.9 -1.2 
 
Figure 21:  Plasma and brain concentration for 12, 50, and 140 
Six-week old C57BL/6 mice were injected via IP with a single dose of 30mg/kg of 12 and 50 and 10 
mg/kg.  Blood samples were taken at 7-intevals (30 min, 1h, 2h, 3h, 4h, 8h, 12 h).  Brain tissues were 
harvested from the cerebrum.  Plasma and brain levels were measured using LC/MS/MS  Each value 
shown is an average of two mice per dose.  *In vivo work done by Pennelope Blakely; plasma and brain 
levels measured by Xiaoqin Li.    
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 Compounds that were taken into in vivo studies (12, 50, and 140) were also 
evaluated in pharmacokinetic studies.  Six-week old female C57BL/6 mice were injected 
via IP with a single dose 30 mg/kg of 12 and 50 and 20 mg/kg of 140.  Blood samples 
were taken at 7 time intervals and brain tissue from the cerebrum was harvested.  The 
samples were analyzed for drug concentrations via LC/MS/MS by Xiaoqin Li.  Figure 21 
shows the different concentrations found in the plasma and brain tissue.  As shown, only 
inhibitor 140 had detectable drug levels in the brain.  This result validated the results of 
the Pgp recognition and metabolic stability experiments.  The compound least recognized 
by Pgp (140) achieved measurable brain levels, while the compound with the greatest 
stability in mouse liver microsomes (50) had the highest level in the plasma.  Both 140 
and 50 had higher brain levels and plasma levels, respectively, than 12. 
Conclusions 
In this chapter we reexamined the role of the indole in the presence of optimized 4-
pyridylethyl amide.  Importantly, we demonstrated a correlation between our Pgp-
recognition and in vitro MLM experiments with pharmacokinetic properties.  In addition, 
we were able to derive some information about metabolically labile sites in these 
replication inhibitors from the MLM SAR, namely that the indole ring is a likely major 
site of metabolism.  Finally, this series of derivatives led to the identification of 110, 
which has improved physicochemical properties compared to 50 and in vivo activity 
against WEEV.   
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CHAPTER VI.    TARGET IDENTIFICATION 
Rationale 
 Currently the target of our RNA replication inhibitors is unknown.  Target 
identification is a very important aspect of drug discovery.  The current cell-based assay 
used in our project is dependent on multiple variables such as cell growth, transfection of 
BHK cells with the WEEV genome, permeability of compounds, and other cellular 
interactions, including metabolism.  Isolation of a target would allow the transition from 
a cell- based assay to a biochemical assay, which would allow a more direct SAR 
interpretation.  It would provide an opportunity to define the binding region by structural 
biology.  Knowing the specific protein of interest would allow the development of 
molecules that selectively manipulate desired biological processes.
132
 In addition, 
identifying other proteins that bind to the compound may aid in predicting off-targets.
133, 
134
   
Biological target identification and Mode of Action 
 Dr. David Miller focused on elucidating the mode of action and biological targets 
for our indole-2-carboxamide inhibitors through various proteomics and genomic 
techniques.  The breadth of antiviral activity of 50 and 140 against several families of 
viruses:  Togaviridae (VEEV), Bunyaviridae (California encephalitis virus - CEV), 
Picornaviridae (EMCV), Paramyxoviridae (Sendai Virus - SeV) and Flaviridae (Dengue 
Virus - DENV) were examined.  These experiments were performed in BE(2)-C cells 
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with a viral inoculation of MOI = 0.1.  Viral titers for VEEV, CEV and EMCV were 
measured 24 hours post-infection.  For DENV, RNA virus levels were measured 96 hours 
post infection.  Both 50 and 140 were used at 25 µM and 2.5 µM.  As shown by Figure 
22, 50 and 140 were able to decrease viral titer against VEEV, CEV, EMCV and SeV.  
Compound 50 was able to decrease viral titer better than 140.  However, both compounds 
were unable to decrease RNA virus levels compared to RNA replication inhibitor, 
mycophenolic acid.
127
  Compounds 50 and 140 were able to inhibit the replication of 
other RNA viruses, but not DENV.  Even though both 50 and 140 were able to inhibit 
replication in other RNA viruses, their activity remains limited.   
 
  
 
Figure 22:  Broad spectrum activity against of compound 50 and 140 
a
VEEV (Venezuelan equine encephalitis virus), CEV (California encephalitis virus), EMCV 
(Encephalomyocarditis virus), DENV (Dengue Fever), MPA (mycophenolic acid) 
b
 experiments were 
performed in BE(2)-C cells with viral inoculation at an MOI = 0.1.  Virus titer were measured 24 hours 
post infection. 
c
DENV RNA levels were measured 96 hours post infection and compared to 
mycophenolic acid. 
d
SeV (Sendai Virus) results not shown.  P < 0.05* or < 0.005**. Experiments 
performed by Dr. David Miller. Figure adapted from Ref. 127      
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In a time course study, BE(2)-C cells were infected with FMV at an MOI of 10.  
Untreated cells showed viral RNA accumulated after 6 hours post infection and a rapid 
increase around 10-12 hours.  Cells were treated with 25 µM of 50 2 hours prior to FMV 
infection to 18 hours post infection.  In the presence of 50, viral titer increase was 
delayed 10-12 hours, at which point the effectiveness of 50 was diminished.    
A WEEV pseudoinfectious particle (PIP), similar to those made for SINV and 
VEEV, was developed and it contained a fLuc gene seen in the replicon system.
73, 127, 135
  
Since WEEV is naturally a recombinant virus whose glycoprotein is derived from Sindbis 
(SINV) virus, a well-developed antibody against SINV glycoprotein E2 can be used as a 
positive control for viral replication inhibition.  When the PIPs were pre-incubated with 
the antibody before addition to HEK293 cells, it showed a suppression of fLuc 
expression.  In contrast, 50 was unable to decrease fLuc activity when pre-incubated with 
PIPs before addition to cells.  However, when cells were allowed to bind to PIPs before 
the addition of 50, fLuc expression decreased.
127
  Both the time course study and the PIPs 
experiment support the notion that 50  inhibits viral replication beyond viral binding and 
entry and its activity can be attributed to inhibition of viral RNA replication.  
 The use of cell-based assay allows inhibitors to target both host and viral proteins.  
Alphaviruses generate their replication complexes on intracellular membranes.
7, 49, 51
  The 
complex can be isolated through differential centrifugation.
136
  Therefore, RNA 
replication activity of the virus can be measured in a cell free system.  It was determined 
that 50 did not suppress RNA-dependent RNA-polymerase activity in vitro.  The rapid 
rate of mutation of RdRp lends itself to the generation of drug-resistant mutants.  
However, compound 50 was not able to generate resistant virus, indicating that it did not 
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target RdRp or any viral enzymatic proteins. 
127
  WEEV replicons were treated in 
combination with 50, 140, MPA (purine biosynthesis inhibitor) or actimycin A 
(mitochondrial electron transport chain and pyrimidine biosynthesis inhibitor).  
Treatment with 50 and 140 showed additive effects in reducing replication; however, 
treatment with 50 and MPA or 50 and actimycin A did not show significant synergism.  
Also, addition of excess purine or pyrimidine did not rescue replicon activity.  These 
results indicated that 50 and 140 acts on similar pathways that are not involved in purine 
or pyrimidine synthesis.
127
 
 A study using Ingenuity Pathway Analysis software identified 22 pathways that 
may be modulated by 50 or 140.  Of those identified, the eIF2 pathway was shown to be 
most affected by 50 and 140.  The eIF2 pathway is involved in gene expression, 
translational control, cellular stress response including to viral infections.
127, 137
 
    
 In order to elucidate whether 50 and 140 were able to inhibit cellular functions, 
the Miller lab utilized the four plasmids shown in Figure 23A to determine fLuc 
suppression.  The pSV40-fLuc represents the nuclear transcription of capped and 
polyadenylated mRNAs and was used with a plasmid containing the pSV40 promoter.  
A 
 
B 
 
  
  
 
Figure 23:  fLuc-encoding reporter plasmids 
(A) Plasmid description shown in left.  Promoters are designated by broad arrows; CITE  (cap- 
independent translation element); An (polyadenylation tail) (B) U (untranslated region), δRz (hepatitis 
δ virus), SGP (subgenomic promoter), An (polyadenylated tail) Images adapted from Ref. 127 
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Transcription in the cytoplasm was determined using a bacteriophage T7 RNA 
polymerase promoter.  T7 RNA polymerase promoters express RNAs that are mainly 
uncapped and without a polyadenylated tail; therefore, a CITE (cap-independent 
translation element) sequence was included in order to improve translation turn over.  
Compounds 50 and 140 were able to inhibit translation using the pSV40-fLuc plasmid, 
but not those with T7 RNA polymerase promoter and CITE.  These results indicated that 
50 and 140 may be inhibiting a mechanism involving cap-dependent translation.   
 Expanding on the transfection study above, two plasmids were generated (Figure 
23B).  These plasmids utilized the original pWR-Luc plasmid used in the replicon 
system; however, one plasmid (pWR-∆Luc) had the nonstructural proteins removed and 
the other (pW-nsP) only contained the nonstructural proteins in the presence of T7 
promoter and CITE sequence.  It was shown that if cells were transfected with either 
pWR-∆Luc or pW-nsP they showed minimal fLuc expression; however, transfection with 
both plasmids increased fLuc expression.  In the presence of 50 and 140, fLuc expression 
was not significantly suppressed indicating that these inhibitors do not target a viral 
protein; instead, they affect host machinery.   
The results of the various biological experiments highlight various aspects of the 
mode of action and target of these indole-2-carboxamide inhibitors.  First, they are able to 
inhibit replication of various, but not all, RNA viruses. Second, they affect replication 
after viral entry into the host cell.  Finally, they do not target viral enzymatic activity; 
instead they modulate a cap-dependent host factor in order to elicit antiviral activity.  
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Tag-free photoaffinity probes 
 One method to explore target identification is the use of photoaffinity probes.  In 
contrast to traditional biotinylated probes or affinity matrices, tag-free photoaffinity 
probes allow the testing of potential probes for similar activity in the same cell-based 
assay as the parent compound, identification of  targets low in quantity and/or affinity, 
and purification of the protein and ligand complex after cell lysis.
138
   A photoprobe for 
our project needs to be used in a live cell assay, and the compound must interact with the 
target in a similar fashion as the parent compound.  As the SAR becomes more defined, 
the proper location for the photolabile group can be identified where it does not 
compromise biological activity.  The probes first bind their target, and subsequent UV 
irradiation generates a new covalent bond between the probe and the target.  The cells are 
lysed and the complex may then be tagged with biotin using click chemistry and purified 
without dissociation using a streptavidin column.  The process we proposed to use for 
target identification using tag-free photoprobes is shown in Figure 24 using the 
synthesized photoprobe 126.     
 Photoprobes utilize reactive functional groups such as azides, diazirines, and 
benzophenones.
132
  Each of the functionalities has its own favorable characteristics as a 
probe.  Phenyl azides have been used the most in photoaffinity labeling. Its popularity is 
mainly from its small size and ease of introduction.
133, 139
  Its reactivity is dependent on 
the amino acid reacting with the azide.  Cysteine reacts the fastest while glycine is 
unreactive.
140
  However, azides do not give stoichiometric labeling.
141
    The low 
photolabeling yields may be caused by several factors.  First, the singlet nitrene 
intermediate upon irradiation interconverts to ketenimine azepine.  However, this 
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intermediate has high stability and is not ideal for rapid protein capturing (Figure 25).
142
  
Second, photoproducts may be unstable to degradation techniques.  Third, the wavelength 
necessary to excite azides (254 nm) may damage biological systems.
139
  Finally, the azide 
functionality itself may be unstable, especially to light.
143, 144
    
 Mechanistically, unsubstituted, benzyl azides covalently bind to proteins in two 
ways: the ketenimine azepine intermediate is nucleophilically attacked by amino and 
hydroxyl functionalities in proteins and a triplet nitrene reacts with •NH-, •O-, and •C- of 
proteins.  Both singlet and triplet nitrene intermediates of 4- tetrafluorophenyl azides may 
insert into CH, NH2, and OH bonds of proteins (Figure 25A).
139, 145, 146
 
 Upon excitement with ~350 nm wavelength, benzophenones generate a triplet 
diradical species.
147
  The stable radical intermediate abstracts α-hydrogens from amino 
acids (Figure 25C).
147
  Benzophenones abstract α-hydrogens at different rates: α to 
nitrogen > α to sulfur > allylic > methylene > methyl.  The lack of an abstractable proton 
results in the regeneration of the photoprobe.
132, 139, 148
  This reversible photoactivation 
allows for  higher yielding and more specific labeling.  
 Diazirines are small, non-bulky functionalities.  It has been shown that the 
position of the diazirine functionality in alkyl chains can have great effects on its 
photoreactivity.
149
  Diazirines have been shown to provide the NH-, CH, OH inserted 
products (Figure 25B).
139
 . 
An azide or acetylene group can be used as a clickable linker between the 
photoprobe and the biotin or fluorophore tag.  We chose to use a terminal acetylene group 
due to its higher lipophilicity relative to an azide group, allowing it to better penetrate the 
cellular membrane.  The terminal acetylene provides a synthetic handle for the Click 
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chemistry to occur in order to tag the target compound with biotin after photocrosslinking 
and cell lysis.
138
  Varying the position of the acetylene and the photolizeable group will 
maximize the chances of successfully labeling and isolating/visualizing the target.
150
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Figure 24:  Representative tag free photoaffinity probe sequence with 126 
(1) Live cell (2) photoprobe incubated with cell (3) Covalent bonding due to UV irradiation (4) Lyse 
cell (5) Click chemistry to tag compound with biotin or fluorophore (6) Purification and identification 
of target through LC/MS  
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Figure 25:  (A) azide (B) diazirine (C) benzophenone  photoprobes protein labeling mechanism.   
Figure adapted from Ref.  
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Synthesis 
 
 Several analogs exploring the optimum position of the propargyl group were 
synthesized.  Scheme 12 shows the synthesis of analog 120.  3-hydroxybenzyl alcohol 
(201) was selectively alkylated using propargyl bromide and cesium carbonate.  
Iodination in the presence of solid supported triphenylphosphine and iodine resulted in 
202.
151
  Solid supported triphenylphospine was used for ease of purification.  Ethyl-2-
indole carboxylate was alkylated with 202 to generate 203.  Subsequent saponification 
with sodium hydroxide and amide coupling with 190 resulted in analog 120.  Another 
analog 121 was synthesized through a peptide coupling using 176 and 190 (Scheme 13).  
Finally, alkylation of 50 with propargyl bromide generated analog 122 (Scheme 14).  
 
 
Scheme 12:  Synthesis of analog 120 
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 Two analogs were synthesized in order to examine the proper position of the 
photolabile group.  The photolabile functionalities chosen were diazirine and azide.  
Scheme 15 describes the synthesis of analog 123.  Indole 165 was coupled to ethyl 
isonipicote.  The resulting ester was demethylated using boron tribromide to generate 
206.  Intermediate 206 was TBDPS-protected.  Alkylation then proceeded in two steps.  
A Finkelstein reaction between 4-chlorobenzyl chloride and sodium iodide resulted in 4-
chlorobenzyl iodide.  The resulting alkyl iodide was used to alkylate the TBDPS 
protected 206.  This sequence of reactions resulted in intermediate 207.  Deprotection 
using TBAF and subsequent alkylation with diazirine 205, synthesized as described by 
 
Scheme 13:  Synthesis of analog 121 
 
 
Scheme 14:  Synthesis of analog 122 
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Dr. Bryan Yestrepsky, resulted in 208.
152
  Ester hydrolysis followed by amide coupling 
with 2-(pyridine-4-yl)ethan-1-amine resulted in analog 123.  
 
 Analog 124 synthesis began with the transformation of the boronic acid 210 to 
aryl azide 211 through a copper mediated azidation.
153
  Indole 155 was alkylated with 
 
Scheme 15:  Synthesis of analog 123 
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aryl azide 211 to give ester 212.  Hydrolysis of 212 followed by peptide coupling with 
synthon 190 resulted in 124 (Scheme 16).  
 
 Indole 172 was silyl protected using tert-butyldiphenylsilyl chloride.  The 
resulting protected indole was alkylated with 202 in the presence of cesium carbonate.  
TBAF deprotection and alkylation with diazirine 205 resulted in 216.  Hydrolysis 
followed by coupling with 190 resulted in photoprobe 125 (Scheme 17).   
  
 
Scheme 16:  Synthesis of analog 124 
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Compound 206 was silyl protected using TBDPSCl.  The silyl protected 206 was 
alkylated with 211.  TBAF deprotection followed by alkylation using propargyl bromide 
resulted in intermediate 218.  Hydrolysis followed by coupling with 2-(pyridine-4-yl) 
ethan-1-amine resulted in photoprobe 126 (Scheme 18).  
 
Scheme 17:  Synthesis of photoprobe 125 
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SAR development  
 Early in the SAR development, two benzophenone derivatives (127 and 128) were 
synthesized (Table 9).  Both of these compounds were inactive indicating that 
benzophenones in the carboxamide position were not well tolerated.  However, further 
SAR development led to compound 50.  It demonstrated that the presence of a 4-
pyridylethyl carboxamide motif was necessary for high potency.  Therefore, further 
photoprobe development contained such a motif.   
 First, it was necessary to explore both the position of the photolabile and the 
acetylene functionality.  Analogs 120-122 demonstrated that placement of the propargyl 
group on the N1-indole or 5-hydroxy indole position was tolerated by the target; 
 
Scheme 18:  Synthesis of photoprobe 126 
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however, N-propargylation of the carboxamide position was detrimental to activity.  
These results indicated that the propargyl group could be placed in the final photoprobes 
either on the N-benzyl group or the 5-hydroxy group with expectation that activity would 
be retained.  Considering the lack of information regarding the binding site of the target, 
it is possible that these inhibitors are binding in different modes.  Compound 121 (Table 
9) may be interacting through the 4-pyridylethyl amide in a hydrogen bonding network 
while the inactive dimethyl amide 102 (IC50 > 50 µM,   
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Table 4) binds the target through the 5-hydroxy indole position and the propargyl group 
is not sufficient in making optimal contacts with the target.    
 Secondly, the proper placement of the photolabile group is necessary for 
photolabeling success.  In the indole substitution SAR studies (Table 8), it was 
discovered that compound 113 (IC50 = .47 μM) and 116 (IC50 = 1.7 µM) maintained 
activity compared to 50 (IC50 = 0.5 µM).  Compound 113 suggested that a small aliphatic 
substitution in the 5-hydroxy indole position is tolerated.  The presence of a highly polar 
nitro group on the N1-benzyl group suggested a small, polar substitution such as an azide 
might be tolerated.   
 Direct comparisons of 50 containing photolabile groups at different positions (123 
and 124) were synthesized.  Both compounds maintained potency compared to 50; 
however, 123 gained substantial toxicity.  Regardless of the cytotoxicity, the azide and 
the diazirine at the N1-indole and 5-hydroxy indole positions, respectively, maintained 
activity.  Based on the preliminary SAR, the two photoprobes we elected to synthesize 
were 125 and 126.  Of these two, 126 was equipotent to 50 while 125 was about 10-fold 
less potent.  Compound 126 was therefore selected for initial target identification studies.    
Current status of target identification 
 This pilot experiment was performed by Dr. David Miller.  The experiment used 
BHK cells with or without replicon.  Probe 126 was examined at 2.5 µM and 25 µM.  
The initial experiment was performed with compound 50 at 25 µM as the competitor.  A 
larger excess of 50 is needed to effectively compete with the photoprobes to differentiate 
specific from non-specific labeling.  As the probes bind to various proteins and are 
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irradiated, they will bind to many different protein targets.  However, the large excess of 
50 will identify specific binding by competing off the probe; therefore, when irradiated,  
bands that are specifically labeled should decrease in intensity.   
An azide-biotin hapten was used for labeling.  An experimental difficulty that 
arose from using biotin as a tagging mechanism is that biotinylated cellular proteins are 
also going to be detected.  Figure 26 shows bands labeled with probe 126 at 25 µM in 
cells with or without replicon.  Possible targets are indicated with question marks.  The 
bands that are visible in the absence of probe identify cellular biotinylated compounds.  
In this preliminary experiment, it is clear that there was a very low overall level of 
labeling, suggesting that the conditions for photolabeling need to be carefully optimized 
in the future (e.g. irradiation time, wavelength, concentration of competitor, 
concentration of inhibitor, etc.).  Furthermore, the issue of biotinylated protein labeling 
could be avoided by using a fluorophore to simply visualize the labeled proteins or by 
using a streptavidin pull-down experiment before attaching the azide-biotin hapten label.  
Once we have successfully visualized bands that are decreased in intensity in the 
presence of competitor, we will repeat the experiment with Click biotinylation and 
protein isolation on a streptavidin column.  After bands are isolated, the target will be 
characterized by proteomics.  
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Conclusions 
 Dr. David Miller and his laboratory have determined that 50 and 140 inhibits 
virus replication by inhibiting a cap-dependent process targeting a host factor instead of a 
viral enzymatic protein.  These inhibitors are active against other RNA viruses, but not 
all.  Finally, preliminary target identification using tag-free photoaffinity probes have 
shown possible targets for 50 and related inhibitors.  
 
  
 
Figure 26:  Pilot target identification experiment with photoprobe 126 
*Figure provided by Dr. David Miller. 
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Table 9:  Photoaffinity probes 
  Structure 
IC50 
(µM)
a
 
CC50 
(µM)
b
 
50 205432 
 
0.5 ± 0.2 49.9 
120 212370 
 
1.9 ± 0.5 45.5 
121 212057 
 
3.1 ± 5.6 6.4 
122 212050 
 
10.9 
N=2 
59.4 
123 
 
 
 
222802 
 
 
 
 
0.55 ± 0.2 29.0 
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  Structure 
IC50 
(µM)
a
 
CC50 
(µM)
b
 
124 222881 
 
0.43 ± 0.1 45.1 
125 222700 
 
5.20 ± .69 89.9 
126 223882 
 
0.52 ± 0.12 >100 
127 208785 
 
>50 >50 
128* 208920 
 
57.0 >50 
a
Inhibition of luciferase expression in WEEV replicon assay. Ribavirin as positive control has an IC50 in the 
assay of 16 µM. Values are mean of at least n=3 independent experiments + SE.  
b
Cell viability determined 
by inhibition of mitochondrial reduction of MTT. Values are mean of at least 3 independent experiments.  
Data provided by Dr. David Miller and Craig Dobry.  *n=2   
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CHAPTER VII.     FUTURE DIRECTION 
Photoprobes 
Presently, the molecular target of our compounds remains unknown.  Even though 
two photoprobes have been synthesized that have similar potencies as the lead inhibitor 
50, preliminary results indicate low labeling efficiency.  Additional photolabile groups 
are available that may lead to more efficient target capture.  We would propose to prepare 
the two photoprobes in Figure 27.  The trifluoroethyldiazirinephenyl group has been 
shown to give higher yields for labeling proteins than its aliphatic ethyl diazirine 
counterpart.
154
  It efficiently inserts into both C-H and O-H bonds.
155
  This functionality 
is also stable in the presence of both mild acidic and basic environments.
156
  
Tetrafluorophenylazide photoprobes also show greater yields of labeling than simple 
benzyl azide analogs.
139, 157
  Both of these inhibitors generate intermediates that have 
greater lifetimes; therefore, increasing their chances in capturing proteins.       
 
 
Figure 27:  Fluorinated photoprobes 
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In vivo Survival Studies with Neuroprotective Agents.  
Presently, Dr. David Irani and Pennelope Blakely are examining the effects on 
survival and disease severity when mice are treated with compound 110 in combination 
with telmisartan, a neuroprotective agent.  Telmisartan is an antagonist of the renin-
angiotensin pathway, leading to angiotensin II inhibition.  Even though the angiotensin II 
dysregulation has been attributed to hypertension, it has also been shown to contribute to 
cerebrovascular inflammation through oxidative stress.
158
  This results in the decrease of 
the BBB integrity and increasing xenobiotic permeability into the CNS.  Angiotensin II is 
upregulated in neurons during viral infections.  It has been previously shown that 
angiotensin II blockade results in faster recovery from the West Nile Virus (WNV).
159
  
Therefore, regulating the angiotensin II expression in neurons is essential in developing 
neuroprotective agents.          
Chikungunya Virus 
 The Chikungunya Virus (CHIKV) is an alphavirus related to WEEV.  The virus is 
endemic in India, Southeast Asia, and most sub-Saharan Africa.
7
  However, the virus has 
emerged in the Caribbean and the United States.  Several factors may have contributed to 
the spread of the disease: urbanization, minimal mosquito control, and changing global 
demographics.
160
  CHIKV causes severe arthritis and maculopapular rash.  Joint pains 
may last for several months after the original infection.
7
  Since compound 50 and 140 
have been shown to inhibit replication in other  RNA viruses, it is possible that these 
inhibitors may also be active against CHIKV.  
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CHAPTER VIII.    EXPERIMENTALS 
All reagents were used as received from commercial sources unless otherwise noted.  
1
H 
and 
13
C spectra were obtained in DMSO-d6 or CDCl3 at room temperature, unless 
otherwise noted, on a Varian Inova 400 MHz, Varian Inova 500 MHz or Bruker Avance 
DRX 500 instruments.  Chemical shifts for the 
1
H NMR and 
13
C NMR spectra were 
recorded in parts per million (ppm) on the δ scale from an internal standard of residual 
tetramethylsilane (0 ppm).  Rotomers are described as a ratio of rotomer A and B if 
possible. Otherwise, NMR peaks are described as multiplets. Mass spectroscopy data 
were obtained on a Waters Corporation LCT.   HPLC retention times were recorded in 
minutes (min) using an Agilent 1100 Series with an Agilent Zorbax Eclipse Plus – C18 
column with the gradient 10% ACN/water (1 min), 10-90% ACN/water (6 min),  90% 
ACN/water (2 min), and 90-10% ACN/water (2 min)  (Gradient A).  Solvent 
abbreviations used:  MeOH (methanol), DCM (dichloromethane), EtOAc (ethyl acetate), 
Hex (hexanes), DMSO (dimethylsulfoxide), DMF (dimethylformamide),H2O (water), 
THF (tetrahydrofuran), ACN (acetonitrile). Reagent abbreviations used: HOBt (1-
hydroxy-1,2,3-benzotriazole), EDCI (N-(3-dimethylaminopropyl)-N’-ethylcarbodiimide 
hydrochloride), DIEA (diisopropylethylamine), PPh3 (triphenylphosphine), MgSO4 
(magnesium sulfate), Na2SO4 (sodium sulfate), NaHCO3 (sodium bicarbonate), Na2CO3 
(sodium carbonate), NH4Cl (ammonium chloride), K2HCO3 (potassium bicarbonate), 
K2CO3 (potassium carbonate), KOH (potassium hydroxide), HCl (hydrogen chloride).  
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Assay abbreviations:  LUC(luciferase), MTT ((3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide.   
Carboxamide Derivatives 
 
1-(4-Chlorobenzyl)-1H-indole-2-carboxylic acid (156):  Ethyl 1-(4-chlorobenzyl)-1H-
indole-2-carboxylate:  Ethyl 1H-indole-2-carboxylate 155 (1.50 g, 7.93 mmol) and 
potassium carbonate (1.42 g, 10.3 mmol) were dissolved in 10 mL of DMF.  A 5.0 mL 
DMF solution of 1-chloro-4-(chloromethyl)benzene (1.66 g, 10.3 mmol) was added.  The 
reaction was placed under nitrogen and heated at 60 
o
C for 24 hours.  The reaction was 
cooled to room temperature and diluted with water (50 mL) and extracted with ethyl 
acetate (80 mL).  The organic layers were combined, washed with saturated sodium 
chloride solution (100 mL x 3), dried over magnesium sulfate, and concentrated in vacuo 
to afford a tan solid.  Trituration with methanol afforded product as a white solid (1.8 g, 
72%).  TLC Rf (50% EA/Hex): 0.5. 
1
H NMR (400 MHz, DMSO-d6) δ = 7.74 (d, J = 8.0 
Hz, 1H), 7.59 (d, J = 8.5 Hz, 1H), 7.41-7.30 (m, 4H), 7.16 (t, J = 7.5 Hz, 1H), 7.04 (d, J = 
8.3 Hz, 2H), 5.85 (s, 2H), 4.29 (q, J = 7.1 Hz, 2H), 1.29 (t, J = 7.1 Hz, 3H). TOF ES+ 
MS:  314.0 (M+H), 336.0 (M+Na).  HPLC (gradient A): ret. time = 7.88 min; purity = 
>95%. 
Ethyl 1-(4-chlorobenzyl)-1H-indole-2-carboxylate and lithium hydroxide (1.53 g, 
63.9 mmol) were dissolved in 10 mL of THF and 20 mL of water. The reaction was 
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heated at 60 
o
C overnight.  The reaction was cooled and diluted with water and washed 
with diethyl ether. The aqueous solution was acidified using 2N HCl acid to pH 2.  The 
resulting suspension was extracted with ethyl acetate.  The organic layer was dried over 
magnesium sulfate, filtered, and concentrated in vacuo to obtain pure product as a white 
solid (1.47 g, 81%).  TLC Rf (50% EA.Hex): 0.2. 
1
H NMR (400 MHz, DMSO-d6) δ = 
13.02 (s, 1H), 7.72 (d, J = 8.0 Hz, 1H), 7.54 (d, J = 8.5 Hz, 1H), 7.37-7.26 (m, 4H), 7.14 
(t, J = 7.5 Hz, 1H), 7.05 (d, J = 5.6 Hz, 2H), 5.87 (s, 2H). TOF ES+ MS:  286.0 (M+H).  
HPLC (gradient A): ret. time = 7.88 min; purity = >95%. 
 
1-(1-(4-Chlorobenzyl)-1H-indole-2-carbonyl)piperidine-4-carboxylic acid (157): 
Ethyl 1-(1-(4-chlorobenzyl)-1H-indole-2-carbonyl)piperidine-4-carboxylate:  Compound 
156 (1.00 g, 3.50 mmol), EDCI (1.34 g, 6.99 mmol), and 1-hydroxybenzotriazole (0.946 
g, 7.00 mmol) were added to an oven dried RBF.  The solids were dissolved in 4.0 mL of 
DCM and allowed to stir at room temperature for 15 minutes.  Ethyl piperidine-4-
carboxylate (1.08 ml, 7.01 mmol) and DIEA (1.22 ml, 7.00 mmol) were added 
sequentially.  The reaction was allowed to stir overnight at room temperature.  The 
reaction was diluted with water and ethyl acetate.  The layers were separated. The ethyl 
acetate layer was washed with saturated sodium chloride.  The organic layer was dried 
over magnesium sulfate, filtered through a silica gel plug, and concentrated to obtain an 
oily product.  The crude material was triturated in ethyl acetate to obtain white solid as 
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the product.  (1.29 g, 87%) TLC Rf  (60% EA/Hex): 0.5. 
1
H NMR (400 MHz, DMSO-d6) 
δ   7.63-7.55 (m, 2H), 7.33-7.28 (m, 2H), 7.22 (t, J = 7.1 Hz, 1H), 7.12-7.02 (m, 3H), 
6.72 (s, 1H), 5.49 (s, 2H), 4.25 (s, 1H), 4.06 (q, J = 7.1, 4.2 Hz, 2H), 3.88 (s, 2H), 2.60-
2.52 (m, 1H), 1.75 (s, 2H), 1.44-1.01 (m, 6H). TOF ES+ MS:  286.0 (M+H).  HPLC 
(gradient A): ret. time = 7.88 min; purity = >95%. 
Ethyl 1-(1-(4-chlorobenzyl)-1H-indole-2-carbonyl)piperidine-4-carboxylate (4.2 
g, 9.8 mmol) and lithium hydroxide hydrate (4.1 g, 98 mmol) were dissolved in 10 mL of 
THF and 40 mL of water. The reaction was allowed to stir overnight. The reaction was 
diluted with water and diethyl ether.  The aqueous layer was washed with another aliquot 
of diethyl ether before it was acidified with 2N HCl to pH ~ 2.  The aqueous layer 
solution was washed with ethyl acetate (3 x 200 mL).  The ethyl acetate layers were 
combined and washed with saturated aqueous solution of sodium chloride, dried over 
magnesium sulfate, filtered and concentrated in vacuo to obtain the product as a white 
solid.  (3.33 g, 86%) TLC Rf (60% EA/Hex): 0.25. 
1
H NMR (400 MHz, DMSO-d6) δ  
12.30 (s, 1H), 7.66 (d, J = 7.9 Hz, 1H), 7.59 (d, J = 8.4 Hz, 1H), 7.35 (d, J = 8.4 Hz, 2H), 
7.25 (t, J = 11.4, 3.9 Hz, 1H), 7.16-7.09 (m, 3H), 6.75 (s, 1H), 5.52 (s, 2H), 4.29 (s, 1H), 
4.04 (s, 1H), 3.06 (s, 2H), 2.52-2.47 (m, 1H), 1.80 (s, 2H), 1.22 (s, 2H).  TOF ES+ MS:  
(M+H).  HPLC (gradient A): ret. time = 6.98 min; purity = >95%. 
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Representative Procedure for Carboxamide Analogs (Method A):   
1-(1-(4-Chlorobenzyl)-1H-indole-2-carbonyl)piperidine-4-carboxylic acid 157 (1.0 eq), 
EDCI (2.0 eq), and 1-hydroxybenzotriazole (2.0 eq) were dissolved in DCM (3.0 mL) 
and allowed to stir at room temperature for 15 minutes.  DIEA (2.0 eq) and desired amine 
(2.0 eq) were added.   The reaction was allowed to stir at room temperature overnight.  
The reaction was diluted with water and ethyl acetate.  The organic layer was washed 
with water, saturated sodium bicarbonate, 1N HCl, and saturated sodium chloride.  The 
organic layer was dried over magnesium sulfate, filtered, and concentrated in vacuo.  The 
crude material was recrystallized in diethyl ether/ethyl acetate to afford desired product. 
 
N-benzyl-1-(1-(4-chlorobenzyl)-1H-indole-2-carbonyl)piperidine-4-carboxamide 
(CCG 102516, 10):  Prepared by Method A using benzylamine.  TLC Rf (70% EA/Hex): 
0.2. 
1
H NMR (400 MHz, DMSO-d6) δ 8.35 (t, J = 5.9 Hz, 1H0, 7.63 (d, J = 7.9 Hz, 1H), 
7.55 (d, J = 8.3 Hz, 1H), 7.38-7.29 (m, 4H), 7.27-7.29 (m, 4H), 7.27-7.18 (m, 4H), 7.14-
7.08 (m, 3H), 6.74 (s, 1H), 5.50(s, 2H), 4.43 (bs, 1H), 4.28 (d, J = 5.9 Hz, 2H), 4.04 (bs, 
1H), 2.95 (bs, 2H), 2.48-2.42 (m, 2H), 1.74 (bs, 2H), 1.47 (bs, 2H). 
13
C NMR (500 MHz, 
DMSO-d6) 173.4, 161.8, 139.5, 137.1, 136.7, 131.7, 126.1, 123.0, 121.3, 120.1, 110.6, 
103.30. TOF ES+ MS:  486.1 (M+H), 508.0 (M+Na).  HPLC (gradient A): ret. time = 
7.73 min; purity = >95% 
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(S)-1-(1-(4-chlorobenzyl)-1H-indole-2-carbonyl)-N-(1-phenylethyl)piperidine-4-
carboxamide (CCG 203927, 11): Prepared by Method A using (S)-1-phenylethylamine.  
White solid (32.9 mg, 26%).  TLC Rf (70% EA/Hex): 0.2. 
1
H NMR (400 MHz, DMSO-
d6) δ 8.25 (d, J = 8.0 Hz, 1H), 7.62 (d, J = 7.9 Hz, 1H), 7.53 (d, J = 8.4 Hz, 1H), 7.35-
7.25 (m, 5H), 7.21 (t, J = 7.3 Hz, 2H), 7.09 (d, J = 7.7 Hz, 3H), 6.72 (s, 1H), 5.48 (s, 2H), 
4.97-4.82 (m, 1H), 4.42 (bs, 1H), 4.03 (bs, 1H), 2.89 (bs, 2H), 2.46-2.39 (m, 1H), 1.68 
(bs, 2H), 1.52-1.26 (m, 5H).  
13
C NMR (400 MHz, DMSO-d6)  172.6, 161.8, 144.8, 
137.1, 136.7, 131.8, 131.7, 128.7, 128.3, 128.1, 126.4, 126.1, 125.7, 123.0, 121.3, 120.1, 
110.6, 103.3, 47.4, 46.1, 41.4, 22.4.  TOF ES+ MS:  500.0 (M+H), 522.1 (M+Na).  
HPLC (gradient A): ret. time = 7.88 min; purity = >95%.  [CHN]  C = 71.8%, H = 
6.07%, N = 8.37 %.  Theoretical [CHN]:  C = 72.06%, 6.05%, 8.4%   
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(R)-1-(1-(4-chlorobenzyl)-1H-indole-2-carbonyl)-N-(1-phenylethyl)piperidine-4-
carboxamide (CCG 203926, 12):  Prepared by Method A using (R)-1-phenylethylamine.  
White solid (282 mg, 45%).  TLC Rf (70% EA/Hex): 0.2. 
1
H NMR (400 MHz, DMSO-
d6) δ 8.25 (d, J = 8.1 Hz, 1H), 7.62 (d, J = 7.9 Hz, 1H), 7.53 (d, J = 8.3 Hz, 1H),  7.36-
7.26 (m, 6H), 7.21 (t, J = 7.4 Hz, 2H), 7.10 (d, J = 8.2 Hz, 3H),  6.72 (s, 1H), 5.48 (s, 
2H), 4.90 (p, J = 7.1 Hz, 1H), 4.41 (bs, 1H), 4.03 (bs, 1H), 2.89 (bs, 2H), 2.47-2.38 (m, 
1H), 1.69 (bs, 2H), 1.52-1.25 (m, 5H).    
13
C NMR (400 MHz, DMSO-d6) 172.6, 161.8, 
144.7, 137.1, 136.7, 131.8, 131.7, 128.7, 128.3, 128.1, 126.4, 126.1, 125.7, 123.0, 121.3, 
120.1, 110.6, 103.3, 47.4, 46.1, 41.4, 22.4.  TOF ES+ MS:  500 (M+H), 522.1 (M+Na).  
HPLC (gradient A): ret. time = 7.87 min; purity = >95%  [CHN]  C = 71.93%, H = 
6.06%, N = 8.39%.  Theoretical [CHN]:  C = 72.06%, 6.05%, 8.4%.  
 
1-(1-(4-chlorobenzyl)-1H-indole-2-carbonyl)-N,N-dimethylpiperidine-4-
carboxamide (CCG 204022, 13). Prepared by Method A using dimethylamine.  Purified 
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by flash chromatography with a gradient of 100% DCM to 5% 7M ammonia in methanol 
diluted with 95% DCM. The product was obtained as a white solid. Yield: 68%. 1H 
NMR (400 MHz, DMSO- d6) δ 7.63 (d, J = 7.8 Hz, 1H), 7.54 (d, J = 8.4 Hz, 1H), 7.38 – 
7.27 (m, 2H), 7.26 – 7.17 (m, 1H), 7.13 – 7.08 (m, 3H), 6.73 (s, 1H), 5.50 (s, 2H), 4.44 
(bs, 1H), 3.99 (bs, 1H), 3.19 – 2.84 (m, 6H), 2.81 (s, 3H), 1.62 (bs, 2H), 1.36 (bs, 2H). 
TOF ES+ MS:  424.0 (M+H). HPLC ret. time  = 7.09 min; purity  > 95%. 
 
1-(1-(4-chlorobenzyl)-1H-indole-2-carbonyl)-N-(3-fluorobenzyl)piperidine-4-
carboxamide (CCG 206399, 14)  Prepared by Method A using (3-fluorophenyl) 
methanamine.  
1
H NMR (500 MHz, DMSO-d6) δ 8.40 (t, J = 6.0 Hz, 1H), 7.58 (dd, J = 
41.7, 8.1 Hz, 2H), 7.40 – 7.29 (m, 3H), 7.24 – 7.18 (m, 1H), 7.14 – 7.00 (m, 6H), 6.73 (s, 
1H), 5.49 (s, 2H), 4.59 – 4.21 (m, 3H), 4.00 (bs, 1H), 3.16 – 2.69 (m, 2H), 2.45 (tt, J = 
11.4, 3.7 Hz, 1H), 1.90 – 1.26 (m, 4H).  TOF ES+ MS:   504.9 (M+H).  HPLC (gradient 
A): ret. time = 7.80 min; purity > 95%  
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(1-(4-chlorobenzyl)-1H-indol-2-yl)(4-(4-methylpiperazine-1-carbonyl)piperidin-1-
yl)methanone (CCG 204023, 15). Prepared by Method A using 4-methylpiperazine. The 
crude material was purified by medium pressure chromatography using 100% DCM to 
5% 7M ammonia in MeOH/95% DCM. The product was obtained as a white solid. Yield: 
57%. 
1
H NMR (400 MHz, DMSO- d6) δ 7.62 (d, J = 7.9 Hz, 1H), 7.54 (d, J = 8.7 Hz, 
1H), 7.37 – 7.29 (m, 2H), 7.26 – 7.17 (m, 1H), 7.14 – 7.05 (m, 3H), 6.73 (s, 1H), 5.49 (s, 
2H), 4.52 – 3.90 (m, 2H), 3.57 – 3.39 (m, 4H), 3.19 – 2.78 (m, 3H), 2.39 – 2.11 (m, 7H), 
1.77 – 1.20 (m, 4H). TOF ES+ MS:  479.1 (M+H). HPLC ret. time  = 5.37 min; purity = 
92%. 
 
1-(1-(4-chlorobenzyl)-1H-indole-2-carbonyl)-N-(4-methoxybenzyl)piperidine-4-
carboxamide (CCG 204025, 16): Prepared by Method A using 4-methoxybenzylamine.  
Trituration in methanol afforded 16 as white solid (104 mg, 80%).  TLC Rf (70% 
EA/Hex): 0.2. 
1
H NMR (400 MHz, DMSO-d6).  δ 8.25 (t, J = 5.8 Hz, 1H), 7.57 (dd, J = 
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34.9, 8.1 Hz, 2H), 7.33 (d,  J = 8.4 Hz, 2H), 7.20 (t, J = 7.7 Hz, 1H),  7.11 (m, 4H), 6.86 
(d, J = 8.6 Hz, 2H), 6.72 (s, 1H), 5.48 (s, 2H), 4.43 (s, 1H), 4.18 (d, J = 5.8 Hz, 2H), 4.01 
(s, 1H), 3.71 (s, 3H), 2.93 (s, 2H), 2.41 (d, J = 11.7 Hz, 1H), 1.70 (s, 2H), 1.42 (s, 2H).  
TOF ES+ MS:  516.1 (M+H), 538.1 (M+Na).  HPLC (gradient A): ret. time = 8.27 min; 
purity = 91%.   
 
1-(1-(4-chlorobenzyl)-1H-indole-2-carbonyl)-N-phenylpiperidine-4-carboxamide 
(CCG 206334, 17): Prepared by Method A using aniline.  Compound 17 was obtained as 
a white solid (77 mg, 65%). TLC Rf (70% EA/Hex): 0.2. 
1
H NMR (400 MHz, DMSO-d6) 
δ  9.89 (s, 1H), 7.66-7.52 (m, 4H), 7.37-7.18 (m, 5H), 7.13-7.07 (m, 3H), 7.02 (t, J = 7.4 
Hz, 1H), 6.75 (s, 1H), 5.51(s, 2H), 4.45 (bs, 1H), 4.03 (bs, 1H), 2.95 (bs, 2H), 2.64-2.55 
(m, 1H), 1.79 (bs, 2H), 1.47 (bs, 2H).   TOF ES+ MS:  472.1 (M+H), 494.1 (M+Na).  
HPLC (gradient A): ret. time = 8.01 min; purity = >95%. 
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(S)-(1-(4-chlorobenzyl)-1H-indol-2-yl)(4-(2-(hydroxymethyl)pyrrolidine-1-
carbonyl)piperidin-1-yl)methanone (CCG 204021, 18). Prepared by Method A using 
L-prolinol.  The crude material was purified using flash chromatography with a gradient 
of 100% DCM to 5% 7M ammonia in methanol diluted with 95% DCM. The product was 
obtained as a white solid. Yield: 98%. 
1
H NMR (400 MHz, DMSO- d6) δ 7.62 (d, J = 8.1 
Hz, 1H), 7.58 – 7.50 (m, 1H), 7.39 – 7.30 (m, 2H), 7.26 – 7.17 (m, 1H), 7.17 – 7.05 (m, 
3H), 6.73 (s, 1H), 5.50 (s, 2H), 4.60 – 3.87 (m, 3H), 3.53 – 3.43 (m, 2H), 3.29 – 3.16 (m, 
1H), 3.14 – 2.77 (m, 2H), 2.72 – 2.64 (m, 1H), 1.98 – 1.19 (m, 8H). TOF ES+ MS:  480.1 
(M+H). HPLC ret. time  = 6.82 min; purity = 94%. 
 
(1-(4-chlorobenzyl)-1H-indol-2-yl)(4-(piperidine-1-carbonyl)piperidin-1-
yl)methanone (CCG 203928, 19):  Prepared by Method A using piperidine.  Flash 
chromatography with 0-5% methanolic ammonia: DCM afforded 19 as a white solid (48 
mg, 41%).   TLC Rf (0-5% methanolic ammonia: DCM): 0.2. 
1
H NMR (400 MHz, 
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DMSO-d6) δ 7.62 (d, J = 7.8 Hz, 1H), 7.54 (d, J = 8.3 Hz, 1H), 7.33 (d, J = 8.5 Hz, 2H), 
7.21 (t, J = 11.8, 4.6 Hz, 1H), 7.13-7.07 (m, 3H), 6.73 (s, 1H), 5.49 (s, 2H), 4.44 (bs, 1H), 
4.02 (bs, 1H), 3.43 (s, 4H), 3.20-3.83 (m, 3H), 1.79-1.20 (m, 10H).  TOF ES+ MS:  464.1 
(M+H), 486.1 (M+Na).  HPLC (gradient A): ret. time = 7.95 min; purity = >95%.   
 
1-(1-(4-chlorobenzyl)-1H-indole-2-carbonyl)-N,N-dimethylpiperidine-4-
carboxamide (CCG 204022, 20).  Prepared by Method A using dimethylamine as 
described for 20. Purified by flash chromatography with a gradient of 100% DCM to 5% 
7M ammonia in methanol diluted with 95% DCM. The product was obtained as a white 
solid. Yield: 68%. 1H NMR (400 MHz, DMSO- d6) δ 7.63 (d, J = 7.8 Hz, 1H), 7.54 (d, J 
= 8.4 Hz, 1H), 7.38 – 7.27 (m, 2H), 7.26 – 7.17 (m, 1H), 7.13 – 7.08 (m, 3H), 6.73 (s, 
1H), 5.50 (s, 2H), 4.44 (bs, 1H), 3.99 (bs, 1H), 3.19 – 2.84 (m, 6H), 2.81 (s, 3H), 1.62 
(bs, 2H), 1.36 (bs, 2H). TOF ES+ MS:  424.0 (M+H). HPLC ret. time  = 7.09 min; purity  
> 95%. 
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N-benzyl-1-(1-(4-chlorobenzyl)-1H-indole-2-carbonyl)-N-methylpiperidine-4-
carboxamide (CCG 203930, 21) Compound 157 (150 mg, 0.378 mmol), HOBt (102 mg, 
0.756 mmol), and EDCI (145 mg, 0.756 mmol) were dissolved in 1.5 mL of DCM. The 
reaction was allowed to stir for ten minutes before N-methyl-1-phenylmethanamine (45.8 
mg, 0.378 mmol) and DIEA (0.132 ml, 0.756 mmol) were added. The reaction was 
stirred for two days before it was diluted with water and ethyl acetate. The layers were 
separated and the organic layer was washed with the following saturated aqueous 
solutions: citric acid, sodium bicarbonate, and sodium chloride. The organic layer was 
dried over magnesium sulfate, filtered and concentrated.  The crude mixture was purified 
using 50% Ethyl Acetate/Hexanes. The product was obtained as a white solid. Yield:  64 
mg (34%). 
1
H NMR (400 MHz, DMSO- d6) 1.5:1 mixture of rotamers  δ 7.67 – 7.59 (m, 
1H), 7.58 – 7.50 (m, 1H), 7.41 – 7.17 (m, 8H), 7.14 – 7.07 (m, 3H), 6.75 (rotamer A, s), 
6.71 (rotamer B, s, 1H), 5.53 – 5.47 (m, 2H), 4.65 (rotamer A, s, 1H), 4.53 – 4.33 (m, 
2H), 4.01 (bs, 1H), 3.20 – 2.89 (m, 5H), 2.78 (rotamer B, s, 1H), 1.52 (bm, 4H). TOF 
ES+ MS:  500 (M+H). HPLC ret. time  = 8.23 min; purity = 94%   
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1-(1-(4-chlorobenzyl)-1H-indole-2-carbonyl)-N-(pyridin-4-ylmethyl)piperidine-4-
carboxamide (CCG 203929, 22): Prepared by Method A using 4-aminomethyl pyridine 
to afford 22  as a white solid (61 mg, 50%).  TLC Rf (100% EA): 0.1. 
1
H NMR (400 
MHz, DMSO-d6).  δ 8.68-8.59 (m, 4H), 7.63 (d, J = 7.8 Hz, 1H), 7.54 (d, J = 8.4 Hz, 
1H), 7.49 (d, J = 5.9 Hz, 4H), 7.36-7.30 (m, 3H), 7.22 (t, J = 7.6 Hz, 1H), 7.14-7.07 (m, 
2H), 6.74 (s, 1H), 5.49 (s, 2H), 4.56-4.14 (m, 4H), 2.97 (bs, 2H), 1.76 (bs, 2H), 1.43 (bs, 
2H).  TOF ES+ MS:  487.1 (M+H). HPLC (gradient A): ret. time = 8.00 min; purity = 
>95%. 
 
(1-(4-chlorobenzyl)-1H-indol-2-yl)(4-(pyrrolidine-1-carbonyl)piperidin-1-
yl)methanone (CCG 102514, 23).  Prepared by Method A using pyrrolidine.  Purified by 
flash chromatography with a gradient of 100% DCM to 5% 7M ammonia in methanol 
diluted with 95% DCM. The product was obtained as a white solid. Yield: 73%. 
1
H NMR 
(400 MHz, DMSO- d6) δ 7.63 (d, J = 7.8 Hz, 1H), 7.54 (d, J = 8.1 Hz, 1H), 7.38 – 7.30 
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(m, 2H), 7.26 – 7.17 (m, 1H), 7.16 – 7.05 (m, 3H), 6.73 (s, 1H), 5.50 (s, 2H), 4.63 – 3.86 
(m, 2H), 3.47 (t, J = 6.7 Hz, 2H), 3.27 (t, J = 6.9 Hz, 2H), 3.13 – 2.80 (m, 2H), 2.77 – 
2.64 (m, 1H), 1.87 (p, J = 6.7 Hz, 2H), 1.81 – 1.27 (m, 6H). TOF ES+ MS:  450.0 
(M+H). HPLC ret. time  = 7.35 min; purity > 95%. 
 
N-benzyl-1-(1-(4-chlorobenzyl)-1H-indole-2-carbonyl)piperidine-3-carboxamide 
(CCG 205483, 24):  Compound 156 (100 mg, 0.319 mmol), EDC (134 mg, 0.699 mmol) 
and 1-hydroxybenzotriazole (95.0 mg, 0.703 mmol) were dissolved in DCM (Volume: 
3.0 ml).  The reaction was allowed to stir for 10 minutes before the addition of DIEA 
(0.122 ml, 0.700 mmol) and ethyl piperidine-3-carboxylate (0.109 ml, 0.707 mmol).  The 
reaction was allowed to stir overnight at room temperature. The reaction was diluted with 
water and ethyl acetate.  The organic phase was washed with water, 1N HCl, saturated 
sodium bicarbonate, and saturated sodium chloride.  The organic layer was dried over 
magnesium sulfate, filtered, and concentrated in vacuo. The crude material was purified 
using Biotage SP1 system with 0-45% ethyl acetate/hexanes to afford ethyl 1-(1-(4-
chlorobenzyl)-1H-indole-2-carbonyl)piperidine-3-carboxylate as white solid. (100 mg, 
67%)  TLC Rf (60% EA/Hex): 0.5. 
1
H NMR (400 MHz, DMSO-d6).  δ 7.63 (d, J = 7.9 
Hz, 1H), 7.55 (d, J = 8.3 Hz, 1H), 7.33 (d, J = 8.4 Hz, 2H), 7.22 (t, J = 7.3 Hz, 1H), 7.16-
7.06 (m, 3H), 6.73 (s, 1H), 5.46 (s, 2H), 4.47 – 3.63 (m, 5H), 3.29-2.70 (m, 2H), 1.94-
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1.03 (m, 4H). TOF ES+ MS:  425.1(M+H), 447.1 (M+Na). HPLC (gradient A): ret. time 
= 8.36 min; purity = >95%.  
Ethyl 1-(1-(4-chlorobenzyl)-1H-indole-2-carbonyl)piperidine-3-carboxylate (100 
mg, 0.235 mmol) and solid lithium hydroxide (99 mg, 2.4 mmol) were dissolved in 1.5 
mL of THF and 3.0 mL of water.   The reaction was allowed to stir overnight.  After 24 
hours at room temperature, the reaction was diluted with water and extracted twice with 
diethyl ether.  The aqueous layer was acidified with 2N HCl aqueous solution to pH 2 
and extracted with three times with ethyl acetate.  The organic layers were combined and 
washed with saturated sodium chloride solution, dried over magnesium sulfate, filtered 
and concentrated in vacuo to obtain a white solid. The crude material was taken directly 
to the next step without further purification.  (50 mg, 53%) TLC Rf (60% EA/Hex): 0.2.  
1
H NMR (400 MHz, DMSO-d6) δ 12.26 (s, 1H), 7.63 (d, J = 7.9 Hz, 1H), 7.54 (d, J = 8.4 
Hz, 1H), 7.33 (d, J = 8.4 Hz, 2H), 7.22 (t, J = 7.6 Hz, 1H), 7.16-7.04 (m, 3H) 6.73 (s, 
1H), 5.46 (s, 2H), 4.21 (s, 1H), 3.94 (s, 1H), 3.02 (s, 2H), 1.99 (s, 1H), 1.96-1.52 (m, 2H), 
1.40-0.97 (m, 2H).  TOF E+ MS:  397.1 (M+H), 419.1 (M+Na).  HPLC (gradient A): ret. 
time = 6.98 min; purity = >95%  
CCG 205483 (24) was prepared by Method A using 1-(1-(4-chlorobenzyl)-1H-
indole-2-carbonyl)piperidine-3-carboxylic acid and benzylamine.  Flash chromatography 
with 0-5% methanolic ammonia: DCM afforded 24 as a white solid (38 mg, 62%).  TLC 
Rf (70% EA/Hex): 0.2. 
1
H NMR (400 MHz, DMSO-d6).  δ  8.44 (s, 1H), 7.60 (d,  J = 7.9 
Hz, 1H), 7.49 (s, 1H), 7.36-7.03 (m, 12H), 6.72 (s, 1H), 5.46 (s, 2H), 4.58-3.74 (m, 4H), 
2.93 (bs, 2H), 2.30 (s, 1H), 1.93-1.48 (m, 3H). TOF ES+ MS:  486.1 (M+H), 508.1 
(M+Na). HPLC (gradient A): ret. time = 7.99 min; purity = >95%. 
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1-(1-(4-chlorobenzyl)-1H-indole-2-carbonyl)-N-(pyridin-3-ylmethyl)piperidine-4-
carboxamide (CCG 205422, 30): Prepared by Method A using 3-aminomethyl pyridine 
to afford 30  as a white solid (315 mg, 70%).  TLC Rf (100% EA): 0.1.  
1
H NMR (400 
MHz, DMSO-d6) - 8.49 (m, 2 H), 8.39 (t, J=5.8 Hz, 1 H), 7.68 (d, J=7.8 Hz, 
1 H), 7.59 (d, J=7.8 Hz, 1 H), 7.51 (d, J=8.4 Hz, 1 H), 7.39 (dd, J=7.5, 5.0 Hz, 1 H), 7.33 
– 7.26 (m, 2 H), 7.18 (t, J=7.6 Hz, 1 H), 7.04 - 7.11 (m, 3 H), 6.70 (s, 1 H), 5.46 (s, 2 H), 
3.84 - 4.59 (m, 4 H), 2.92 (br. s., 2 H), 2.42 (tt, J =11.2, 3.9 Hz, 1 H), 1.27 - 1.82 (m, 4 H)  
TOF ES+ MS:  487.1 (M+H). HPLC (gradient A): ret. time = 5.62 min; purity = >95%. 
 
(R)-1-(1-(4-chlorobenzyl)-1H-indole-2-carbonyl)-N-(1-(pyridin-4-yl)ethyl)piperidine-
4-carboxamide  (CCG 212090, 31). Prepared by Method A using (R)-1-(pyridin-4-
yl)ethanamine.  The crude solid was recrystallized using diethyl ether/ethyl acetate. The 
product was obtained as a white solid after filtration. Yield: 55%. 
1
H NMR (500 MHz, 
DMSO- d6) δ 8.51 – 8.46 (m, 2H), 8.37 (d, J = 7.7 Hz, 1H), 7.62 (d, J = 7.9 Hz, 1H), 7.54 
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(d, J = 8.3 Hz, 1H), 7.36 – 7.25 (m, 4H), 7.25 – 7.18 (m, 1H), 7.13 – 7.06 (m, 3H), 6.73 
(s, 1H), 5.48 (s, 2H), 4.88 (p, J = 7.2 Hz, 1H), 4.44 (bs, 1H), 4.02 (bs, 1H), 3.13 – 2.70 
(m, 2H), 2.50 – 2.44 (m, 1H), 1.85 – 1.30 (m, 7H). TOF ES+ MS:  501.2  (M+H). HPLC 
ret. time  = 5.62 min; purity >95% . 
 
1-(1-(4-chlorobenzyl)-1H-indole-2-carbonyl)-N-(1-(pyridin-4-yl)ethyl)piperidine-4-
carboxamide (CCG 206329, 32): Prepared by Method A using 1-(pyridin-4-
yl)ethanamine .  Crude material was triturated with ether and ethyl acetate and filtered to 
obtain 27a as a white solid. Yield: 37.9 mg, 30%   
1
H NMR (400 MHz, DMSO-d6) δ 8.52 
– 8.45 (m, 2H), 8.35 (d, J = 7.7 Hz, 1H), 7.62 (d, J = 7.8 Hz, 1H), 7.53 (d, J = 8.8 Hz, 
1H), 7.37 – 7.17 (m, 5H), 7.14 – 7.05 (m, 3H), 6.72 (s, 1H), 5.48 (s, 2H), 4.87 (p, J = 7.1 
Hz, 1H), 4.03 (m, 2H), 2.95 (bs, 2H), 2.49 – 2.42 (m, 1H), 1.79 – 1.28 (m, 7H). TOF ES+ 
MS:  501.2  (M+H). HPLC ret. time  = 5.73 min; purity >95% . 
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1-(1-(4-chlorobenzyl)-1H-indole-2-carbonyl)-N-((1-methyl-1H-imidazol-4-
yl)methyl)piperidine-4-carboxamide (CCG 205455, 33). Prepared by Method A using 
(1-methyl-1H-imidazol-4-yl)methanamine. The crude material was triturated with ether 
and ethyl acetate and filtered to obtain white solid as a product. Yield: 23%.  
1
H NMR 
(400 MHz, DMSO- d6) δ 8.07 (t, J = 5.5 Hz, 1H), 7.62 (d, J = 7.9 Hz, 1H), 7.53 (d, J = 
8.3 Hz, 1H), 7.46 (s, 1H), 7.38 – 7.30 (m, 2H), 7.26 – 7.16 (m, 1H), 7.15 – 7.05 (m, 3H), 
6.87 (s, 1H), 6.73 (s, 1H), 5.49 (s, 2H), 4.49 – 3.92 (m, 4H), 3.32 (s, 3H), 2.90 (bs, 2H), 
2.48 – 2.36 (m, 1H), 1.78 – 1.33 (m, 4H). TOF ES+ MS:  490.1 (M+H). HPLC ret. time  
= 5.48 min; purity > 95%.  
 
1-(1-(4-chlorobenzyl)-1H-indole-2-carbonyl)-N-((1-methyl-1H-pyrazol-3-
yl)methyl)piperidine-4-carboxamide (CCG 205454, 34). Prepared by Method A using 
(1-methyl-1H-pyrazol-3-yl)methanamine. The crude product was triturated with ethyl 
acetate to obtain white solid as the product. Yield: 18%.  
1
H NMR (400 MHz, DMSO- 
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d6) δ 8.17 (t, J = 5.7 Hz, 1H), 7.66 – 7.50 (m, 3H), 7.38 – 7.29 (m, 2H), 7.25 – 7.16 (m, 
1H), 7.15 – 7.05 (m, 3H), 6.72 (s, 1H), 6.04 (d, J = 2.2 Hz, 1H), 5.49 (s, 2H), 4.17 (m, 
4H), 3.76 (s, 3H), 2.92 (bs, 2H), 2.47 – 2.37 (m, 1H), 1.81 – 1.23 (m, 4H). TOF ES+ MS:  
490.1 (M+H). HPLC ret. time  = 6.62 min; purity = 94% . 
 
1-(1-(4-chlorobenzyl)-1H-indole-2-carbonyl)-N-((1-methylpiperidin-4-
yl)methyl)piperidine-4-carboxamide (CCG 205429, 35).  Prepared by Method A using 
(1-methylpiperidin-4-yl)methanamine.  The crude product was triturated with diethyl 
ether/ethyl acetate to afford the product as a white solid. Yield:  65%. 
1
H NMR (400 
MHz, DMSO- d6) δ 7.79 (t, J = 5.8 Hz, 1H), 7.62 (d, J = 7.9 Hz, 1H), 7.54 (d, J = 8.0 Hz, 
1H), 7.38 – 7.29 (m, 2H), 7.26 – 7.17 (m, 1H), 7.15 – 7.05 (m, 3H), 6.72 (s, 1H), 5.49 (s, 
2H), 4.61 – 3.82 (m, 2H), 2.99 – 2.73 (m, 4H), 2.44 – 2.30 (m, 1H), 2.19 (s, 3H), 1.96 – 
1.05 (m, 13H). TOF ES+ MS:  507.1 (M+H). HPLC ret. time  = 5.41 min; purity > 95% . 
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1-(1-(4-chlorobenzyl)-1H-indole-2-carbonyl)-N-((6-oxo-1,2,3,6-tetrahydropyridin-3-
yl)methyl)piperidine-4-carboxamide (CCG 211760, 36). Prepared by Method A using 
5-(aminomethyl)pyridin-2(1H)-one.   Yield: 33 mg, 26 %. 
1
H NMR (500 MHz, DMSO-
d6) δ 11.42 (br. s., 1 H), 8.18 (t, J=5.5 Hz, 1 H), 7.58 (dd, J=33.0, 7.8 Hz, 2 H), 7.27 - 
7.37 (m, 3 H), 7.16 - 7.25 (m, 2 H), 7.04 - 7.14 (m, 3 H), 6.72 (s, 1 H), 6.30 (d, J=9.5 Hz, 
1 H), 5.49 (br. s., 2 H), 4.44 (br. s., 1 H), 3.78 - 4.17 (m, 3 H), 2.70 - 3.10 (m, 2 H), 2.39 
(tt, J=11.3, 3.6 Hz, 1 H), 1.18 - 1.86 (m, 4 H).  TOF ES+ MS: 503.2 (M+H); 525.2 
(M+Na).  HPLC (gradient A): ret. time = 6.00 min; purity > 95 % 
 
1-(1-(4-chlorobenzyl)-1H-indole-2-carbonyl)-N-((2-methoxypyridin-4-
yl)methyl)piperidine-4-carboxamide (CCG 208787, 37)  Prepared by Method A using 
(2-methoxypyridin-4-yl)methanamine.  Yield:  60 mg, 41 %.  
1
H NMR (400 MHz, 
DMSO-d6) δ 8.41 (t, J=6.2 Hz, 1 H), 8.07 (d, J=5.1 Hz, 1 H), 7.59 (dd, J=26.0, 7.6 Hz, 2 
H), 7.29 - 7.37 (m, 2 H), 7.18 - 7.26 (m, 1 H), 7.06 - 7.14 (m, 3 H), 6.83 (d, J=5.3 Hz, 1 
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H), 6.74 (s, 1 H), 6.61 (s, 1 H), 5.49 (s, 2 H), 4.44 (br. s, 1 H), 4.24 (d, J=6.1 Hz, 2 H), 
4.07 (br. s., 1 H), 3.82 (s, 3 H), 2.91 (br. s., 2 H), 2.46 (tt, J=9.8, 3.9 Hz, 1 H), 1.27 - 1.89 
(m, 4 H).  TOF ES+ MS:  516.9 (M+H), 538.9 (M+Na). HPLC (gradient A): ret. time = 
6.62 min; purity = 94 % 
 
(1-(4-chlorobenzyl)-1H-indol-2-yl)(4-(4-methylpiperazine-1-carbonyl)piperidin-1-
yl)methanone (CCG 204023, 38). Prepared by Method A using 4-methylpiperazine.  
The crude material was purified by medium pressure chromatography using 100% DCM 
to 5% 7M ammonia in MeOH/95% DCM. The product was obtained as a white solid. 
Yield: 57%. 
1
H NMR (400 MHz, DMSO- d6) δ 7.62 (d, J = 7.9 Hz, 1H), 7.54 (d, J = 8.7 
Hz, 1H), 7.37 – 7.29 (m, 2H), 7.26 – 7.17 (m, 1H), 7.14 – 7.05 (m, 3H), 6.73 (s, 1H), 5.49 
(s, 2H), 4.52 – 3.90 (m, 2H), 3.57 – 3.39 (m, 4H), 3.19 – 2.78 (m, 3H), 2.39 – 2.11 (m, 
7H), 1.77 – 1.20 (m, 4H). TOF ES+ MS:  479.1 (M+H). HPLC ret. time  = 5.37 min; 
purity = 92%. 
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(1-(4-chlorobenzyl)-1H-indol-2-yl)(4-(morpholine-4-carbonyl)piperidin-1-
yl)methanone (CCG 204024, 39). Prepared by Method A using morpholine.  Purified by 
flash chromatography with a gradient of 100% DCM to 5% 7M ammonia in methanol 
diluted with 95% DCM. The product was obtained as a white solid. Yield: 73%. 1H 
NMR (400 MHz, DMSO- d6) δ 7.63 (d, J = 7.8 Hz, 1H), 7.54 (d, J = 8.4 Hz, 1H), 7.37 – 
7.29 (m, 2H), 7.26 – 7.17 (m, 1H), 7.14 – 7.05 (m, 3H), 6.73 (s, 1H), 5.49 (s, 2H), 4.43 
(bs, 1H), 4.01 (bs, 1H), 3.58 – 3.38 (m, 8H), 3.11 – 2.85 (m, 3H), 1.77 – 1.20 (m, 4H). 
TOF ES+ MS:  466.1 (M+H). HPLC ret. time  = 7.00 min; purity > 95%. 
 
1-(1-(4-chlorobenzyl)-1H-indole-2-carbonyl)-N-((4-(pyridin-3-ylmethyl)piperazin-1-
yl)methyl)piperidine-4-carboxamide (CCG 205430, 40) Prepared by Method A using 
1-(pyridin-3-ylmethyl)piperazine. Yield:  105 mg, 75% 
1
H NMR (400 MHz, DMSO-d6) δ 
8.47 (d, J=1.8 Hz, 1 H), 8.45 (dd, J=4.9, 1.8 Hz, 1 H), 7.68 (dt, J=7.5, 1.9 Hz, 1 H), 7.47 
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- 7.62 (m, 2 H), 7.27 - 7.36 (m, 3 H), 7.14 - 7.22 (m, 1 H), 7.03 - 7.11 (m, 3 H), 6.70 (s, 1 
H), 5.46 (s, 2 H), 4.36 (br. s., 1 H), 4.00 (br. s., 1 H), 3.38 - 3.56 (m, 6 H), 2.75 - 3.12 (m, 
3 H), 2.21 - 2.40 (m, 5 H), 1.22 - 1.76 (m, 4 H).  TOF ES+ MS:  556.1 (M+H).  HPLC 
(gradient A): ret. time = 5.73 min.; purity > 95%  
  
1-(1-(4-chlorobenzyl)-1H-indole-2-carbonyl)-N-(2-(pyridin-4-yl)ethyl)piperidine-4-
carboxamide (CCG 205432, 50). Prepared by Method A using 2-(pyridin-4-
yl)ethanamine. The crude material was triturated with ethyl acetate to afford the product 
as a white solid. Yield:  328 mg, 80%. 
1
H NMR (500 MHz, DMSO- d6) δ 8.48 – 8.42 (m, 
2H), 7.89 (t, J = 5.5 Hz, 1H), 7.63 (d, J = 7.8 Hz, 1H), 7.54 (d, J = 8.5 Hz, 1H), 7.37 – 
7.30 (m, 2H), 7.25 – 7.18 (m, 3H), 7.13 – 7.07 (m, 3H), 6.71 (s, 1H), 5.48 (s, 2H), 4.53 – 
3.82 (m, 2H), 3.32 – 3.29 (m, 2H), 3.08-2.67 (m, 4H), 2.36 – 2.27 (m, 1H), 1.75 – 1.18 
(m, 4H). 
13
C NMR (500 MHz, DMSO-d6) 226.99, 183.03, 173.53, 161.90, 149.39, 
148.39, 137.21, 136.81, 131.91, 131.80, 128.80, 128.49, 126.16, 124.27, 123.15, 121.41, 
120.27, 110.67, 103.40, 46.13, 41.42, 38.79, 34.20, 14.12, 14.09 [CHN]  C = 69.28%, H 
= 5.88%, N = 11.23%. Theoretical [CHN]: C = 69.52%, H = 5.83%, N = 11.18% TOF 
ES+ MS:  501.0 (M+H). HPLC ret. time  = 5.50 min; purity >95%.  
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1-(1-(4-chlorobenzyl)-1H-indole-2-carbonyl)-N-methyl-N-(2-(pyridin-4-
yl)ethyl)piperidine-4-carboxamide (CCG 211761, 51). Prepared by Method A using N-
methyl-2-(pyridin-4-yl)ethanamine.  The resulting crude material was purified using SP1 
Biotage chromatography with a 25 g silica cartridge and a gradient of 20% ethyl 
acetate/hexanes to 100% ethyl acetate.  The product was obtained as a white solid. Yield: 
32%.  
1
H NMR (400 MHz, DMSO- d6) 1.3:1 mixture of rotamers δ 8.49 – 8.45 (m, 2H), 
7.64 – 7.61 (m, 1H), 7.54 (t, J = 10Hz, 1H), 7.35 – 7.30 (m, 3H), 7.24-7.19 (m, 2H), 7.12 
– 7.08 (m, 3H), 6.72 (rotamer A, s), 6.70 (rotamer B, s, 1H), 4.50 – 4.75 (m, 2H), 4.41 
(bs, 1H), 3.97 (bs, 1H), 3.63 (t, J = 6.8 Hz, 1H), 3.53 (t, J = 7.3 Hz, 1H),  3.09 - 2.69 (m, 
8H), 2.84- 2.50 (m, 1H), 1.17 – 1.10 (m, 4H). TOF ES+ MS:  515.3 (M+H). HPLC ret. 
time  = 5.84 min; purity > 95%. 
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1-(1-(4-chlorobenzyl)-1H-indole-2-carbonyl)-N-(4-methylphenethyl)piperidine-4-
carboxamide  (CCG 102518, 52):  Prepared by Method A using 4-methyl 
phenethylamine.  Flash chromatography with 0-5% methanolic ammonia: DCM afforded 
52 as a white solid (24 mg, 19%).   TLC Rf (0-5% methanolic ammonia: DCM): 0.25. 
1
H 
NMR (400 MHz, DMSO-d6).  δ 7.86 (t, J = 5.5 Hz, 1H), 7.64 (d, J = 8.0 Hz, 1H), 7.56 
(d, J = 8.3 Hz, 1H),  7.35 (d, J = 8.4 Hz, 2H), 7.23 (t, J = 7.6 Hz, 1H), 7.14-7.03 (m, 7H), 
6.73 (s, 1H), 5.50 (s, 2H), 4.40 (bs, 1H), 3.91 (bs, 1H), 3.24 (q, J = 12.0, 6.3 Hz, 2H), 
2.90 (bs, 2H), 2.66 (t, J = 7.3 Hz, 2H), 2.40-2.30 (m, 1H), 2.27 (s, 3H), 1.65 (bs, 2H), 
1.36 (bs, 2H).  TOF ES+ MS:  514.1 (M+H), 536.1 (M+Na). HPLC (gradient A): ret. 
time = 8.15 min; purity = >95%. 
 
1-(1-(4-chlorobenzyl)-1H-indole-2-carbonyl)-N-(2-(pyridin-3-yl)ethyl)piperidine-4-
carboxamide (CCG 205433, 53). Prepared by Method A using 2-(pyridin-3-
125 
 
yl)ethanamine-HCl.  The reaction was diluted with water and ethyl acetate. The organic 
layer was washed with saturated sodium bicarbonate, 10% aqeuous citric acid solution, 
followed by saturated sodium chloride solution. The organic layer was dried over 
magnesium sulfate, filtered and concentrated. The resulting solid was triturated with ethyl 
acetate to obtain the product as a white solid. Yield: 20%. 
1
H NMR (400 MHz, DMSO- 
d6) δ 8.44 – 8.37 (m, 2H), 7.88 (t, J = 5.7 Hz, 1H), 7.66 – 7.50 (m, 3H), 7.38 – 7.26 (m, 
3H), 7.26 – 7.17 (m, 1H), 7.14 – 7.06 (m, 3H), 6.71 (s, 1H), 5.48 (s, 2H), 4.63 – 3.80 (m, 
2H), 3.34 – 3.25 (m, 2H), 2.89 (bs, 2H), 2.73 (t, J = 7.0 Hz, 2H), 2.38 – 2.27 (m, 1H), 
1.74 – 1.21 (m, 4H). TOF ES+ MS:  501.0 (M+H), 523.1 (M+Na). HPLC ret. time  = 
5.46 min; purity >95%.  
 
1-(1-(4-chlorobenzyl)-1H-indole-2-carbonyl)-N-(2-(pyridin-4-yl)propyl)piperidine-4-
carboxamide  (CCG 206580, 54). Prepared by Method A using 2-(pyridin-4-yl)propan-
1-amine.  The crude material was triturated in ethyl acetate to obtain product. Yield: 
40%.  
1
H NMR (500 MHz, CDCl3) δ 8.58 – 8.52 (m, 2H), 7.68 – 7.61 (m, 1H), 7.37 – 
7.31 (m, 1H), 7.31 – 7.10 (m, 5H), 7.06 – 6.99 (m, 2H), 6.62 (s, 1H), 5.46 (s, 2H), 5.31 (t, 
J = 5.1 Hz, 1H), 4.68 – 3.98 (m, 3H), 3.64 – 3.54 (m, 1H), 3.37 – 3.26 (m, 1H), 3.04 – 
2.96 (m, 1H), 2.88 – 2.81 (m, 1H), 2.22 – 2.13 (m, 1H), 1.85 – 1.20 (m, 6H). TOF ES+ 
MS:  515.1 (M+H). HPLC ret. time  = 5.80 min; purity = 85%  . 
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1-(1-(4-chlorobenzyl)-1H-indole-2-carbonyl)-N-(2-methyl-2-(pyridin-4-
yl)propyl)piperidine-4-carboxamide (CCG 209022, 55).  Prepared by Method A using 
2-methyl-2-(pyridin-4-yl)propan-1-amine.  The crude material was triturated in ethyl 
acetate. The white solid was filtered to obtain product. Yield: 23%.  
1
H NMR (500 MHz, 
DMSO- d6) δ 8.49 – 8.45 (m, 2H), 7.69 – 7.59 (m, 2H), 7.53 (d, J = 8.5 Hz, 1H), 7.36 – 
7.31 (m, 4H), 7.25 – 7.17 (m, 1H), 7.14 – 7.06 (m, 3H), 6.71 (s, 1H), 5.48 (s, 2H), 4.55 – 
3.79 (m, 2H), 3.28 (d, J = 6.2 Hz, 2H), 2.88 (bs, 2H), 2.42 – 2.34 (m, 1H), 1.67 – 1.19 
(m, 10H). TOF ES+ MS:  529.3 (M+H). HPLC ret. time  = 6.01 min; purity > 95%.  
 
1-(1-(4-chlorobenzyl)-1H-indole-2-carbonyl)-N-phenethylpiperidine-4-carboxamide 
(CCG 206397, 56): Prepared by Method A using 2-phenethylamine.  White solid (76 mg, 
60%). TLC Rf (70% EA/Hex): 0.2. 
1
H NMR (400 MHz, DMSO-d6) δ 7.85 (t, J = 5.4 Hz, 
1H), 7.62 (d, J = 7.8 Hz, 1H), 7.53 (d, J = 8.4 Hz, 1H), 7.36-7.05 (m, 10H), 6.71 (s, 1H), 
5.48 (s, 2H), 4.38 (bs, 1H), 4.01 (bs, 1H), 3.26 (q, J = 13.6, 6.7 Hz, 2H), 2.90 (bs, 2H), 
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2.69 (t, J = 13.6, 6.5 Hz, 2H), 2.39-2,28 (m, 2H), 1.61 (bs, 2H), 1.36 (bs, 2H).  TOF ES+ 
MS:  500.2 (M+H), 522.1 (M+Na).  HPLC (gradient A): ret. time = 7.90 min; purity = 
>95%. 
 
1-(1-(4-chlorobenzyl)-1H-indole-2-carbonyl)-N-(2-(pyridin-2-yl)ethyl)piperidine-4-
carboxamide (CCG 205456, 57 ).  Prepared by Method A using 2-(pyridin-2-
yl)ethanamine. The crude material was triturated with ether and ethyl acetate and filtered 
to obtain the product as a white solid. Yield:  10%. 
1
H NMR (400 MHz, DMSO- d6) δ 
8.52 – 8.45 (m, 1H), 7.87 (t, J = 5.6 Hz, 1H), 7.72 – 7.66 (m, 1H), 7.63 (d, J = 7.9 Hz, 
1H), 7.54 (d, J = 8.3 Hz, 1H), 7.38 – 7.30 (m, 2H), 7.25 – 7.17 (m, 3H), 7.14 – 7.05 (m, 
3H), 6.72 (s, 1H), 5.49 (s, 2H), 4.52 – 3.78 (m, 2H), 3.40 (q, J = 6.9 Hz, 2H), 3.08 – 2.76 
(m, 4H), 2.38 – 2.29 (m, 1H), 1.74 – 1.23 (m, 4H). TOF ES+ MS:  501.1 (M+H), 523.1 
(M+Na). HPLC ret. time  = 5.51 min; purity >95% 
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1-(1-(4-chlorobenzyl)-1H-indole-2-carbonyl)-N-(4-chlorophenethyl)piperidine-4-
carboxamide (CCG 206400, 58).  Prepared by Method A using 2-(4-
chlorophenyl)ethanamine.  The crude material was triturated in ethyl acetate to give the 
product as a white solid. Yield: 45%.  
1
H NMR (400 MHz, DMSO- d6) δ 7.85 (t, J = 5.7 
Hz, 1H), 7.63 (d, J = 7.8 Hz, 1H), 7.54 (d, J = 8.4 Hz, 1H), 7.37 – 7.30 (m, 4H), 7.26 – 
7.17 (m, 3H), 7.14 – 7.06 (m, 3H), 6.71 (s, 1H), 5.49 (s, 2H), 4.54 – 3.86 (m, 2H), 3.26 
(q, J = 6.7 Hz, 2H), 2.90 (bs, 2H), 2.69 (t, J = 7.1 Hz, 2H), 2.36 – 2.30 (m, 1H), 1.76 – 
1.22 (m, 4H). TOF ES+ MS:  534.1 (M+H), 556.1 (M+Na). HPLC ret. time  = 8.25 min; 
purity > 95%. 
 
1-(1-(4-chlorobenzyl)-1H-indole-2-carbonyl)-N-(4-fluorophenethyl)piperidine-4-
carboxamide (CCG 206396, 59) Prepared by Method A using 2-(4-
fluorophenyl)ethanamine.  The crude material was triturated with ethyl acetate to obtain 
product as a white solid. Yield: 85%. 
1
H NMR (400 MHz, DMSO- d6) δ 7.84 (t, J = 5.7 
Hz, 1H), 7.62 (d, J = 7.9 Hz, 1H), 7.54 (d, J = 8.4 Hz, 1H), 7.37 – 7.30 (m, 2H), 7.26 – 
7.17 (m, 3H), 7.14 – 7.05 (m, 5H), 6.71 (s, 1H), 5.49 (s, 2H), 4.52 – 3.78 (m, 2H), 3.25 
(q, J = 6.9 Hz, 2H), 2.91 (bs, 2H), 2.69 (t, J = 7.2 Hz, 2H), 2.38 – 2.28 (m, 1H), 1.62 (bs, 
2H), 1.36 (bs, 2H).  TOF ES+ MS:  518.1 (M+H), 540.1 (M+Na). HPLC ret. time  = 7.91 
min; purity > 95%. 
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1-(1-(4-chlorobenzyl)-1H-indole-2-carbonyl)-N-(4-methoxyphenethyl)piperidine-4-
carboxamide (CCG 206398, 60).  Prepared by Method A using 2-(4-
methoxyphenyl)ethanamine.  The crude material was triturated with ethyl acetate to 
obtain product as a white solid. Yield: 63%. 
1
H NMR (400 MHz, DMSO- d6) δ 7.83 (t, J 
= 5.6 Hz, 1H), 7.63 (d, J = 7.8 Hz, 1H), 7.54 (d, J = 8.4 Hz, 1H), 7.37 – 7.30 (m, 2H), 
7.26 – 7.17 (m, 1H), 7.14 – 7.05 (m, 6H), 6.88 – 6.81 (m, 2H), 6.71 (s, 1H), 5.49 (s, 2H), 
4.49 – 3.84 (m, 2H), 3.71 (s, 3H), 3.22 (q, J = 6.8 Hz, 2H), 2.91 (bs, 2H), 2.63 (t, J = 7.3 
Hz, 2H), 2.39 – 2.28 (m, 1H), 1.62 (bs, 2H), 1.37 (bs, 2H). TOF ES+ MS:  530.1 (M+H), 
552.1 (M+Na). HPLC ret. time  = 7.81 min; purity > 95%.  
 
1-(1-(4-chlorobenzyl)-1H-indole-2-carbonyl)-N-(3-methoxyphenethyl)piperidine-4-
carboxamide (CCG 206395, 61). Prepared by Method A using 2-(3-
methoxyphenyl)ethanamine.  The crude material was triturated with ethyl acetate to 
obtain product as a white solid. Yield: 67%. 
1
H NMR (400 MHz, DMSO- d6) δ 7.85 (t, J 
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= 5.6 Hz, 1H), 7.63 (d, J = 7.8 Hz, 1H), 7.54 (d, J = 8.4 Hz, 1H), 7.37 – 7.30 (m, 2H), 
7.26 – 7.14 (m, 2H), 7.14 – 7.06 (m, 3H), 6.78 – 6.73 (m, 3H), 6.71 (s, 1H), 5.49 (s, 2H), 
4.51 – 3.86 (m, 2H), 3.72 (s, 3H), 3.26 (q, J = 6.7 Hz, 2H), 2.94 (s, 2H), 2.67 (t, J = 7.2 
Hz, 2H), 2.37 – 2.30 (m, 1H), 1.62 (s, 2H), 1.37 (s, 2H). TOF ES+ MS:  530.1 (M+H), 
552.1 (M+Na). HPLC ret. time  = 7.86 min; purity > 95%. 
 
1-(1-(4-chlorobenzyl)-1H-indole-2-carbonyl)-N-(4-isopropylphenethyl)piperidine-4-
carboxamide (CCG 206461, 62).  Prepared by Method A using 2-(4-
isopropylphenyl)ethanamine.  The crude material purified using medium pressure silica 
gel chromatography with a gradient of 0-60% ethyl acetate/hexanes to obtain product as a 
white solid. Yield: 37%.  
1
H NMR (500 MHz, DMSO- d6) δ 7.89 (t, J = 5.7 Hz, 1H), 7.62 
(d, J = 7.9 Hz, 1H), 7.55 (d, J = 8.3 Hz, 1H), 7.37 – 7.31 (m, 2H), 7.26 – 7.18 (m, 1H), 
7.17 – 7.07 (m, 7H), 6.71 (s, 1H), 5.49 (s, 2H), 4.52 – 3.83 (m, 2H), 3.24 (q, J = 6.9 Hz, 
2H), 3.10 – 2.75 (m, 3H), 2.66 (t, J = 7.4 Hz, 2H), 2.39 – 2.31 (m, 1H), 1.85 – 1.10 (m, 
10H). TOF ES+ MS:  542.2 (M+H), 564.1 (M+Na). HPLC ret. time  = 8.71 min; purity > 
95%. 
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1-(1-(4-chlorobenzyl)-1H-indole-2-carbonyl)-N-(3-(pyridin-4-yl)propyl)piperidine-4-
carboxamide (CCG 208788, 63). Prepared by Method A using 3-(pyridin-4-yl)propan-
1-amine.  The crude solid was triturated with ethyl acetate, giving a white solid. Yield: 40 
mg, 31%.  
1
H NMR (400 MHz, DMSO- d6) δ 8.48 – 8.41 (m, 2H), 7.85 (t, J = 5.6 Hz, 
1H), 7.62 (d, J = 7.9 Hz, 1H), 7.54 (d, J = 8.4 Hz, 1H), 7.37 – 7.30 (m, 2H), 7.26 – 7.17 
(m, 3H), 7.14 – 7.05 (m, 3H), 6.72 (s, 1H), 5.49 (s, 2H), 4.41 (bs, 2H), 4.14 – 3.99 (m, 
4H), 3.10 – 2.75 (m, 4H), 2.62 – 2.50 (m, 2H), 2.38 – 2.30 (m, 1H), 1.77 – 1.64 (m, 4H), 
1.49 – 1.25 (m, 2H). TOF ES+ MS:  514.9 (M+H). HPLC ret. time  = 5.58 min; purity > 
95%   
 
1-(1-(4-chlorobenzyl)-1H-indole-2-carbonyl)-N-((2,3-dihydrofuro[2,3-c]pyridin-3-
yl)methyl)piperidine-4-carboxamide (CCG 206581, 64). Prepared by Method A using 
(2,3-dihydrofuro[2,3-c]pyridin-3-yl)methanamine.  The crude material was triturated in 
ethyl acetate, filtered and concentrated to obtain a white solid. Yield: 50%. 
1
H NMR (500 
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MHz, DMSO- d6) δ 8.14 – 8.06 (m, 3H), 7.63 (d, J = 7.9 Hz, 1H), 7.55 (d, J = 8.3 Hz, 
1H), 7.37 – 7.28 (m, 4H), 7.25 – 7.18 (m, 1H), 7.14 – 7.06 (m, 2H), 6.72 (s, 1H), 5.49 (s, 
2H), 4.63 – 4.55 (m, 1H), 4.39 – 4.32 (m, 2H), 4.14 – 3.87 (m, 2H), 3.73 – 3.63 (m, 1H), 
3.17 (d, J = 5.3 Hz, 1H), 2.86 – 2.82 (m, 2H), 2.40 – 2.34 (m, 1H), 1.76 – 1.15 (m, 4H). 
TOF ES+ MS:  529.1 (M+H). HPLC ret. time  = 5.78 min; purity > 95%.  
 
N-((1H-indazol-4-yl)methyl)-1-(1-(4-chlorobenzyl)-1H-indole-2-carbonyl)piperidine-
4-carboxamide (CCG 215061, 70)  Prepared by Method A using (1H-indazol-4-
yl)methanamine.  Product isolated as white solid.  Yield: 32 %. 
1
H NMR (500 MHz, 
DMSO-d6) δ ppm 13.09 (s, 1 H), 8.43 (t, J=6.1 Hz, 1 H), 8.00 - 8.20 (m, 1 H), 7.63 (d, 
J=8.1 Hz, 1 H), 7.54 (d, J=8.3 Hz, 1 H), 7.42 (d, J=8.3 Hz, 1 H), 7.32 - 7.37 (m, 2 H), 
7.25 - 7.30 (m, 1 H), 7.19 - 7.24 (m, 1 H), 7.08 - 7.14 (m, 3 H), 6.95 (d, J=6.8 Hz, 1 H), 
6.73 (s, 1 H), 5.49 (d, J=0.5 Hz, 2 H), 3.89 - 4.65 (m, 4 H), 2.68 - 3.12 (m, 2 H), 2.46 (tt, 
J=11.2, 3.9 Hz, 1 H), 1.30 - 1.90 (m, 4 H).  TOF ES+ MS:  526.2 (M+H), 548.1 (M+Na). 
HPLC (gradient A): ret. time = 6.85 min; purity > 95 % 
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N-(2-(1H-pyrrolo[2,3-b]pyridin-3-yl)ethyl)-1-(1-(4-chlorobenzyl)-1H-indole-2-
carbonyl)piperidine-4-carboxamide (CCG 222940, 71)  Prepared by Method A using 
2-(1H-pyrrolo[2,3-b]pyridin-3-yl)ethan-1-amine.  Product isolated as white solid.  Yield: 
20 %.  
1
H NMR (500 MHz, DMSO-d6) δ ppm 11.34 (s, 1 H), 8.18 (dd, J=4.6, 1.7 Hz, 1 
H), 7.84 - 8.01 (m, 2 H), 7.63 (d, J=7.8 Hz, 1 H), 7.54 (d, J=8.5 Hz, 1 H), 7.29 - 7.40 (m, 
2 H), 7.15 - 7.29 (m, 2 H), 7.06 - 7.15 (m, 3 H), 7.03 (dd, J=7.8, 4.6 Hz, 1 H), 6.72 (s, 1 
H), 5.49 (s, 2 H), 4.40 (br. s., 1 H), 3.96 (br. s., 1 H), 3.31 (q, J=7.1 Hz, 1 H), 2.73 - 3.09 
(m, 4 H), 2.34 (tt, J=11.1, 3.5 Hz, 1 H), 1.24 - 1.81 (m, 4 H).  TOF ES+ MS:  540.1 
(M+H).   HPLC (gradient A): ret. time = 5.84 min; purity > 95 % 
 
 
1-(1-(4-chlorobenzyl)-1H-indole-2-carbonyl)-N-(3,4-dichlorophenethyl)piperidine-4-
carboxamide (CCG 222720, 72)  Prepared by Method A using 2-(3,4-
dichlorophenyl)ethan-1-amine. Isolated product as white solid. Yield: 37%  
1
H NMR 
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(500 MHz, DMSO-d6) δ ppm 7.85 (t, J=5.5 Hz, 1 H), 7.63 (d, J=8.1 Hz, 1 H), 7.54 (dd, 
J=8.3, 3.2 Hz, 2 H), 7.44 - 7.48 (m, 1 H), 7.34 (d, J=8.3 Hz, 2 H), 7.16 - 7.25 (m, 2 H), 
7.07 - 7.13 (m, 3 H), 6.71 (s, 1 H), 5.49 (br. s., 2 H), 4.40 (br. s., 1 H), 3.95 (br. s., 1 H), 
3.28 (q, J=6.8 Hz, 2 H), 2.99 (br. s., 1 H), 2.84 (br. s., 1 H), 2.71 (t, J=6.8 Hz, 2 H), 2.32 
(tt, J=11.2, 3.9 Hz, 1 H), 1.17 - 1.77 (m, 4 H).  TOF ES+ MS:  568.0 (M+H), 590.0 
(M+Na).  HPLC (gradient A): ret. time = 8.41 min; purity > 95%   
 
N-(3-(1H-pyrazol-4-yl)propyl)-1-(1-(4-chlorobenzyl)-1H-indole-2-
carbonyl)piperidine-4-carboxamide (CCG 222760, 73)  Prepared by Method A using 
3-(1H-pyrazol-4-yl)propan-1-amine.  Product isolated as white solid.  Yield: 35 %.  
1
H 
NMR (500 MHz, DMSO-d6) δ ppm 12.51 (brs, 1 H), 7.81 (t, J=5.5 Hz, 1 H), 7.52 - 7.64 
(m, 2 H), 7.49 (brs, 1 H), 7.28 - 7.36 (m, 3 H), 7.19 - 7.24 (m, 1 H), 7.07 - 7.13 (m, 3 H), 
6.72 (s, 1 H), 5.49 (brs, 2 H), 4.41 (brs, 1 H), 4.02 (brs, 1 H), 2.76 - 3.10 (m, 4 H), 2.31 - 
2.44 (m, 3 H), 1.32 - 1.83 (m, 7 H).  TOF ES+ MS:   504.3 (M+H).  HPLC (gradient A): 
ret. time = 6.02 min; purity > 95 %. 
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N-(2-(1H-indol-3-yl)ethyl)-1-(1-(4-chlorobenzyl)-1H-indole-2-carbonyl)piperidine-4-
carboxamide (CCG222900, 74)  Prepared by Method A using 2-(1H-indol-3-yl)ethan-1-
amine. Product isolated as white solid.  Yield: 30 %.  
1
H NMR (500 MHz, DMSO-d6) δ 
10.80 (s, 1H), 7.91 (t, J = 5.6 Hz, 1H), 7.63 (d, J = 7.9 Hz, 1H), 7.54 (t, J = 7.2 Hz, 2H), 
7.37 – 7.30 (m, 3H), 7.22 (t, J = 7.4 Hz, 1H), 7.15 – 7.08 (m, 4H), 7.06 (t, J = 7.2 Hz, 
1H), 6.97 (t, J = 7.3 Hz, 1H), 6.72 (s, 1H), 5.49 (s, 2H), 4.54 – 3.81 (m, 2H), 3.32 (q, J = 
7.0, 6.4 Hz, 2H), 3.07 – 2.76 (m, 4H), 2.36 (tt, J = 11.2, 3.5 Hz, 1H), 1.74 – 1.26 (m, 4H).  
TOF ES+ MS:  539.1 (M+H). HPLC (gradient A): ret. time = 7.69 min; purity > 95 % 
 
N-((1H-indazol-5-yl)methyl)-1-(1-(4-chlorobenzyl)-1H-indole-2-carbonyl)piperidine-
4-carboxamide (CCG 215060, 75)  Prepared by Method A using (1H-indazol-5-
yl)methanamine.  Isolated product as white solid.  Yield: 53%.  
1
H NMR (500 MHz, 
DMSO-d6) δ ppm 13.00 (s, 1 H), 8.35 (t, J=6.0 Hz, 1 H), 8.02 (t, J=1.3 Hz, 1 H), 7.63 (d, 
J=7.8 Hz, 1 H), 7.58 (s, 1 H), 7.54 (d, J=8.3 Hz, 1 H), 7.48 (d, J=8.8 Hz, 1 H), 7.32 - 7.37 
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(m, 2 H), 7.19 - 7.26 (m, 2 H), 7.07 - 7.14 (m, 3 H), 6.73 (s, 1 H), 5.49 (s, 2 H), 4.26 - 
4.58 (m, 3 H), 4.00 (br. s., 1 H), 2.73 - 3.10 (m, 2 H), 2.45 (tt, J=11.2, 3.7 Hz, 1 H), 1.30 - 
1.89 (m, 4 H).  TOF ES+ MS:  526.2 (M+H), 548.1 (M+Na).  HPLC (gradient A): ret. 
time = 6.74 min; purity > 95%  
 
1-(1-(4-chlorobenzyl)-1H-indole-2-carbonyl)-N-(2-(1-methyl-1H-pyrazol-4-
yl)ethyl)piperidine-4-carboxamide (CCG 215080, 76)  Prepared by Method A using 2-
(1-methyl-1H-pyrazol-4-yl)ethan-1-amine.  Isolated product as white solid.  Yield: 45 %.   
1
H NMR (500 MHz, DMSO-d6) δ ppm 7.86 (t, J=5.7 Hz, 1 H), 7.63 (dt, J=8.1, 1.0 Hz, 1 
H), 7.54 (dd, J=8.3, 0.7 Hz, 1 H), 7.46 (s, 1 H), 7.32 - 7.36 (m, 2 H), 7.20 - 7.24 (m, 2 H), 
7.09 - 7.13 (m, 3 H), 6.72 (d, J=0.7 Hz, 1 H), 5.49 (s, 2 H), 4.41 (br. s., 1 H), 3.97 (br. s., 
1 H), 3.76 (s, 3 H), 3.12 - 3.21 (m, 2 H), 2.75 - 3.09 (m, 2 H), 2.50 (m, 2H), 2.35 (tt, 
J=11.3, 3.7 Hz, 1 H), 1.22 - 1.82 (m, 4 H).  TOF ES+ MS:   504.1 (M+H), 526.1 (M+Na).  
HPLC (gradient A): ret. time = 6.45 min; purity > 95 % 
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N-(2-(1H-imidazol-1-yl)ethyl)-1-(1-(4-chlorobenzyl)-1H-indole-2-
carbonyl)piperidine-4-carboxamide (CCG 206582, 77).  Prepared by Method A using 
2-(1H-imidazol-1-yl)ethanamine-HCl.  The resulting crude solid was triturated with ethyl 
acetate to give a white solid. Yield: 18%. 
1
H NMR (500 MHz, DMSO- d6) δ 7.94 (t, J = 
5.6 Hz, 1H), 7.63 (d, J = 7.9 Hz, 1H), 7.57 – 7.51 (m, 2H), 7.37 – 7.31 (m, 2H), 7.25 – 
7.18 (m, 1H), 7.13 – 7.06 (m, 4H), 6.87 (s, 1H), 6.71 (s, 1H), 5.49 (s, 2H), 4.39 (s, 1H), 
4.07 – 3.99 (m, 3H), 3.39 – 3.31 (m, 2H), 2.93 (bs, 2H), 2.39 – 2.29 (m, 1H), 1.79 – 1.20 
(m, 4H). TOF ES+ MS:  490.1 (M+H). HPLC ret. time  = 5.69 min; purity = 90%. 
 
N-(2-(1H-pyrazol-4-yl)ethyl)-1-(1-(4-chlorobenzyl)-1H-indole-2-carbonyl)piperidine-
4-carboxamide (CCG 215153, 78)  Prepared by Method A using 2-(1H-pyrazol-4-
yl)ethan-1-amine.  Product obtained as white solid.  Yield: 43 %. 
1
H NMR (500 MHz, 
DMSO-d6) δ ppm 12.53 (br. s., 1 H), 7.87 (t, J=5.5 Hz, 1 H), 7.63 (d, J=7.8 Hz, 1 H), 
7.54 (d, J=8.3 Hz, 1 H), 7.42 (br. s., 1 H), 7.32 - 7.36 (m, 2 H), 7.18 - 7.25 (m, 1 H), 7.07 
- 7.14 (m, 3 H), 6.72 (s, 1 H), 5.49 (s, 2 H), 4.42 (br. s., 1 H), 3.98 (br. s., 1 H), 3.19 (q, 
J=7.0 Hz, 2 H), 2.71 - 3.09 (m, 2 H), 2.55 (t, J=7.3 Hz, 2 H), 2.36 (tt, J=11.4, 3.8 Hz, 1 
H), 1.25 - 1.84 (m, 4 H).  TOF ES+ MS:  489.9 (M+H), 511.9 (M+Na).  HPLC (gradient 
A): ret. time = 5.90 min; purity > 95% 
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N1-indole derivatives 
 
Ethyl 1-(1H-indole-2-carbonyl)piperidine-4-carboxylate (160).  Ethyl 1H-indole-2-
carboxylate (155, 3.0 g, 16 mmol) and lithium hydroxide, H2O (3.3 g, 79 mmol) were 
dissolved in 2/1 water/THF (30 mL). The reaction was stirred overnight. The reaction 
was diluted with water and diethyl ether. The water layer was washed with diethyl ether 
twice. The aqueous layer was acidified to pH 2 using 2N HCl. The suspension was 
extracted using ethyl acetate. The organic layer was washed with saturated sodium 
chloride solution, dried over magnesium sulfate, filtered and concentrated to obtain 1H-
Indole-2-carboxylic acid   as a white solid. Yield: 2.39 g, 94%. 
1
H NMR (400 MHz, 
DMSO- d6) δ 12.95 (s, 1H), 11.74 (s, 1H), 7.67 – 7.60 (m, 1H), 7.47 – 7.39 (m, 1H), 7.28 
– 7.19 (m, 1H), 7.11 – 7.01 (m, 2H).   
1H-indole-2-carboxylic acid (2.49 g, 15.45 mmol), EDCI (4.44 g, 23.18 mmol), 
and HOBt (3.55 g, 23.18 mmol) were dissolved in THF (30 mL). The reaction was 
allowed to stir for 15 minutes before DIEA (4.05 ml, 23.18 mmol) and ethyl piperidine-4-
carboxylate (3.57 mL, 23.18 mmol) were added to the reaction. The reaction was diluted 
with water and ethyl acetate. The organic layer was washed with saturated sodium 
bicarbonate, 1M HCl, and saturated sodium chloride. The organic layer was then dried 
over magnesium sulfate, filtered and concentrated. The resulting solid was triturated with 
ethyl acetate to obtain the product as a white solid. Yield: 3.27 g, 71%.  
1
H NMR (400 
MHz, DMSO- d6) δ 11.55 (s, 1H), 7.60 (d, J = 8.1 Hz, 1H), 7.41 (d, J = 8.2 Hz, 1H), 7.22 
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– 7.13 (m, 1H), 7.08 – 7.00 (m, 1H), 6.80 – 6.74 (m, 1H), 4.34 (dt, J = 13.4, 3.9 Hz, 2H), 
4.09 (q, J = 7.1 Hz, 2H), 3.18 (bs, 2H), 2.76 – 2.64 (m, 1H), 1.99 – 1.88 (m, 2H), 1.65 – 
1.50 (m, 2H), 1.20 (t, J = 7.1 Hz, 3H). 
 
N-benzyl-1-(1H-indole-2-carbonyl)-N-methylpiperidine-4-carboxamide (90) Ester 
160 (3.0 g, 10 mmol) and lithium hydroxide, H2O (4.19 g, 100 mmol)) were dissolved 
inTHF (Ratio: 1, Volume: 20 ml)and Water (Ratio: 2, Volume: 40.0 ml) and allowed to 
stir overnight at room temperature. The reaction was diluted with water, and extracted 
with diethyl ether. The aqueous layer was acidified using 2N HCl to pH ~2. A fine, white 
suspension resulted. The aqueous layer was extracted with ethyl acetate twice. The 
combined ethyl acetate layers were dried over magnesium sulfate, filtered and 
concentrated to afford the 1-(1H-indole-2-carbonyl)piperidine-4-carboxylic acid as a 
white solid. Yield:  678 mg, 25%.  
1
H NMR (400 MHz, DMSO- d6) δ 12.33 (s, 1H), 
11.54 (s, 1H), 7.60 (d, J = 8.0 Hz, 1H), 7.41 (d, J = 7.5 Hz, 1H), 7.22 – 7.13 (m, 1H), 
7.08 – 6.99 (m, 1H), 6.79 – 6.74 (m, 1H), 4.32 (d, J = 13.3 Hz, 2H), 3.17 (bs, 1H), 2.65 – 
2.54 (m, 1H), 1.96 – 1.87 (m, 2H), 1.63 – 1.49 (m, 2H). HPLC ret. time  = 5.31 min; 
purity > 95%.  
1-(1H-indole-2-carbonyl)piperidine-4-carboxylic acid (1.00g, 3.67 mmol), EDCI 
(1.408 g, 7.34 mmol), and HOBt hydrate (1.125 g, 7.34 mmol) were dissolved in DCM 
(10 ml). The reaction was allowed to stir for 10 minutes before adding DIEA (1.283 ml, 
7.34 mmol) and N-methyl-1-phenylmethanamine (0.836 ml, 7.34 mmol). The reaction 
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was allowed to stir overnight at room temperature. The reaction was diluted with water 
and ethyl acetate. The organic phase was washed with saturated sodium bicarbonate, 1N 
HCl, and saturated sodium chloride solution. The organic layer was dried over 
magnesium sulfate, filtered and concentrated. The crude material was purified by silica 
gel chromatography using 30% to 60% ethyl acetate: hexanes to obtain product as a white 
solid. Yield: 1.03 g, 75%  
1
H NMR (400 MHz, DMSO- d6) 1.7:1 mixture of rotamers δ 
11.59 – 11.53 (m, 1H), 7.64 – 7.56 (m, 1H), 7.45 – 7.13 (m, 7H), 7.09 – 6.99 (m, 1H), 
6.78 (rotamer A, s), 6.75 (rotamer B, s, 1H), 4.69 (rotamer A, s, 1H), 4.54 – 4.37 (m, 3H), 
3.28 – 2.92 (m, 5H), 2.79 (rotamer B, s, 1H), 1.86 – 1.77 (m, 1H), 1.75 – 1.55 (m, 3H). 
TOF ES+ MS:  376.2 (M+H), 398.1 (M+Na). HPLC ret. time  = 6.10 min; purity = 93%. 
 
N-benzyl-1-(1-isobutyl-1H-indole-2-carbonyl)-N-methylpiperidine-4-carboxamide 
(CCG 206332, 80). Compound 90  (100 mg, 0.27 mmol) was dissolved in 1.0 mL of 
DMF and added to a suspension of sodium hydride (12.8 mg, 0.32 mmol) in 2.0 mL of 
DMF. The reaction was stirred at 80 °C for 10 minutes before adding 1-iodo-2-
methylpropane  (0.061 mL, 0.53 mmol). The reaction was allowed to stir overnight. After 
18 hours, the reaction was cooled to room temperature before diluting with water and 
ethyl acetate. The organic phase was washed with water followed by saturated sodium 
chloride, dried over magnesium sulfate, filtered and concentrated. The crude material was 
purified via column chromatography using 50% ethyl acetate/hexanes to 100% ethyl 
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acetate. The purification provided the product as a white solid. Yield:  28 mg (25%).  
1
H 
NMR (400 MHz, DMSO- d6) δ 7.64 – 7.50 (m, 2H), 7.42 – 7.15 (m, 6H), 7.12 – 7.03 (m, 
1H), 6.67 (rotamer A, s), 6.64 (rotamer B, s, 1H), 4.67 (rotamer A, s, 1H), 4.60-4.26 (s, 
3H), 4.24-3.98 (m, 2H), 3.00 (s, 5H), 2.79 (s, 1H), 2.06 – 1.92 (m, 1H), 1.78 (bs, 1H), 
1.72 – 1.49 (m, 3H), 0.84 – 0.71 (m, 6H). TOF ES+ MS:  432.2 (M+H), 454.2 (M+Na). 
HPLC ret. time  = 7.80 min; purity = 94%.  
 
N-benzyl-1-(1-(4-methoxybenzyl)-1H-indole-2-carbonyl)-N-methylpiperidine-4-
carboxamide (CCG 205477, 81) Compound 90 (100 mg, 0.266 mmol) was added to a 
suspension of sodium hydride (12.8 mg, 0.32 mmol) in THF (1.5 mL). The reaction was 
stirred for 10 minutes before 1-(bromomethyl)-4-methoxybenzene (0.039 mL, 0.27 
mmol) was added. The reaction was allowed to stir at room temperature overnight. The 
reaction was diluted with water and extracted with ethyl acetate. The organic layer was 
washed with water and saturated sodium chloride solution. It was dried over magnesium 
sulfate, filtered and concentrated. The crude material was purified by flash 
chromatography using a gradient of 50% - 100% ethyl acetate in hexanes to obtain the 
product as a white solid. Yield: 42 mg (32%). 
1
H NMR (400 MHz, DMSO- d6) 1.7:1 
mixture of rotamers δ 7.66 – 7.57 (m, 2H), 7.40 – 7.04 (m, 8H), 6.85-6.81(m, 3H), 6.69 
(rotamer A, s), 6.65 (rotamer B, s, 1H), 5.46 – 5.39 (m, 2H), 4.64 (rotamer A, s, 1H), 
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4.53-4.20 (m, 2H), 3.97 (bs, 1H), 3.69-3.66(m, 3H), 3.19 – 2.83 (m, 5H), 2.78 (rotamer 
B, s, 1H), 1.82 – 1.24 (m, 4H). TOF ES+ MS:  496.1  (M+H), 518.1 (M+Na). HPLC ret. 
time  = 7.83 min; purity = 92%. 
 
N-benzyl-N-methyl-1-(1-(pyridin-4-ylmethyl)-1H-indole-2-carbonyl)piperidine-4-
carboxamide (CCG 208789, 82)  Pyridin-4-ylmethanol (180 mg, 1.65 mmol) and TEA 
(0.22 mL, 1.6 mmol) were dissolved in THF (7 mL) and cooled to 0 °C. Methanesulfonyl 
chloride (0.125 mL, 1.6 mmol) was added dropwise and the reaction was allowed to 
warm to room temperature and stirred overnight. To a suspension of 60 wt% sodium 
hydride (21.5 mg, 0.538 mmol) in 3.5 mL of DMF, compound 90 (200 mg, 0.533 mmol) 
was added as a 1.0 mL DMF solution. The reaction was allowed to stir for 10 minutes 
before a 0.5 mL DMF solution of mesylated alcohol was added. The reaction was stirred 
at room temperature overnight. After 15 hours, the reaction was diluted with water and 
ethyl acetate. The aqueous phase was washed with another aliquot of ethyl acetate. The 
combined organic phases were washed with saturated sodium chloride, dried over 
magnesium sulfate, filtered and concentrated. The crude black oil was purified via SP1 
Biotage using a gradient of 100% ethyl acetate to 10% methanol: ethyl acetate. The 
product isolated as a white solid. Yield:  25 mg (10%).  
1
H NMR (500 MHz, DMSO- d6) 
1.8:1 mixture of rotamers δ 8.48 – 8.42 (m, 2H), 7.69 – 7.62 (m, 1H), 7.51 – 7.45 (m, 
1H), 7.41 – 7.08 (m, 7H), 7.02 – 6.96 (m, 2H), 6.80 (rotamer A, s), 6.77 (rotamer B, s, 
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1H), 5.59 – 5.53 (m, 2H), 4.65 (rotamer A, s, 1H), 4.52 – 4.48 (m, 2H), 4.11 (bs, 1H), 
3.17 (d, J = 5.3 Hz, 2H), 3.10-2.87 (m, H), 2.77 (rotamer B, s, 1H), 1.86-1.33 (bm, 4H). 
TOF ES+ MS:  467.0(M+H). HPLC ret. time  = 5.52 min; purity > 95%.  
 
N-benzyl-1-(1-benzyl-1H-indole-2-carbonyl)-N-methylpiperidine-4-carboxamide 
(CCG 205404, 83) Compound 90 (50 mg, 0.133 mmol) was dissolved in 0.5 mL of DMF 
and cooled to 0 
o
C. Lithium bis(trimethylsilyl)amide (0.146 ml, 0.146 mmol) was added 
dropwise and the reaction was allowed to stir for 10 minutes. Benzyl bromide (0.024 ml, 
0.20 mmol) was added to the reaction, and it was allowed to stir overnight at room 
temperature. The reaction was quenched with water. It was then extracted with ethyl 
acetate. The organic extracts were washed with saturated sodium chloride solution three 
times and dried over magnesium sulfate, filtered and concentrated. The crude material 
was purified through flash silica gel chromatography using 25% EtOAc:DCM to give the 
product as a white solid. Yield: 41 mg (66%).  
1
H NMR (400 MHz, DMSO- d6) 1.6:1 
mixture of rotamers δ 7.68 – 7.52 (m, 2H), 7.45 – 6.98 (m, 12H), 6.72 (rotamer A, s), 
6.69 (rotamer B, s, 1H), 5.54-5.41 (m, 2H), 4.64 (s, 1H), 4.52 – 4.23 (m, 2H), 4.01 (bs, 
1H), 3.18 – 2.85 (m, 5H), 2.78 (rotamer B, s, 1H), 1.73 – 1.23 (m, 4H). TOF ES+ MS:  
466.2 (M+H), 488.2 (M+Na). HPLC ret. time  = 7.86 min; purity > 95%. 
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N-benzyl-N-methyl-1-(1-(4-nitrobenzyl)-1H-indole-2-carbonyl)piperidine-4-
carboxamide (CCG 205484, 84) Compound 90 (50 mg, 0.133 mmol) was added to a 
suspension of sodium hydride (60 wt% in oil, 8.0 mg, 0.20 mmol) in DMF (2 ml). The 
reaction was allowed to stir for 10 minutes at 60 °C. 1-(chloromethyl)-4-nitrobenzene 
(45.7 mg, 0.266 mmol) and potassium iodide (44.2 mg, 0.266 mmol) were added and the 
reaction was stirred overnight at 60 °C. The reaction was diluted with water and ethyl 
acetate. The organic layer was washed with water and saturated sodium chloride solution. 
It was dried over magnesium sulfate, filtered and concentrated. The crude material was 
purified using 40-100% ethyl acetate: hexanes to afford the product as a white solid. 
Yield:  11 mg, 16%. 
1
H NMR (400 MHz, DMSO- d6) 1.7:1 mixture of rotamers δ 8.20 – 
8.11 (m, 2H), 7.70 – 7.62 (m, 1H), 7.55 (d, J = 8.4 Hz, 1H), 7.40 – 7.10 (m, 9H), 6.80 
(rotamer A, s), 6.77 (rotamer B, s, 1H), 5.70 – 5.63 (m, 2H), 4.62 (rotamer A, s, 1H), 4.49 
– 4.25 (m, 2H), 4.08 (bs, 1H), 3.18 – 2.87 (m, 5H), 2.74 (rotamer B, s, 1H), 1.39 (bm, 
4H). TOF ES+ MS:  511.1 (M+H). HPLC ret. time  = 7.56 min; purity > 95%. 
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N-benzyl-N-methyl-1-(1-(4-(trifluoromethyl)benzyl)-1H-indole-2-
carbonyl)piperidine-4-carboxamide (CCG 208917, 85) Compound 90 (200 mg, 0.533 
mmol), Cs2CO3 (347 mg, 1.065 mmol), and 1-(bromomethyl)-4-(trifluoromethyl)benzene 
(0.124 mL, 0.799 mmol) were dissolved in DMF (5.0 mL) and heated to 70 °C overnight. 
The reaction was diluted with water and ethyl acetate and ether (1:1). The aqueous layer 
was back extracted with ethyl acetate. The organic phase was washed with saturated 
sodium chloride (3x), dried over sodium sulfate, filtered and concentrated. The resulting 
crude material was purified via SP1 Biotage with a gradient of 30% ethyl acetate/hexanes 
to 100% ethyl acetate. The product was isolated as a white solid. Yield:  90 mg (32%). 
1
H 
NMR (500 MHz, DMSO- d6) 2:1 mixture of rotamers δ 7.68 – 7.61 (m, 3H), 7.55 – 7.49 
(m, 1H), 7.41 – 7.07 (m, 9H), 6.79 (rotamer A, s), 6.75 (rotamer B, s, 1H), 5.64 – 5.59 
(m, 2H), 4.64 (s, 1H), 4.51 – 4.25 (m, 1H), 4.09 (bs, 1H), 2.96 (s, 5H), 2.77 (s, 1H), 1.86 
– 1.22 (m, 4H). TOF ES+ MS:  534.0 (M+H), 556.0 (M+Na). HPLC ret. time  = 8.25 
min; purity = 92%. 
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N-benzyl-1-(1-(4-cyanobenzyl)-1H-indole-2-carbonyl)-N-methylpiperidine-4-
carboxamide (CCG 206330, 86)  Sodium iodide (99 mg, 0.660 mmol) and 4-
(chloromethyl)benzonitrile (100 mg, 0.660 mmol) were dissolved in acetone (2.2 mL) 
and allowed to stir at room temperature for 4 hours. The resulting solid was filtered and 
the filtrate concentrated to obtain crude 4-(iodomethyl)benzonitrile (130 mg, 0.535 
mmol, 81% yield) as an orange oil. It was taken directly to the next step without 
characterization and purification. Compound 90 (100 mg, 0.266 mmol) was dissolved in 
1.0 mL of DMF and added to a suspension of sodium hydride (12.78 mg, 0.320 mmol) in 
2.0 of DMF. The reaction was stirred at 80 °C for 10 minutes before adding 4-
(iodomethyl)benzonitrile (129 mg, 0.533 mmol) dissolved in 2.0 mL of DMF. The 
reaction was allowed to stir overnight. After 18 hours, the reaction was cooled to room 
temperature before diluting with water and ethyl acetate. The organic phase was washed 
with water followed by saturated sodium chloride, dried over magnesium sulfate, filtered 
and concentrated. The crude material was purified via flash column chromatography 
using a gradient of 50% ethyl acetate/hexanes to 100% ethyl acetate. The purification 
provided product as a white solid. Yield:  50 mg, 38%. 
1
H NMR (400 MHz, DMSO- d6) 
1.7:1 mixture of rotamers δ 7.78 – 7.70 (m, 2H), 7.69 – 7.61 (m, 1H), 7.52 (d, J = 8.4 Hz, 
1H), 7.43 – 7.07 (m, 9H), 6.78 (rotamer A, s,), 6.75 (rotamer B, s, 1H), 5.64 – 5.57 (m, 
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2H), 4.64 (rotamer A, s, 1H), 4.52 – 4.25 (m, 2H), 4.04 (bs, 1H), 3.18 - 2.84 (m, 5H), 
2.78 (rotamer B, s, 1H), 1.78 – 1.17 (m, 4H). TOF ES+ MS:  491.1 (M+H).  HPLC ret. 
time  = 7.54 min; purity = 94%. 
 
1-(1-acetyl-1H-indole-2-carbonyl)-N-benzyl-N-methylpiperidine-4-carboxamide 
(CCG 206333, 87) A solution of compound 90 (100 mg, 0.27 mmol) in 1 mL of DMF 
was added to a suspension of sodium hydride (11.7 mg, 0.29 mmol) in 2.0 mL DMF. The 
reaction was stirred at 80 °C for 10 minutes before adding acetic anhydride (0.050 ml, 
0.53 mmol). The reaction was allowed to stir for 5 hours before it was cooled to room 
temperature and diluted with ammonium chloride and ethyl acetate. The organic phase 
was washed with saturated ammonium chloride twice, followed by saturated sodium 
chloride, dried over magnesium sulfate, filtered and concentrated. The crude material was 
purified via flash chromatography using a gradient of 50% ethyl acetate/hexanes to 100% 
ethyl acetate. Purification afforded the product as a white. Yield:  13 mg (12%). 
1
H NMR 
(400 MHz, DMSO- d6) 1.6:1 mixture of rotamers δ 8.15 – 8.07 (m, 1H), 7.69 – 7.61 (m, 
1H), 7.44 – 7.15 (m, 6H), 6.91 (rotamer A, s,), 6.88 (rotamer B, s, 1H), 4.67 (rotamer A, 
s, 1H), 4.56 – 4.33 (m, 2H), 4.00 – 3.84 (m, 1H), 3.21 – 2.85 (m, 5H), 2.79 (s, 1H), 2.61 
(rotamer A, s, 2H), 2.59 (rotamer B, s, 1H), 1.91 – 1.48 (m, 4H). TOF ES+ MS:  418.1 
(M+H), 440.1 (M+Na). HPLC ret. time  = 6.52 min; purity > 95%.  
148 
 
 
N-benzyl-1-(1-(2-methoxyethyl)-1H-indole-2-carbonyl)-N-methylpiperidine-4-
carboxamide (CCG 206331, 88) Compound 90 (50 mg, 0.13 mmol) dissolved in 0.5 mL 
of DMF was added to a suspension of sodium hydride (7.99 mg, 0.200 mmol) in 1.0 mL 
of DMF. The reaction was heated at 70 °C for ten minutes before adding 2-methoxyethyl 
4-methylbenzenesulfonate (0.144 mL, 0.266 mmol). The reaction was allowed to stir 
overnight. After 18 hours, the reaction was cooled to room temperature before diluting 
with water and ethyl acetate. The organic phase was washed with water followed by 
saturated sodium chloride, dried over magnesium sulfate , filtered and concentrated. The 
crude material was purified via flash column chromatography using a gradient of 50-80% 
ethyl acetate/hexanes. The purification provided the product as a white solid. Yield:  20 
mg (35%).  
1
H NMR (400 MHz, DMSO- d6) 1.7:1 mixture of rotamers δ 7.63 – 7.50 (m, 
2H), 7.42 – 7.15 (m, 6H), 7.13 – 7.03 (m, 1H), 6.64 (rotamer A, s), 6.60 (rotamer B, s, 
1H), 4.68 (s, 1H), 4.61 – 4.37 (m, 4H), 4.18 (bs, 1H), 3.62 – 3.44 (m, 2H), 3.19 – 3.14 
(m, 3H), 3.11 – 2.92 (m, 5H), 2.79 (s, 1H), 1.89 – 1.48 (m, 4H).  TOF ES+ MS:  434.2 
(M+H), 456.1 (M+Na). HPLC ret. time  = 7.03 min; purity > 95%.  
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N-benzyl-N-methyl-1-(1-(prop-2-yn-1-yl)-1H-indole-2-carbonyl)piperidine-4-
carboxamide (CCG 206401, 89)  sodium hydride (12.78 mg, 0.320 mmol) was added to 
an oven dried flask and placed under nitrogen.  It was then suspended in 1.0 mL of DMF.  
The suspension was placed in a 70 °C oil bath before adding N-benzyl-1-(1H-indole-2-
carbonyl)-N-methylpiperidine-4-carboxamide 90 (100 mg, 0.266 mmol) as a 0.5 mL 
DMF solution.  The reaction was allowed to stir for 20 minutes before the addition of 3-
bromoprop-1-yne (0.047 ml, 0.533 mmol) dropwise.  The reaction was allowed to stir 
overnight.   The reaction was cooled and diluted with saturated ammonium chloride and 
ethyl acetate.  The organic layer was washed with saturated ammonium chloride followed 
by saturated sodium chloride.  The organic layer was dried over magnesium sulfate, 
filtered, and concentrated.  The yellow crude material was purified via Biotage column 
30-70% ethyl acetate:hexanes 4 gram silicycle column to obtain white solid.   Yield:  50 
mg, 46%  
1
H NMR (500 MHz, DMSO-d6 - 7.69 (m, 2 H), 7.08 - 7.43 (m, 7 
H), 6.75 (rotomer A, s, 0.6 H), 6.71 (rotomer B, s, 0.3 H), 5.09 - 5.17 (m, 2 H), 3.87 - 
4.71 (m, 4 H), 3.23 - 3.29 (m, 1 H), 2.89 - 3.13 (m, 5 H), 2.79 (s, 1 H), 1.51 - 2.00 (m, 4 
H).  ES+ MS:   414.1 (M+H), 436.1 (M+Na).  HPLC (gradient A): ret. time = 7.10 min; 
purity = 93 % 
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N-benzyl-N-methyl-1-(1-methyl-1H-indole-2-carbonyl)piperidine-4-carboxamide 
(CCG 205428, 91)  N-benzyl-1-(1H-indole-2-carbonyl)-N-methylpiperidine-4-
carboxamide (100 mg, 0.266 mmol) was added to a suspension of sodium hydride (12.78 
mg, 0.320 mmol) in THF (Volume: 1.5 mL) at 0 °C.  The reaction was stirred for 10 
minutes before iodomethane (0.200 mL, 3.20 mmol) was added.  The reaction was 
allowed to stir at room temperature overnight.  The reaction was diluted with water and 
extracted with ethyl acetate.  The organic layer was washed with water and saturated 
sodium chloride solution.  It was dried over magnesium sulfate, filtered and concentrated.  
The crude material was purified using 50% - 100% ethyl acetate in hexanes.  To obtain 
product as white solid.  Yield:  42 mg, 40 %.  
1
H NMR (400 MHz, DMSO-d6) δ ppm 
7.54 - 7.60 (m, 1 H), 7.45 - 7.50 (m, 1 H), 7.13 - 7.39 (m, 6 H), 7.03 - 7.09 (m, 1 H), 6.57 
- 6.63 (m, 1 H), 4.65 (s, 1 H), 3.95 - 4.55 (m, 2 H), 3.67 - 3.77 (m, 3 H), 2.82 - 3.18 (m, 4 
H), 2.76 (s, 1 H), 1.48 - 1.86 (m, 4 H).  ES+ MS:   390.1 (M+H), 412.1 (M+Na).  HPLC 
(gradient A): ret. time = 6.92 min; purity > 95 % 
HPLC (gradient A): ret. time = 4.32 min; purity > 95 % 
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5-hydroxy indole derivatives 
 
ethyl 1-(1-(4-chlorobenzyl)-5-methoxy-1H-indole-2-carbonyl)piperidine-4-
carboxylate (166)  ethyl 1-(5-methoxy-1H-indole-2-carbonyl)piperidine-4-carboxylate 
was prepared by Method A using 5-methoxy-1H-indole-2-carboxylic acid (3.0 g, 15.7 
mmol) and ethyl piperidine-4-carboxylate (4.8 mL, 31.4 mmol).  Product obtained as a 
peach solid.  Yield:  3.2 g, 62.1 %.  
1
H NMR (500 MHz, DMSO-d6) δ ppm 11.40 (s, 1 H), 
7.30 (d, J=8.8 Hz, 1 H), 7.06 (d, J=2.4 Hz, 1 H), 6.83 (dd, J=8.9, 2.6 Hz, 1 H), 6.68 (d, 
J=1.5 Hz, 1 H), 4.33 (dt, J=13.5, 4.1 Hz, 2 H), 4.09 (q, J=7.1 Hz, 2 H), 3.75 (s, 3 H), 3.17 
(br. s., 2 H), 2.69 (tt, J=11.0, 4.0 Hz, 1 H), 1.88 - 1.97 (m, 2 H), 1.48 - 1.64 (m, 2 H), 1.20 
(t, J=7.1 Hz, 3 H) 
 1-chloro-4-(chloromethyl)benzene (366 mg, 2.270 mmol) and sodium iodide (340 
mg, 2.270 mmol) were dissolved in Acetone (Ratio: 1.000, Volume: 5.00 mL) and stirred 
overnight.  The resulting precipate was filtered and the filtrate was concentrated to obtain 
4-chlorobenzyl iodide.  Ethyl 1-(5-methoxy-1H-indole-2-carbonyl)piperidine-4-
carboxylate (500 mg, 1.513 mmol), cesium carbonate (986 mg, 3.03 mmol), and 4-
chlorobenzyl iodide were dissolved in DMF (Ratio: 1.000, Volume: 5 mL) and heated to 
60 oC overnight.  The reaction was diluted with water and ethyl acetate.  The aqueous 
layer was washed with another portion of ethyl acetate.  The organic phases were 
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combined, washed with saturated sodium chloride, dried over sodium sulfate, filtered and 
concentrated.  The crude material was purified using flash chromatography with 10-70% 
ethyl acetate/hexanes to obtain product as a white solid.   Yield:  606 mg, 88 %.  1H 
NMR (500 MHz, DMSO-d6) δ ppm 7.48 (d, J=9.0 Hz, 1 H), 7.27 - 7.35 (m, 2 H), 7.11 (d, 
J=2.4 Hz, 1 H), 7.01 - 7.08 (m, 2 H), 6.87 (dd, J=8.9, 2.6 Hz, 1 H), 6.63 (s, 1 H), 5.45 (s, 
2 H), 3.81 - 4.42 (m, 2 H), 3.76 (s, 3 H), 2.68 - 3.25 (m, 1 H), 2.57 (tt, J=11.0, 3.9 Hz, 1 
H), 0.97 - 1.95 (m, 5 H).   
 
1-(1-(4-chlorobenzyl)-5-methoxy-1H-indole-2-carbonyl)-N,N-dimethylpiperidine-4-
carboxamide (CCG 211759, 100)  166  (1.2 g, 2.64 mmol) was dissolved in Ethanol 
(Volume: 30 ml).  Aqueous lithium hydroxide (26.4 ml, 26.4 mmol).  The reaction was 
stirred overnight at room temperature.  It was concentrated under vacuum to remove the 
ethanol.  The resulting crude material was diluted with diethyl ether/ethyl acetate solution 
and water.  The aqueous phase was acidified using 2N HCl to pH 2.  The resulting 
suspension was washed with ethyl acetate.  The organic phase was washed with saturated 
sodium chloride, dried over sodium sulfate, filtered and concentrated to obtain 1-(1-(4-
chlorobenzyl)-5-methoxy-1H-indole-2-carbonyl)piperidine-4-carboxylic acid.  Yield: 915 
mg, 81 %.  
1
H NMR (500 MHz, DMSO-d6) δ ppm 12.27 (br. s., 1 H), 7.45 (d, J=9.0 Hz, 
1 H), 7.23 - 7.38 (m, 2 H), 7.10 (d, J=2.4 Hz, 1 H), 7.01 - 7.09 (m, 2 H), 6.86 (dd, J=8.8, 
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2.4 Hz, 1 H), 6.63 (s, 1 H), 5.45 (s, 2 H), 3.80 - 4.49 (m, 1 H), 3.76 (s, 3 H), 3.03 (br. s., 1 
H), 2.47 (tt, J=11.0, 3.9 Hz, 1 H), 1.12 - 1.88 (m, 2 H) 
 A large pressure vessel was purged with nitrogen. 1-(1-(4-chlorobenzyl)-5-
methoxy-1H-indole-2-carbonyl)piperidine-4-carboxylic acid (907 mg, 2.125 mmol),1-
Hydroxybenzotriazole (574 mg, 4.25 mmol)), EDCI (815 mg, 4.25 mmol)were dissolved 
in DCM (Volume: 20 ml).  The reaction was cooled using an ice bath stirred for 15 
minutes before Hunig'sBase (0.742 ml, 4.25 mmol)and Dimethylamine in THF (2.125 
ml, 4.25 mmol) were added.  The pressure vessel was tightly sealed and the reaction was 
allowed to warm to room temperature overnight.  The reaction was diluted with water 
and ethyl acetate.  The organic phase was washed with 1N HCl, saturated sodium 
chloride, dried over sodium sulfate, filtered and concentrated.  The crude material was 
purified using 10-80% ethyl acetate/hexanes to obtain product.  Yield: 743 mg, 77 %.  
1
H 
NMR (500 MHz, DMSO-d6) δ ppm 7.43 (d, J=8.8 Hz, 1 H), 7.28 - 7.38 (m, 2 H), 7.04 - 
7.14 (m, 3 H), 6.85 (dd, J=9.0, 2.4 Hz, 1 H), 6.63 (s, 1 H), 5.45 (br. s., 2 H), 4.41 (br. s, 1 
H), 4.03 (br. s, 1 H), 3.70 - 3.80 (m, 3 H), 2.83 - 3.24 (m, 6 H), 2.76 - 2.83 (m, 3 H), 1.20 
- 1.87 (m, 4 H).  TOF ES+ MS:   476.2 (M+Na).  HPLC (gradient A): ret. time = 6.92 
min; purity = 90 %   
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1-(5-hydroxy-1H-indole-2-carbonyl)-N,N-dimethylpiperidine-4-carboxamide (CCG 
212051, 105)  100 (100 mg, 0.220 mmol) was dissolved in anhydrous DCM (Volume: 3 
mL) and cooled to -78 
o
C. BBr3 (0.661 mL, 0.661 mmol) was added dropwise.  The 
reaction was allowed to warm to room temperature and stirred until the TLC showed 
complete consumption of starting material.  The reaction was cooled with an ice bath 
before slowly adding saturated sodium bicarbonate.  The reaction was diluted with ethyl 
acetate.  The organic phase was washed with saturated sodium bicarbonate until the 
aqueous layer from the separatory funnel is basic.  It was washed with saturated sodium 
chloride and dried over sodium sulfate, filtered and concentrated.  The crude material was 
purified using 10-80% ethyl acetate/hexanes to obtain product as a white solid.  Yield:  
24 mg, 34 %.  
1
H NMR (500 MHz, DMSO-d6) δ ppm 11.25 (s, 1 H), 8.79 (s, 1 H), 7.20 
(d, J=8.8 Hz, 1 H), 6.83 - 6.93 (m, 1 H), 6.65 - 6.78 (m, 1 H), 6.51 - 6.61 (m, 1 H), 4.34 - 
4.50 (m, 2 H), 3.02 - 3.21 (m, 4 H), 2.98 (tt, J=11.1, 3.6 Hz, 1 H), 2.82 (s, 3 H), 1.67 - 
1.78 (m, 2 H), 1.45 - 1.59 (m, 2 H).  TOF ES+ MS:   316.1 (M+H), 338.1 (M+Na).   
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1-(tert-Butoxycarbonyl)piperidine-4-carboxylic acid (170).  ethyl piperidine-4-
carboxylate (0.490 mL, 3.18 mmol) and Hunig'sBase (0.833 mL, 4.77 mmol) were added 
to 6.0 mL of THF.  Di-tert-butyl dicarbonate (1041 mg, 4.77 mmol) was added as a 3.0 
mL solution of THF.  The reaction was stirred overnight.  The reaction was diluted with 
water and ethyl acetate.  The organic layer was washed with saturated, aqeuous solution 
of sodium chloride, dried over magnesium sulfate, filtered and concentrated.  The TLC of 
the reaction mxiture showed conversion of starting material to product.  1-tert-butyl 4-
ethyl piperidine-1,4-dicarboxylate was taken directly to the next step.   
1-tert-butyl 4-ethyl piperidine-1,4-dicarboxylate (10 g, 38.9 mmol) was placed in 
Ethanol (Ratio: 1.000, Volume: 100 ml) and 2N NaOH (Ratio: 1.000, Volume: 100 ml).  
The reaction was stirred for 2 days.  It was concentrated to half volume.  The resulting 
suspension was diluted with minimal water to allow free movement of a stir bar.  The 
suspension was cooled by an ice bath and acidified using 2N HCl to pH 2.  The 
suspension was extracted using ethyl acetate.  The aqueous phase was washed with 
another aliquout of ethyl acetate.  The combined organic phases were washed with 
saturated sodium chloride, filtered and concentrated to obtain product as a white solid.  
Yield: 8.1 g, 91 %.   
1
H NMR (400 MHz, DMSO-d6) δ 12.25 (s, 1H), 3.81 (d, J = 13.3 
Hz, 2H), 2.78 (s, 2H), 2.38 (tt, J = 11.1, 3.9 Hz, 1H), 1.76 (dd, J = 13.3, 3.1 Hz, 2H), 1.47 
– 1.24 (m, 10H). 
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N,N-dimethylpiperidine-4-carboxamide hydrochloride (171):  A large pressure vessel 
was purged with nitrogen.  170 (1.5 g, 6.54 mmol), DMAP (0.799 g, 6.54 mmol), EDCI 
(2.508 g, 13.08 mmol) were dissolved in DCM (Volume: 25 ml).  The reaction was 
cooled using an ice bath stirred for 15 minutes before Hunig'sBase (2.285 ml, 13.08 
mmol) and dimethylamine in THF (6.54 ml, 13.08 mmol) were added.  The pressure 
vessel was tightly sealed and the reaction was allowed to warm to room temperature 
overnight.  The reaction was diluted with water and ethyl acetate.  The organic phase was 
washed with 1N HCl, saturated sodium chloride, dried over sodium sulfate, filtered and 
concentrated.  Product was taken directly to the next step.  TOF ES+ MS:  279.2 (M+Na).  
Tert-butyl 4-(dimethylcarbamoyl)piperidine-1-carboxylate (700 mg, 2.73 mmol) 
was dissolved in 1,4 Dioxane (Volume: 2.0 ml).  HCl in 1,4 dioxane (6.83 ml, 27.3 
mmol) was added and after 10 minutes, a peach solid formed.  the reaction was stirred for 
an additional 30 minutes before it was concentrated under vacuum.  It was placed under 
high vacuum to isolate 171 as sticky peach solid.  TOF ES+ MS:  193.2  (M+H).      
 
Ethyl 5-hydroxy-1H-indole-2-carboxylate (172)  5-methoxy-1H-indole-2-carboxylic 
acid (6.0 g, 31.4 mmol) was dissolved in EtOH (Volume: 150 mL) and cooled by an ice 
bath. HCl (g) (0.954 mL, 31.4 mmol) was bubbled to saturation.  The reaction was stirred 
overnight.  Nitrogen gas was bubbled into the reaction for 30 minutes.  After which point, 
the reaction was concentrated under vacuum.  The crude slurry was dissolved with ethyl 
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acetate.  The organic phase was cooled by an ice bath before saturated sodium carbonate 
was added slowly.  The layers were separated using a separatory funnel.  The organic 
phase was washed with saturated sodium carbonate (2x) then saturated sodium chloride.  
The organic phase was dried over sodium sulfate.  Filtered and concentrated to obtain 
ethyl 5-methoxy-1H-indole-2-carboxylate.  Yield:  5.86 g, 85 %.  
1
H NMR (500 MHz, 
DMSO-d6) δ ppm 11.75 (br. s., 1 H), 7.35 (d, J=9.0 Hz, 1 H), 7.10 (d, J=2.4 Hz, 1 H), 
7.05 (dd, J=2.4, 0.7 Hz, 1 H), 6.92 (dd, J=8.8, 2.4 Hz, 1 H), 4.33 (q, J=7.1 Hz, 2 H), 3.76 
(s, 3 H), 1.34 (t, J=7.2 Hz, 3 H).   
Using an oven dried flask charged with argon, ethyl 5-methoxy-1H-indole-2-
carboxylate (3.0 g, 13.68 mmol) was dissolved in DCM (Volume: 150 ml).  It was cooled 
to -78 
o
C before adding BBr3 in DCM (27.4 ml, 27.4 mmol) via addition funnel.  The 
reaction was allowed to warm slowly to room temperature.  After 3 hours, the reaction 
was cooled to 0 
o
C and slowly diluted with water.  The resulting suspension was 
transferred to a separatory funnel and further diluted with water and ethyl acetate.  The 
organic phase was washed with saturated sodium bicarbonate until the aqueous layer 
showed to be basic by pH paper.  The organic phase was washed with saturated sodium 
chloride, dried over sodium sulfate, filtered, and concentrated to obtain pure product. 
1
H 
NMR (500 MHz, DMSO-d6) δ ppm 11.58 (s, 1 H), 8.92 (br. s., 1 H), 7.26 (d, J=8.8 Hz, 1 
H), 6.89 - 6.97 (m, 2 H), 6.81 (dd, J=8.8, 2.4 Hz, 1 H), 4.31 (q, J=7.2 Hz, 2 H), 1.32 (t, 
J=7.1 Hz, 3 H) 
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Ethyl 1-(4-chlorobenzyl)-5-hydroxy-1H-indole-2-carboxylate (175):  172 (780 mg, 
3.80 mmol) and imidazole (776 mg, 11.40 mmol) were dissolved in DCM (35.0 mL) and 
stirred at room temperature for 30 minutes. TBS-Cl (1146 mg, 7.60 mmol) was dissolved 
in DCM (10.0 mL) and stirred at room temperature overnight.  The reaction was diluted 
with ethyl acetate and water.  The organic phase was washed with 1N HCl and saturated 
sodium chloride.  The organic phase was dried over sodium sulfate, filtered and 
concentrated.  The crude material was purified via flash chromatography 0 - 40% ethyl 
acetate/hexanes to obtain ethyl 5-((tert-butyldimethylsilyl)oxy)-1H-indole-2-carboxylate.  
Yield: 1.2 g, 99%.  
1
H NMR (500 MHz, DMSO-d6) δ ppm 11.74 (s, 1 H), 7.33 (d, J=9.0 
Hz, 1 H), 7.05 – 7.02 (m, 2 H), 6.83 (dd, J=6.5, 2.5 Hz, 1 H), 4.33 (q, J=7.0 Hz, 2 H), 
1.33 (t, J=7.0 Hz, 3 H), 0.97 (s, 9H), .17 (s, 6H).  
In a dried flask, purged with argon, sodium hydride (28.2 mg, 0.704 mmol) was 
added and suspended in DMF (1.0 mL) and cooled using an ice bath.  Ethyl 5-((tert-
butyldimethylsilyl)oxy)-1H-indole-2-carboxylate (150 mg, 0.470 mmol) was dissolved in 
DMF (1.0 mL) and added dropwise to the flask.  The reaction was stirred for 10 minutes 
before a 1-chloro-4-(chloromethyl)benzene (0.066 mL, 0.516 mmol) dissolved in DMF 
(0.5 mL) was added.  The reaction was allowed to warm to room temperature and stirred 
for an additional 30 minutes before it was diluted with saturated sodium chloride and 
ethyl acetate.  The aqueous phase was washed with another aliquot with ethyl acetate.  
The organic phases were combined and washed with saturated sodium chloride.  It was 
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dried over sodium sulfate, filtered and concentrated.  Ethyl 5-((tert-
butyldimethylsilyl)oxy)-1-(4-chlorobenzyl)-1H-indole-2-carboxylate and ethyl 1-(4-
chlorobenzyl)-5-((4-chlorobenzyl)oxy)-1H-indole-2-carboxylate was isolated in a 3:1 
ratio.  The mixture was taken directly to the next step. 
 Ethyl 5-((tert-butyldimethylsilyl)oxy)-1-(4-chlorobenzyl)-1H-indole-2-
carboxylate and ethyl 1-(4-chlorobenzyl)-5-((4-chlorobenzyl)oxy)-1H-indole-2-
carboxylate (473 mg, 1.065 mmol) was dissolved in THF (Volume: 6 mL) and cooled to 
0 
o
C.  TBAF in THF (1.598 mL, 1.598 mmol) was added dropwise and then warmed to 
room temperature.  The reaction was stirred overnight.  Then it was diluted with ethyl 
acetate and water.  The organic phase was washed with saturated sodium chloride, 
filtered and concentrated.  The crude material was purified using 0-20% ethyl acetate: 
hexanes biotage 4 g column.  To obtain 175 as a white solid.  Yield:  226 mg, 64 %.  
1
H 
NMR (500 MHz, DMSO-d6) δ ppm 9.08 (s, 1 H) 7.38 (d, J=9.03 Hz, 1 H) 7.31 - 7.35 (m, 
2 H) 7.19 (d, J=0.73 Hz, 1 H) 6.99 - 7.04 (m, 2 H) 6.98 (d, J=2.20 Hz, 1 H) 6.85 (dd, 
J=9.03, 2.44 Hz, 1 H) 5.76 (s, 2 H) 4.25 (q, J=7.08 Hz, 2 H) 1.27 (t, J=7.08 Hz, 3 H) 
 
1-(4-chlorobenzyl)-5-(prop-2-yn-1-yloxy)-1H-indole-2-carboxylic acid (176) 
Compound 175  (200mg, 0.606 mmol) and cesium carbonate (296 mg, 0.910 mmol) were 
dissolved in DMF (Volume: 5 mL).  3-bromoprop-1-yne (0.092 mL, 1.213 mmol) was 
added.  The reaction was allowed to stir at room temperature overnight before it was 
diluted with saturated sodium chloride and ethyl acetate.  The aqueous phase was washed 
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with ethyl acetate.  The organic phases were combined and washed with saturated sodium 
chloride.  It was dried over sodium sulfate, filtered and concentrated.  The crude material 
was purified using 0-60% ethyl acetate/hexanes to obtain ethyl 1-(4-chlorobenzyl)-5-
(prop-2-yn-1-yloxy)-1H-indole-2-carboxylate as a white solid.  Yield:  160 mg, 72 %.    
1
H NMR (500 MHz, DMSO-d6) δ ppm 7.52 (d, J=9.0 Hz, 1 H), 7.33 (d, J=8.5 Hz, 2 H), 
7.29 (s, 1H), 7.26 (d, J=2 Hz, 1H), 7.01 - 7.03 (m, 3 H), 5.81 (s, 2H),  4.79 (d, J=2.0 Hz, 
2 H),  4.27 (q, J=7.0 Hz, 2 H), 3.56 (t, J=2.0 Hz, 1 H), 1.28 (t, J=7.0 Hz, 3H).  
Ethyl 1-(4-chlorobenzyl)-5-(prop-2-yn-1-yloxy)-1H-indole-2-carboxylate (160 
mg, 0.435 mmol) was dissolved in Ethanol (Ratio: 1.000, Volume: 6.00 ml) and aq. 
NaOH (Ratio: 1.000, Volume: 6 ml) and allowed to stir overnight.  The reaction was 
concentrated by half of the volume, cooled to 0 
o
C, acidified with 2M HCl.  The resulting 
suspension filtered under vacuum.  The solid was dried under vacuum to obtain 176 as a 
white solid.  Yield: 83 mg, 57 %.  
1
H NMR (500 MHz, DMSO-d6) δ ppm 12.98 (s, 1 H), 
7.47 (d, J=9.0 Hz, 1 H), 7.31 - 7.36 (m, 2 H), 7.23 - 7.26 (m, 2 H), 7.00 - 7.04 (m, 2 H), 
6.98 (dd, J=9.0, 2.4 Hz, 1 H), 5.83 (s, 2 H), 4.79 (d, J=2.4 Hz, 2 H), 3.56 (t, J=2.4 Hz, 1 
H).  HPLC (gradient A): ret. time = 7.37 min; purity > 95 %. 
 
1-(1-(4-chlorobenzyl)-5-(prop-2-yn-1-yloxy)-1H-indole-2-carbonyl)-N,N-
dimethylpiperidine-4-carboxamide (CCG 212058, 102) 176 (36 mg, 0.106 mmol), 
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EDCI (40.6 mg, 0.212 mmol) and 1-Hydroxybenzotriazole (28.6 mg, 0.212 mmol)  were 
dissolved in DCM (Ratio: 3.00, Volume: 3 ml) and stirred for 30 minutes at room 
temperature. 171 (57.3 mg, 0.212 mmol) was added as a DCM (Ratio: 1.000, Volume: 1 
ml) solution , followed by Hunig'sBase (0.043 ml, 0.247 mmol).  The reaction was 
further stirred at room temperature overnight at room temperature.  The reaction was 
diluted with water and ethyl acetate.  The organic phase was washed with saturated 
sodium carbonate, 1N HCl, and brine.  The organic phase was dried over sodium sulfate,  
filtered and concentrated.  The crude material was purified via Biotage SP1 with 30% to 
60%  ethyl acetate/hexanes.   The product was a white solid.  Yield:  24 mg, 48 %.  
1
H 
NMR (500 MHz, DMSO-d6) δ ppm 7.46 (d, J=9.0 Hz, 1 H), 7.31 - 7.36 (m, 2 H), 7.19 (d, 
J=2.7 Hz, 1 H), 7.07 - 7.12 (m, 2 H), 6.90 (dd, J=8.9, 2.6 Hz, 1 H), 6.65 (s, 1 H), 5.46 (s, 
2 H), 4.77 (d, J=2.2 Hz, 2 H), 4.44 (br. s., 1 H), 4.03 (br. s., 1 H), 3.54 (t, J=2.3 Hz, 1 H), 
2.85 - 3.21 (m, 6 H), 2.81 (s, 3 H), 1.21 - 1.83 (m, 4 H).  TOF ES+ MS:   478.3 (M+H), 
500.3 (M+Na).  HPLC (gradient A): ret. time = 6.93 min; purity > 95 % 
 
5-(benzyloxy)-1-(4-chlorobenzyl)-1H-indole-2-carboxylic acid (177)  Cesium 
carbonate (222 mg, 0.682 mmol) and ethyl 1-(4-chlorobenzyl)-5-hydroxy-1H-indole-2-
carboxylate (150 mg, 0.455 mmol) were dissolved in DMF (Volume: 4.0 ml).  It was 
stirred for 20 minutes before benzyl bromide (0.081 ml, 0.682 mmol) was added.  The 
reaction was stirred overnight. The reaction was diluted by water and ethyl 
acetate/diethyl ether.  The water phase was washed again with ethyl acetate/diethyl ether.  
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The combined organic phases were washed with saturated sodium carbonate followed by 
saturated sodium chloride.  It was dried over saturated sodium sulfate, filtered, and 
concentrated.  The crude material was purified via sp1 biotage using 0-45% ethyl acetate-
hexanes gradient.  The product was obtained as a white solid.   TOF ES+ MS:  420.0 
(M+H), 442.2 (M+Na).  HPLC (gradient A): ret. Time = 9.88 min; purity > 95%  
Ethyl 5-(benzyloxy)-1-(4-chlorobenzyl)-1H-indole-2-carboxylate (150 mg, 0.357 
mmol) was dissolved in Ethanol (Ratio: 1.000, Volume: 2 ml), 2N NaOH (Ratio: 1.000, 
Volume: 2.000 ml).  It was stirred overnight.  The reaction was concentrated to half 
volume and diluted with water to allow free movement of a stir bar.  It was cooled by an 
ice bath and acidified using 2N HCl to pH 2.  The resulting suspension was extracted 
with ethyl acetate (2X).  The organic phases were combined and washed with saturated 
sodium chloride, dried over sodium sulfate, filtered and concentrated.  The product was 
isolated as a white solid.  Yield:  106 mg, 76 %.  1H NMR (500 MHz, DMSO-d6) δ ppm 
12.96 (br. s., 1 H), 7.45 - 7.49 (m, 3 H), 7.37 - 7.42 (m, 2 H), 7.31 - 7.35 (m, 3 H), 7.27 
(d, J=2.4 Hz, 1 H), 7.22 (s, 1 H), 6.99 - 7.05 (m, 3 H), 5.83 (s, 2 H), 5.10 (s, 2 H).  HPLC 
(gradient A): ret. Time = 8.29 min; purity > 95% 
 
1-(5-(benzyloxy)-1-(4-chlorobenzyl)-1H-indole-2-carbonyl)-N,N-dimethylpiperidine-
4-carboxamide (CCG 212151, 103)  Compound 177 (87 mg, 0.222 mmol), EDCI (85 
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mg, 0.444 mmol) and 1-Hydroxybenzotriazole (60.0 mg, 0.444 mmol)  were dissolved in 
DCM (Ratio: 3.00, Volume: 3 ml) and stirred for 30 minutes at room temperature. 171 
(120 mg, 0.444 mmol) was added as a DCM (Ratio: 1.000, Volume: 1 ml) solution , 
followed by Hunig'sBase (0.043 ml, 0.247 mmol).  The reaction was further stirred at 
room temperature overnight at room temperature. The reaction was diluted with water 
and ethyl acetate.  The organic phase was washed with saturated sodium carbonate, 1N 
HCl, and brine.  The organic phase was dried over sodium sulfate.  The drying agent was 
used filtered and crude material concentrated. The crude material was purified via 
Biotage SP1 with 50% ethyl acetate/hexanes to 100% ethyl acetate.   The product was a 
white solid.  Yield:  40 mg, 34 %.  
1
H NMR (500 MHz, DMSO-d6) δ ppm 7.42 - 7.49 (m, 
3 H), 7.37 - 7.42 (m, 2 H), 7.30 - 7.35 (m, 3 H), 7.19 (d, J=2.4 Hz, 1 H), 7.07 - 7.11 (m, 2 
H), 6.94 (dd, J=9.0, 2.4 Hz, 1 H), 6.62 (s, 1 H), 5.45 (br. s., 2 H), 5.10 (s, 2 H), 4.44 (br. 
s., 1 H), 4.04 (br. s., 1 H), 2.85 - 3.21 (m, 6 H), 2.81 (s, 3 H), 1.23 - 1.82 (m, 4 H).  ES+ 
MS:   552.0 (M+Na).  HPLC (gradient A): ret. time = 7.96 min; purity > 95 % 
 
 
1-(4-chlorobenzyl)-5-propoxy-1H-indole-2-carboxylic acid (178)  Cesium carbonate 
(222 mg, 0.682 mmol) and ethyl 1-(4-chlorobenzyl)-5-hydroxy-1H-indole-2-carboxylate 
(150 mg, 0.455 mmol) were dissolved in DMF (Volume: 4.0 ml).  It was stirred for 20 
minutes before 1-bromopropane (0.042 ml, 0.455 mmol) was added.  The reaction was 
stirred at room temperature overnight.  The reaction was diluted by water and ethyl 
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acetate/diethyl ether.  The water phase was washed again with ethyl acetate/diethyl ether.  
The combined organic phases were washed with saturated sodium carbonate followed by 
saturated sodium chloride.  It was dried over saturated sodium sulfate, filtered, and 
concentrated.  The crude material was purified via sp1 biotage using 0-45% ethyl acetate-
hexanes gradient.  ethyl 1-(4-chlorobenzyl)-5-propoxy-1H-indole-2-carboxylate was 
obtained as a white solid.  Yield: 155 mg, 92 %.  
1
H NMR (500 MHz, DMSO-d6) δ ppm 
7.47 (d, J=9.0 Hz, 1 H), 7.31 - 7.35 (m, 2 H), 7.26 (s, 1 H), 7.17 (d, J=2.2 Hz, 1 H), 6.99 - 
7.02 (m, 2 H), 6.97 (dd, J=9.0, 2.4 Hz, 1 H), 5.80 (s, 2 H), 4.27 (q, J=7.1 Hz, 2 H), 3.92 
(t, J=6.6 Hz, 2 H), 1.74 (sxt, J=7.1 Hz, 2 H), 1.28 (t, J=7.1 Hz, 3 H), 0.99 (t, J=7.3 Hz, 3 
H) 
Ethyl 1-(4-chlorobenzyl)-5-propoxy-1H-indole-2-carboxylate (150 mg, 0.403 
mmol) was dissolved in Ethanol (Ratio: 1.000, Volume: 2 ml) and 2N NaOH (Ratio: 
1.000, Volume: 2.000 ml).    It was stirred overnight.  The reaction was concentrated to 
half volume and diluted with water to allow free movement of a stir bar.  It was cooled by 
an ice bath and acidified using 2N HCl to pH 2.  The resulting suspension was extracted 
with ethyl acetate (2X).  The organic phases were combined and washed with saturated 
sodium chloride, dried over sodium sulfate, filtered and concentrated.  The product was 
isolated as a white solid.  Yield:  56 mg, 40 %.  1H NMR (500 MHz, DMSO-d6) δ ppm 
12.93 (br. s., 1 H), 7.43 (d, J=9.3 Hz, 1 H), 7.31 - 7.35 (m, 2 H), 7.22 (s, 1 H), 7.15 (d, 
J=2.4 Hz, 1 H), 7.01 (m, J=8.3 Hz, 2 H), 6.94 (dd, J=9.0, 2.4 Hz, 1 H), 5.82 (s, 2 H), 3.92 
(t, J=6.6 Hz, 2 H), 1.74 (sxt, J=7.1 Hz, 2 H), 0.99 (t, J=7.4 Hz, 3 H). 
165 
 
 
1-(1-(4-chlorobenzyl)-5-propoxy-1H-indole-2-carbonyl)-N,N-dimethylpiperidine-4-
carboxamide (CCG 212138, 104)  178 (50 mg, 0.145 mmol), EDCI (55.8 mg, 0.291 
mmol) and 1-Hydroxybenzotriazole (39.3 mg, 0.291 mmol)  were dissolved in DCM 
(Ratio: 3.00, Volume: 3 ml) and stirred for 30 minutes at room temperature. 171 (79 mg, 
0.291 mmol) was added as a DCM (Ratio: 1.000, Volume: 1 ml) solution , followed by 
Hunig'sBase (0.043 ml, 0.247 mmol).  The reaction was further stirred at room 
temperature overnight at room temperature.  The reaction was diluted with water and 
ethyl acetate.  The organic phase was washed with saturated sodium carbonate, 1N HCl, 
and brine.  The organic phase was dried over sodium sulfate.  The drying agent was used 
filtered and crude material concentrated.  The crude material was purified via Biotage 
SP1 with 50% ethyl acetate/hexanes to 100% ethyl acetate.   The product was a white 
solid.  Yield:  22 mg, 32 %.  
 1
H NMR (500 MHz, Chloroform-d) δ ppm 7.19 - 7.23 (m, 2 
H), 7.17 (d, J=9.0 Hz, 1 H), 7.06 (d, J=2.4 Hz, 1 H), 7.00 - 7.04 (m, 2 H), 6.91 (dd, 
J=8.8, 2.4 Hz, 1 H), 6.57 (s, 1 H), 5.42 (s, 2 H), 4.11 - 4.84 (m, 2 H), 3.94 (t, J=6.6 Hz, 2 
H), 3.05 (s, 3 H), 2.87 - 3.00 (m, 5 H), 2.75 (quin, J=7.3 Hz, 1 H), 1.58 - 1.87 (m, 6 H), 
1.05 (t, J=7.4 Hz, 3 H).  TOF ES+ MS:   482.4 (M+H), 504.4 (M+Na).  HPLC (gradient 
A): ret. time = 7.83 min; purity > 95 % 
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1-(5-((tert-butyldiphenylsilyl)oxy)-1H-indole-2-carbonyl)-N,N-dimethylpiperidine-4-
carboxamide (180)  Imidazole (23.31 mg, 0.342 mmol) and 105 (72 mg, 0.228 mmol) 
were dissolved in DCM (Volume: 5 ml) and stirred at room temperature for 10 minutes.  
TBDPS-Cl (0.088 ml, 0.342 mmol) was added.  The reaction was stirred for another 2 
hours before it was diluted with ethyl acetate and water.  The organic phase was washed 
with 1N HCl, saturated sodium carbonate, then saturated sodium chloride.  It was then 
dried over sodium sulfate, filtered and concentrated.   The crude material was purified 
using 0-60% ethyl acetate/hexanes to obtain product as an off white solid.  Yield:  124 
mg, 98%.  TOF ES+ MS:  554.1 (M+H) ,  576.1 (M+Na).    
 
1-(5-((tert-butyldiphenylsilyl)oxy)-1-(4-chlorobenzyl)-1H-indole-2-carbonyl)-N,N-
dimethylpiperidine-4-carboxamide (181)  1-(bromomethyl)-4-chlorobenzene (21.71 
mg, 0.106 mmol) and sodium iodide (10.56 mg, 0.070 mmol) were dissolved in Acetone 
(Ratio: 1.000, Volume: 5.00 ml) and stirred for 3 hours.  The resulting suspension was 
filtered and the filtrate was concentrated to obtain 4-chlorobenzyl iodide.   180 (39 mg, 
0.070 mmol), cesium carbonate (34.4 mg, 0.106 mmol) and 4-chlorobenzyl iodide were 
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dissolved in DMF and stirred at 60 
o
C for 4 hours.  The reaction was diluted with water 
and ethyl acetate.  The aqueous phase was washed with ethyl acetate (2X).  The organic 
phases were combined and washed with saturated sodium chloride (2X).  It was dried 
over sodium sulfate, filtered and concentrated.  The resulting crude material was purified 
using 0-60% ethyl acetate/hexanes to obtain product.  Yield:  40 mg, 84 %. TOF ES+ 
MS:  678.1 (M+H) 
 
1-(1-(4-chlorobenzyl)-5-hydroxy-1H-indole-2-carbonyl)-N,N-dimethylpiperidine-4-
carboxamide (CCG 222701, 101) 181 (34 mg, 0.050 mmol) was dissolved in THF 
(Volume: 5002 µl) and cooled to -78 oC.  TBAF (55.1 µl, 0.055 mmol) was added 
dropwise and the reaction was stirred for 2 hours before it was diluted with water and 
ethyl acetate.  The organic phase was washed with saturated sodium chloride, dried over 
sodium sulfate, filtered and concentrated.  The crude material was purified using 0-80% 
ethyl acetate/hexanes to obtain white solid as a product.  Yield:  17 mg, 78%  
1
H NMR 
(500 MHz, DMSO-d6) δ ppm 8.91 (s, 1 H), 7.28 - 7.36 (m, 3 H), 7.09 (d, J=8.5 Hz, 2 H), 
6.90 (d, J=2.2 Hz, 1 H), 6.72 (dd, J=8.8, 2.4 Hz, 1 H), 6.54 (s, 1 H), 5.41 (s, 2 H), 3.92 - 
4.61 (m, 2 H), 2.77 - 3.20 (m, 9 H), 1.23 - 1.79 (m, 4 H).  TOF ES+ MS:   440.1 (M+H), 
462.1 (M+Na).  HPLC (gradient A): ret. time = 5.70 min; purity > 95 %  
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Indole replacement derivatives 
 
N-(2-(pyridin-4-yl)ethyl)piperidine-4-carboxamide dihydrochloride (190). The 
following was added to DCM: 170 (600 mg, 2.62 mmol), DIEA (1.37 mL, 7.85 mmol), 
EDCI (552 mg, 2.88 mL), HOBt (441 mg, 2.88 mmol), and 2-(4-pyridylethyl)amine 
(0.34 mL, 2.88 mL). The solution was stirred at rt for 17 h, at which time the DCM was 
stripped off and 10% aq. sodium carbonate was added. Material was extracted out with 
EtOAc (3X). The organic extractions were pooled, dried over magnesium sulfate, and 
concentrated in vacuo. The residue was taken up in a small amount of EtOAc and diethyl 
ether was added. The precipitate was collected over a filter and washed with diethyl ether 
to give tert-butyl 4-((2-(pyridin-4-yl)ethyl)carbamoyl)piperidine-1-carboxylate as an off-
white solid. Yield: 634 mg (73%). 
1
H NMR (400 MHz, CDCl3) δ 8.49 (d, J = 5.9 Hz, 
2H), 7.09 (d, J = 5.9 Hz, 2H), 5.59 (t, J = 5.3 Hz, 1H), 4.22 – 3.95 (m, 2H), 3.52 (q, J = 
6.8 Hz, 2H), 2.81 (t, J = 6.9 Hz, 2H), 2.68 (t, J = 12.5 Hz, 2H), 2.14 (tt, J = 11.6, 3.8 Hz, 
1H), 1.77 – 1.65 (m, 2H), 1.56 (qd, J = 12.1, 4.3 Hz, 2H), 1.43 (s, 9H). 
Tert-Butyl 4-((2-(pyridin-4-yl)ethyl)carbamoyl)piperidine-1-carboxylate (575 mg, 
1.72 mmol) was suspended in diethyl ether at room temperature, and 4M HCl in dioxane 
(6 mL, 24 mmol) was added. The mixture was stirred at room temperature for 30 min, at 
which time the organic solution was decanted off and the solid material collected and 
dried in vacuo. The title compound was thus obtained as a tan powder. Yield: 448 mg 
(97%). 
1
H NMR (400 MHz, DMSO-d6) δ 9.22 (bs, 1H), 8.91 (bs, 1H), 8.79 (d, J = 6.4 
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Hz, 2H), 8.18 (t, J = 5.6 Hz, 1H), 7.89 (d, J = 6.3 Hz, 2H), 3.40 (q, J = 6.2 Hz, 2H), 3.15 
(d, J = 12.6 Hz, 2H), 3.00 (t, J = 6.4 Hz, 2H), 2.83 – 2.69 (m, 2H), 2.39 – 2.26 (m, 1H), 
1.80 – 1.59 (m, 4H). TOF ES+ MS: (M+H) 234.2, (M+Na) 256.1.  
 
Ethyl 1-(1-(4-chlorobenzyl)-1H-benzo[d]imidazole-2-carbonyl)piperidine-4-
carboxylate (193). 1H-benzo[d]imidazole-2-carboxylic acid hydrate 191 (500 mg, 2.78 
mmol), EDCI (1170 mg, 6.11 mmol), and HOBt (825 mg, 6.11 mmol) were dissolved in 
DCM. The reaction was allowed to stir for 10 minutes before DIEA (1.066 mL, 6.11 
mmol) and ethyl piperidine-4-carboxylate (0.941 mL, 6.11 mmol) were added. The 
reaction was allowed to stir overnight at room temperature. The reaction was diluted with 
water and ethyl acetate. The organic phase was washed with 1N HCl, saturated sodium 
bicarbonate, and saturated sodium chloride solution. The ethyl acetate layer was dried 
over magnesium sulfate, filtered and concentrated. The resulting crude material was 
triturated with ethyl acetate to obtain ethyl 1-(1H-benzo[d]imidazole-2-
carbonyl)piperidine-4-carboxylate as a white solid. Yield:  113 mg (14%). 
1
H NMR (400 
MHz, DMSO- d6) δ 13.09 (s, 1H), 7.63 (dd, J = 84.6, 8.0 Hz, 2H), 7.28 (dt, 2H), 5.30 (d, 
J = 13.5 Hz, 1H), 4.42 (d, J = 13.0 Hz, 1H), 4.09 (q, J = 14.2, 7.0 Hz, 2H), 3.48 (t, J = 
11.7 Hz, 1H), 3.05 (t, J = 11.3 Hz, 1H), 2.77 – 2.65 (m, 1H), 1.97 (d, J = 13.7 Hz, 2H), 
1.69 – 1.52 (m, 2H), 1.19 (t, J = 7.1 Hz, 3H). TOF ES+ MS:  302.1 (M+H), 324.1 
(M+Na). HPLC ret. time  = 5.44 min; purity > 95%.  
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Ethyl 1-(1H-benzo[d]imidazole-2-carbonyl)piperidine-4-carboxylate (80 mg, 
0.265 mmol) and cesium carbonate (130 mg, 0.398 mmol) were dissolved in DMF 
(Volume: 2.0 ml). 1-Chloro-4-(chloromethyl)benzene (0.051 ml, 0.40 mmol) was added 
and the reaction was heated at 80 °C overnight. After 18 hours, the reaction was cooled to 
room temperature and diluted with water and ethyl acetate. The organic phase was 
washed with saturated sodium chloride four times before it was dried over magnesium 
sulfate, filtered and concentrated. The isolated beige solid was taken directly to the next 
step without purification. Yield:  85 mg (75%). 
1
H NMR (400 MHz, DMSO- d6) δ 7.74 
(d, J = 7.7 Hz, 1H), 7.66 (d, J = 7.7 Hz, 1H), 7.49 – 7.27 (m, 6H), 5.63 – 5.48 (m, 1H), 
5.15 (s, 1H), 4.42 – 4.32 (m, 1H), 4.08 (q, J = 8 Hz, 8Hz, 2H), 3.97 – 3.86 (m, 1H), 3.22 
– 3.10 (m, 1H), 3.05 – 2.93 (m, 1H), 2.70 – 2.55 (m, 1H), 1.97 – 1.88 (m, 1H), 1.76 – 
1.67 (m, 1H), 1.53 – 1.38 (m, 1H), 1.21 (t, J = 8 Hz, 3H). TOF ES+ MS:  426.0 (M+H), 
448.0  (M+Na).  
 
1-(1-(4-chlorobenzyl)-1H-benzo[d]imidazole-2-carbonyl)-N-(2-(pyridin-4-
yl)ethyl)piperidine-4-carboxamide  (CCG 206565, 112). 193 (60 mg, 0.141 mmol) and 
lithium hydroxide, H2O (23.6 mg, 0.564 mmol) were dissolved in 2/1 water/THF (0.75 
ml). The reaction was stirred for two hours before it was diluted with water and diethyl 
ether. The aqueous phase was washed with diethyl ether twice. It was then acidified to 
171 
 
pH ~ 2 and extracted with ethyl acetate. The organic phase was washed with saturated 
sodium chloride, dried over magnesium sulfate, filtered and concentrated to obtain crude 
acid as a white solid. No further purification was performed. Yield: 54 mg, 96%. 
1
H 
NMR (400 MHz, DMSO- d6) δ 12.31 (s, 1H), 7.74 (d, J = 7.8 Hz, 1H), 7.63 (d, J = 7.7 
Hz, 2H), 7.41 – 7.20 (m, 6H), 5.55 (s, 2H), 4.39 – 4.30 (m, 1H), 3.95 – 3.86 (m, 1H), 3.21 
– 3.09 (m, 1H), 3.06 – 2.95 (m, 1H), 1.98 – 1.85 (m, 1H), 1.76 – 1.68 (m, 1H), 1.50 – 
1.42 (m, 1H), 1.30 – 1.22 (m, 1H). TOF ES+ MS:  398.1 (M+H), 420.1  (M+Na). HPLC 
ret. time  = 6.01 min; purity > 95%.  
The crude acid from above (50 mg, 0.13 mmol), EDCI (48.2 mg, 0.251 mmol), 
and HOBt (34.0 mg, 0.251 mmol) were dissolved in DCM (2.0 mL). The reaction was 
allowed to stir for 10 minutes before the addition of DIEA (0.044 mL, 0.251 mmol) and 
2-(pyridin-4-yl)ethanamine (0.030 mL, 0.251 mmol). The reaction was allowed to stir 
overnight. The reaction was diluted with water and ethyl acetate. The organic layer was 
washed with saturated sodium bicarbonate and saturated sodium chloride. The ethyl 
acetate layer was dried over magnesium sulfate, filtered and concentrated. The crude 
material was triturated in diethyl ether/ethyl acetate to obtain 112 white solid. Yield:  19 
mg (30%). 
1
H NMR (500 MHz, DMSO- d6) δ 8.48 – 8.43 (m, 2H), 7.92 (t, J = 5.7 Hz, 
1H), 7.74 (d, J = 8.8 Hz, 1H), 7.61 (d, J = 8.1 Hz, 1H), 7.42 – 7.19 (m, 8H), 5.61 – 5.49 
(m, 2H), 4.45 (d, J = 13.3 Hz, 1H), 3.98 (d, J = 13.6 Hz, 1H), 3.35 – 3.28 (m, 2H), 3.10 – 
3.00 (m, 1H), 2.92 – 2.83 (m, 1H), 2.73 (t, J = 7.0 Hz, 2H), 2.41 – 2.31 (m, 1H), 1.79 – 
1.31 (m, 4H). TOF ES+ MS:  502.1 (M+H), 524.1 (M+Na). HPLC ret. time  = 5.20 min; 
purity > 95%.  
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Ethyl 1-(1-(4-chlorobenzyl)-6-fluoro-1H-indole-2-carbonyl)piperidine-4-carboxylate 
(194). 6-fluoro-1H-indole-2-carboxylic acid  192 (500 mg, 2.79 mmol), EDCI (1070 mg, 
5.58 mmol), and HOBt (754 mg, 5.58 mmol) were dissolved in DCM (14 mL). The 
reaction was allowed to stir for 20 minutes before adding ethyl piperidine-4-carboxylate 
(0.860 mL, 5.58 mmol) and DIEA (0.975 mL, 5.58 mmol).   The reaction was stirred at 
room temperature overnight. After 18 hours, it was diluted with water and ethyl acetate. 
The organic phase was washed with 1N HCl, saturated sodium carbonate, and saturated 
sodium chloride. It was dried over sodium sulfate, filtered and concentrated. No further 
purification was done on the material. Yield:  140 mg (16%).  
1
H NMR (500 MHz, 
DMSO- d6) δ 11.64 (s, 1H), 7.62 (dd, J = 8.7, 5.5 Hz, 1H), 7.13 (dd, J = 10.0, 2.5 Hz, 
1H), 6.96 – 6.88 (m, 1H), 6.81 (dd, J = 2.3, 0.9 Hz, 1H), 4.33 (dt, J = 13.3, 3.2 Hz, 2H), 
4.09 (q, J = 7.1 Hz, 2H), 3.19 – 3.08 (m, 2H), 2.75 – 2.65 (m, 1H), 1.97 – 1.89 (m, 2H), 
1.57 (q, J = 11.1 Hz, 2H), 1.20 (t, J = 7.1 Hz, 3H). TOF ES+ MS:  319.0 (M+H), 341.0 
(M+Na). HPLC ret. time  = 6.76 min; purity > 95% 
Ethyl 1-(6-fluoro-1H-indole-2-carbonyl)piperidine-4-carboxylate (140 mg, 0.440 mmol) 
and Cs2CO3 (287 mg, 0.880 mmol) were dissolved in DMF (5.0 mL). 1-chloro-4-
(chloromethyl)benzene (0.617 ml, 4.83 mmol) was added as a liquid. The reaction was 
heated at 60 °C overnight.  The reaction was cooled and diluted with water and ethyl 
acetate. The aqueous layer was washed with another aliquot of ethyl acetate. The 
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combined organic phases were washed with saturated sodium chloride solution four 
times. It was dried over sodium sulfate, filtered and concentrated. The crude oil was 
purified using flash chromatography (0-10% ethyl acetate/hexanes). The product was 
isolated as a white solid.   Yield:  170 mg (87%). 
1
H NMR (500 MHz, DMSO- d6) δ 7.64 
(dd, J = 8.7, 5.5 Hz, 1H), 7.54 (dd, J = 10.5, 2.3 Hz, 1H), 7.36 – 7.29 (m, 2H), 7.10 – 
7.04 (m, 2H), 7.02 – 6.94 (m, 1H), 6.75 (d, J = 0.8 Hz, 1H), 5.50 – 5.46 (m, 2H), 4.30 
(bs, 1H), 4.07 (q, J = 7.1 Hz, 2H), 3.88 (bs, 1H), 2.99 (m, 2H), 2.62 – 2.52 (m, 2H), 2.01 
– 1.54 (m, 4H), 1.18 (t, J = 7.1 Hz, 3H). TOF ES+ MS:  443.1 (M+H), 465.0 (M+Na). 
HPLC ret. time  = 8.39 min; purity >95%.  
 
1-(1-(4-chlorobenzyl)-6-fluoro-1H-indole-2-carbonyl)-N-(2-(pyridin-4-
yl)ethyl)piperidine-4-carboxamide (CCG 208918, 117). 194 (140 mg, 0.316 mmol) 
and  lithium hydroxide, H2O (133 mg, 3.16 mmol) were dissolved in 1/1 THF/water (4 
ml). The reaction was stirred overnight at room temperature. After 16 hours, the reaction 
was concentrated until a suspension formed. It was cooled by an ice bath and diluted with 
minimal amount of water to allow a stir bar to move freely. 2N HCl was added dropwise 
until pH 2 was reached. The resulting suspension was diluted with ethyl acetate. The 
aqueous phase was washed with another aliquot of ethyl acetate. The organic phases were 
combined and washed with saturated sodium chloride, filtered, and concentrated. No 
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further purification was performed.  The product was isolated as a white solid. Yield:  
106 mg, 81%  
1
H NMR (400 MHz, DMSO- d6) δ 12.28 (s, 1H), 7.64 (dd, J = 8.8, 5.5 Hz, 
1H), 7.51 (dd, J = 10.5, 2.3 Hz, 1H), 7.37 – 7.29 (m, 2H), 7.12 – 7.05 (m, 2H), 7.03 – 
6.93 (m, 1H), 6.75 (s, 1H), 5.47 (s, 2H), 4.26 (s, 1H), 3.87 (s, 1H), 3.00 (bs, 2H), 2.48 – 
2.43 (m, 1H), 1.95 – 1.21 (m, 4H). TOF ES+ MS:  415.0  (M+H), 437.0 (M+Na). HPLC 
ret. time  = 7.02 min; purity > 95%. 
The crude acid from above (106 mg, 0.256 mmol), EDCI (98 mg, 0.511 mmol), 
and DMAP (62.4 mg, 0.511 mmol) were suspended  in DCM (Volume: 5.0 mL). The 
reaction was stirred for 10 minutes before 2-(pyridin-4-yl)ethanamine (0.061 mL, 0.511 
mmol) and DIEA (0.089 mL, 0.511 mmol) were added. The reaction was stirred 
overnight. The reaction was diluted with water and ethyl acetate. The organic phase was  
washed with water, saturated sodium carbonate, and saturated sodium chloride. It was 
dried over sodium sulfate, filtered and concentrated. The crude material was triturated 
using ethyl acetate. The white solid was filtered to obtain the desired product 117. Yield:  
90 mg (68%).  
1
H NMR (500 MHz, DMSO- d6) δ 8.48 – 8.43 (m, 2H), 7.89 (t, J = 5.7 
Hz, 1H), 7.64 (dd, J = 8.7, 5.5 Hz, 1H), 7.49 (dd, J = 10.4, 2.3 Hz, 1H), 7.38 – 7.32 (m, 
2H), 7.24 – 7.18 (m, 2H), 7.13 – 7.08 (m, 2H), 7.01 – 6.93 (m, 1H), 6.74 (s, 1H), 5.47 (s, 
2H), 4.37 (bs, 1H), 3.93 (bs, 1H), 3.34 – 3.28 (m, 2H), 3.04 – 2.70 (m, 4H), 2.36 – 2.26 
(m, 1H), 1.71 – 1.18 (m, 4H). TOF ES+ MS:  519.0 (M+H). HPLC ret. time  = 5.83 min; 
purity > 95%.  
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1-Benzyl-1H-indole-2-carboxylic acid (195).  Ester 155 (1.0 g, 5.3 mmol), potassium 
carbonate (1.461 g, 10.57 mmol) were dissolved in DMF (15 ml) and heated to 60 °C. 
The reaction was stirred for 20 minutes before the addition of (bromomethyl)benzene 
(0.942 ml, 7.93 mmol). The reaction was stirred overnight at 60 °C. After cooling to 
room temperature, it was diluted with water and an ethyl acetate/diethyl ether mixture. 
The aqueous phase was washed with another aliquot of the same organic mixture. The 
organic phases were combined and washed with saturated sodium chloride (2x), dried 
over sodium sulfate, filtered and concentrated. The resulting crude material was purified 
via SP1 biotage (25 g silica cartridge) with 0-40% ethyl acetate/hexanes gradient. Ethyl 
1-benzyl-1H-indole-2-carboxylate  was obtained as an off-white solid. Yield:  396 mg, 
27%. . 
1
H NMR (500 MHz, DMSO- d6) δ 7.72 (dt, J = 8.0, 1.0 Hz, 1H), 7.57 (dd, J = 8.5, 
0.9 Hz, 1H), 7.38 (d, J = 0.9 Hz, 1H), 7.35 – 7.11 (m, 5H), 7.05 – 6.99 (m, 2H), 5.86 (s, 
2H), 4.28 (q, J = 7.1 Hz, 2H), 1.28 (t, J = 7.1 Hz, 3H). HPLC ret. time  = 8.58 min; purity 
> 95%.  
  The ester from above (390 mg, 1.396 mmol) was dissolved in THF (1 ml) and  2N 
aqueous sodium hydroxide (3.49 ml, 6.98 mmol). The reaction was stirred for 3 hours 
before it was concentrated under vacuum until a white precipitate formed. The resulting 
suspension was cooled by an ice bath and diluted with water until a stir bar was able to 
stir. 2N HCl was added dropwise until pH 2 was reached. The acidic aqueous suspension 
was extracted with ethyl acetate. The aqueous layer was washed with another aliquot of 
ethyl acetate. The organic phases were combined and washed with saturated sodium 
chloride, filtered and concentrated. No further purification of 24f was necessary.  Yield:  
339 mg, 27%  
1
H NMR (500 MHz, DMSO- d6) δ 12.97 (s, 1H), 7.70 (dt, J = 8.1, 0.9 Hz, 
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1H), 7.54 (dd, J = 8.5, 1.0 Hz, 1H), 7.35 – 7.17 (m, 5H), 7.16 – 7.09 (m, 1H), 7.05 – 7.00 
(m, 2H), 5.88 (s, 2H). TOF ES+ MS:  252.1(M+H), 274.1(M+Na). HPLC ret. time  = 
7.13 min; purity > 95%. 
 
1-(1-benzyl-1H-indole-2-carbonyl)-N-(2-(pyridin-4-yl)ethyl)piperidine-4-carboxamide 
(CCG 209023, 110). 195 (48.5 mg, 0.193 mmol), DMAP (23.56 mg, 0.193 mmol), and 
EDCI (37.0 mg, 0.193 mmol) were dissolved in THF (3.0 ml). The reaction remained a 
suspension after 30 minutes.  Amine 190 (30 mg, 0.129 mmol) was added followed by 
DIEA (0.034 ml, 0.193 mmol) . The reaction was stirred overnight at room temperature.  
The reaction was diluted with water and ethyl acetate. The organic phase was washed 
with water and saturated sodium chloride, then it was dried over sodium sulfate. The 
resulting crude material was purified using SP1 Biotage using a gradient of 30% ethyl 
acetate: hexanes to 100% ethyl acetate. The product was isolated as a white solid.  Yield:  
20 mg (33%). 
1
H NMR (500 MHz, DMSO- d6) δ 8.48 – 8.43 (m, 2H), 7.88 (t, J = 5.6 Hz, 
1H), 7.62 (dt, J = 7.8 Hz, 1H), 7.58 (dd, J = 8.4, 0.9 Hz, 1H), 7.29 – 7.17 (m, 7H), 7.13 – 
7.05 (m, 4H), 6.69 (s, 1H), 5.49 (s, 2H), 4.40 (bs, 1H), 3.92 (bs, 1H), 3.30 (m, 2H), 2.89 
(bs, 2H), 2.73 (t, J = 6.9 Hz, 2H), 2.35 – 2.25 (m, 1H), 1.74 – 1.21 (m, 4H). TOF ES+ 
MS:  467.2 (M+H), 489.2 (M+Na). HPLC ret. time  = 5.30 min; purity >95%.  
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1-(2,6-Difluorobenzyl)-1H-indole-2-carboxylic acid (196). 60 wt% sodium hydride 
(127 mg, 3.17 mmol) was suspended in DMF (8 ml) and cooled with an ice bath. The 
reaction was stirred at for twenty minutes before a DMF (2 ml) solution of 8 (500 mg, 
2.64 mmol) was added dropwise. The reaction was allowed to stir for 20 minutes before 
2-(bromomethyl)-1,3-difluorobenzene (821 mg, 3.96 mmol) was added dropwise as a 
solution in DMF (3 ml). It was allowed to stir at room temperature overnight. The 
reaction was diluted with saturated ammonium chloride and a mixture of ethyl 
acetate/diethyl ether. The aquoeous phase was washed with another aliquout of ethyl 
acetate/diethyl ether. The organic phases were combined and washed with saturate 
sodium chloride, dried over sodium sulfate, filtered and concentrated. The resulting crude 
material was purified via SP1 Biotage (25 g silica gel column) using a gradient of 100% 
hexanes to 30% ethyl acetate/hexanes. The product ethyl 1-(2,6-difluorobenzyl)-1H-
indole-2-carboxylate was isolated as a white solid. Yield:  586 mg (70%).  
1
H NMR (500 
MHz, DMSO- d6) δ 7.68 (dt, J = 8.0, 1.0 Hz, 1H), 7.50 (dd, J = 8.4, 1.0 Hz, 1H), 7.39 – 
7.27 (m, 3H), 7.16 – 7.09 (m, 1H), 7.08 – 7.01 (m, 2H), 5.99 (s, 2H), 4.32 (q, J = 7.1 Hz, 
2H), 1.31 (t, J = 7.1 Hz, 3H). TOF ES+ MS:  316.1(M+H), 338.0 (M+Na). HPLC ret. 
time  = 8.53 min; purity >95%.  
The ester from above (500 mg, 1.59 mmol) was dissolved in ethanol (3 ml) and 
aqueous sodium hydroxide  (3.96 ml, 7.93 mmol). The reaction was stirred for 3 hours 
before it was concentrated under vacuum until white precipitate formed. The resulting 
suspension was cooled using an ice bath and diluted with water until a stir bar was 
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spinning freely. 2N HCl was added dropwise until the aqueous solution reached pH 2. It 
was diluted with ethyl acetate (2x). The organic phases were combined and washed with 
saturated sodium chloride, dried over sodium sulfate, filtered and concentrated. The 
resulting solid 196 was taken to the next step without purification. Yield:  396 mg, 87%   
1
H NMR (500 MHz, DMSO- d6) δ 12.99 (s, 1H), 7.67 (d, J = 7.9 Hz, 1H), 7.46 (d, J = 
8.4 Hz, 1H), 7.40 – 7.23 (m, 3H), 7.14 – 6.99 (m, 3H), 6.02 (s, 2H). TOF ES+ MS:  288.1 
(M+H), 310.1 (M+Na). HPLC ret. time  = 7.10 min; purity > 95%. 
 
1-(1-(2,6-difluorobenzyl)-1H-indole-2-carbonyl)-N-(2-(pyridin-4-yl)ethyl)piperidine-
4-carboxamide (CCG 209024, 111). 196 (104 mg, 0.361 mmol), HOBt (56.3 mg, 0.417 
mmol), and EDCI (80 mg, 0.417 mmol) were dissolved in THF (Volume: 3.0 ml). The 
reaction was stirred for 30 minutes. Solid 16 (30 mg, 0.13 mmol) was added followed by 
DIEA (0.073 ml, 0.417 mmol). The reaction was stirred overnight at room temperature.  
The reaction was diluted with water and ethyl acetate. The organic phase was washed 
with water and saturated sodium chloride; it was dried over sodium sulfate. The resulting 
crude material was purified using SP1 Biotage using a gradient of 30% ethyl acetate: 
hexanes to 100% ethyl acetate. The product was isolated as a white solid. Yield:  68 mg 
(49%). 
1
H NMR (500 MHz, DMSO- d6) δ 8.49 – 8.44 (m, 2H), 7.91 (t, J = 5.6 Hz, 1H), 
7.61 – 7.55 (m, 2H), 7.41 – 7.31 (m, 1H), 7.28 – 7.20 (m, 3H), 7.12 – 7.01 (m, 3H), 6.67 
(s, 1H), 5.63 (s, 4H), 4.42 (bs, 1H), 3.97 (bs, 1H), 3.37 – 3.29 (m, 3H), 3.03 – 2.69 (m, 
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4H), 2.37 – 2.27 (m, 1H), 1.73 – 1.31 (m, 4H). TOF ES+ MS:  503.2 (M+H) HPLC ret. 
time  = 5.37 min; purity = 92%.  
 
1-(1-(3-nitrobenzyl)-1H-indole-2-carbonyl)-N-(2-(pyridin-4-yl)ethyl)piperidine-4-
carboxamide (212150, 116) 
Cesium carbonate (2.58 g, 7.93 mmol) and 155 (1.0 g, 5.29 mmol) was dissolved 
in 10 mL of DMF.  It was stirred at room temperature for 30 minutes before an 8 mL 
DMF solution of 1-(bromomethyl)-3-nitrobenzene (1.713 g, 7.93 mmol).  The reaction 
was allowed to stir overnight.  It was diluted with saturated ammonium chloride and ethyl 
acetate/THF.  The aqueous phase was washed with the same organic phase combination.  
The combined organic phases were washed with saturated sodium chloride.  It was dried 
over sodium sulfate, filtered, and concentrated.  The resulting crude solid was triturated 
with ethyl acetate and filtered to obtain ethyl 1-(3-nitrobenzyl)-1H-indole-2-carboxylate 
as a white solid.  Yield:  373 mg, 22 %.   
 Ethyl 1-(3-nitrobenzyl)-1H-indole-2-carboxylate (373 mg, 1.150 mmol) was 
dissolved in EtOH (Ratio: 2, Volume: 2 ml), THF (Ratio: 1.000, Volume: 1.000 ml) and 
2N NaOH (Ratio: 1.000, Volume: 1.000 ml).  The reaction was stirred overnight.  The 
reaction was concentrated by half volume and diluted with water to allow free movement 
of a stirbar.  It was cooled by and ice bath and acidified using 2N HCl.  The resulting 
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suspension was extracted using ethyl acetate.  The organic phase was washed with 
saturated sodium chloride, dried over sodium sulfate, filtered and concentrated.  The 
product 220 was obtained as a white solid.  The crude material was taken directly to the 
next step.  Yield:  314 mg, 92 % 
Compound 220 (160 mg, 0.539 mmol), 1-Hydroxybenzotriazole (97 mg, 0.718 
mmol), and EDCI (138 mg, 0.718 mmol) were dissolved in THF (Volume: 5 ml) and 
stirred for 20 minutes before 190 (110 mg, 0.359 mmol) was added a solid.  It was 
followed by the addition of Hunig'sBase (0.188 ml, 1.078 mmol).  The reaction was 
stirred overnight.  The reaction was diluted with water and ethyl acetate/THF.  The 
organic phase was washed with sodium carbonate and saturated sodium chloride.  The 
organic phase was dried over sodium sulfate, filtered and concentrated.  The crude 
material was purified using sp1 biotage with gradient of 100% ethyl acetate to 10% 
methanol/ethyl acetate to obtain product as a white solid.  
1
H NMR (500 MHz, DMSO-
d6) δ ppm 8.41 - 8.50 (m, 2 H), 8.10 (d, J=8.1 Hz, 1 H), 7.96 (s, 1 H), 7.89 (t, J=5.6 Hz, 1 
H), 7.66 (d, J=7.8 Hz, 1 H), 7.55 - 7.62 (m, 2 H), 7.50 - 7.55 (m, 1 H), 7.19 - 7.27 (m, 3 
H), 7.09 - 7.16 (m, 1 H), 6.77 (s, 1 H), 5.65 (s, 2 H), 4.39 (br. s., 1 H), 4.01 (br. s., 1 H), 
3.30 (q, J=6.8 Hz, 2 H), 2.68 - 3.16 (m, 4 H), 2.31 (tt, J=11.1, 3.6 Hz, 1 H), 1.08 - 1.78 
(m, 4 H).  TOF ES+ MS:   512.1 (M+H).  HPLC (gradient A): ret. time = 5.51 min; purity 
> 95 % 
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1-(1-(4-chlorobenzyl)-5-methoxy-1H-indole-2-carbonyl)-N-(2-(pyridin-4-
yl)ethyl)piperidine-4-carboxamide (CCG 209025, 113)  A suspension of sodium 
hydride (37.5 mg, 0.937 mmol) in DMF (2.0 mL) was cooled to 0 
o
C.  A 1.0 mL DMF 
solution of 225 (137 mg, 0.625 mmol) was added dropwise and the reaction was stirred 
for 15 minutes before a 1.0 mL DMF solution of 1-chloro-4-(chloromethyl)benzene 
(0.120 ml, 0.937 mmol).  The reaction was warmed to room temperature and stirred for 5 
hours.  The reaction was diluted with water and ethyl acetate.  The aqueous layer was 
washed with another portion of ethyl acetate.  The organic phases were combined and 
washed with saturated sodium chloride (3x), dried over sodium sulfate, filtered, and 
concentrated.  The crude material was purified via column chromatogray using 0-50% 
ethyl acetate/hexanes.  The product was obtained as a white solid and taken directly to the 
next step    Yield:  191 mg, 89% 
Ethyl 1-(4-chlorobenzyl)-5-methoxy-1H-indole-2-carboxylate (350 mg, 1.018 
mmol) was dissolved in EtOH (Volume: 2.0 ml) and 2N sodium hydroxide (5.09 ml, 
10.18 mmol).  The reaction was stirred for 4 hours, before it was concentrated under 
vacuum to remove the ethanol.  The resulting thick solution was diluted with water and 
acidifed using 2N HCl.  The white suspension was sonicated for 10 minutes before the 
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solid was filtered to obtain 220.  The carboxylic acid was taken directly to the next step.  
Yield:  260 mg, 81 %      
Compound 230 (50 mg, 0.158 mmol), EDCI (45.5 mg, 0.238 mmol), DMAP 
(29.0 mg, 0.238 mmol) were dissolved in THF (Volume: 3.0 ml) and stirred at room 
temperature for 30 minutes.  Compound 190 (55.5 mg, 0.206 mmol) was added as a solid.  
Subsequently, Hunig's Base (0.041 ml, 0.238 mmol) was added.  The reaction was stirred 
at room temperature overnight.  The reaction was diluted with water and ethyl acetate.  
The organic phase was washed with saturated sodium carbonate and saturated sodium 
chloride.  It was dried over sodium sulfate, filtered and concentrated.  The resulting crude 
material was purified via flash column chromatography using 0-70% ethyl 
acetate/hexanes to obtain product as a white solid.  
1
H NMR (500 MHz, DMSO-d6) δ 
ppm 8.43 - 8.49 (m, 2 H), 7.89 (t, J=5.6 Hz, 1 H), 7.43 (d, J=9.0 Hz, 1 H), 7.31 - 7.35 (m, 
2 H), 7.19 - 7.24 (m, 2 H), 7.05 - 7.12 (m, 3 H), 6.85 (dd, J=9.0, 2.4 Hz, 1 H), 6.62 (s, 1 
H), 5.44 (s, 2 H), 4.35 (br. s., 1 H), 3.98 (br. s., 1 H), 3.76 (s, 3 H), 3.27 - 3.32 (m, 6 H), 
2.77 - 3.08 (m, 2 H), 2.73 (t, J=7.0 Hz, 2 H), 2.32 (tt, J=11.1, 3.6 Hz, 1 H), 1.21 - 1.74 
(m, 4 H).  TOF ES+ MS:   531.2 (M+H), 553.2 (M+Na).  HPLC (gradient A): ret. time = 
5.55 min; purity > 95 % 
 
1-(1H-indole-2-carbonyl)-N-(2-(pyridin-4-yl)ethyl)piperidine-4-carboxamide (CCG 
212059, 114)  Ethyl 1H-indole-2-carboxylate (155, 3.0 g, 16 mmol) and lithium 
hydroxide, H2O (3.3 g, 79 mmol) were dissolved in 2/1 water/THF (30 mL). The reaction 
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was stirred overnight. The reaction was diluted with water and diethyl ether. The water 
layer was washed with diethyl ether twice. The aqueous layer was acidified to pH 2 using 
2N HCl. The suspension was extracted using ethyl acetate. The organic layer was washed 
with saturated sodium chloride solution, dried over magnesium sulfate, filtered and 
concentrated to obtain 1H-Indole-2-carboxylic acid   as a white solid. Yield: 2.39 g, 94%. 
1
H NMR (400 MHz, DMSO- d6) δ 12.95 (s, 1H), 11.74 (s, 1H), 7.67 – 7.60 (m, 1H), 7.47 
– 7.39 (m, 1H), 7.28 – 7.19 (m, 1H), 7.11 – 7.01 (m, 2H).   
1H-indole-2-carboxylic acid (100 mg, 0.621 mmol), EDCI (178 mg, 0.931 mmol), 
1-Hydroxybenzotriazole (126 mg, 0.931 mmol) were dissolved in DCM (Volume: 5 ml) 
and stirred for 30 minutes at room temperature.  N-(2-(pyridin-4-yl)ethyl)piperidine-4-
carboxamide, 2HCl (285 mg, 0.931 mmol) was added as a solid, followed by 
Hunig'sBase (0.542 ml, 3.10 mmol).  The reaction was further stirred at room 
temperature overnight at room temperature.   The reaction was diluted with water and 
ethyl acetate/THF.  The organic phase was washed with saturated sodium carbonate, 
sodium bicarbonate, and brine.  The organic phase was dried over sodium sulfate.  The 
drying agent was used filtered and crude material concentrated.  The crude material was 
purified via Biotage SP1 with 50% ethyl acetate/hexanes to 100% ethyl acetate.  The 
product was a white solid.  Yield:  140 mg, 60 %.  
1
H NMR (500 MHz, DMSO-d6) δ ppm 
8.43 - 8.49 (m, 2 H), 7.96 (t, J=5.6 Hz, 1 H), 7.60 (d, J=8.1 Hz, 1 H), 7.41 (d, J=8.1 Hz, 1 
H), 7.20 - 7.25 (m, 2 H), 7.14 - 7.20 (m, 1 H), 7.01 - 7.07 (m, 1 H), 6.75 (d, J=1.5 Hz, 1 
H), 4.42 (dt, J=13.4, 3.7 Hz, 2 H), 3.33 (q, J=6.8 Hz, 3 H), 3.05 (br. s., 2 H), 2.74 (t, 
J=7.0 Hz, 2 H), 2.41 (tt, J=11.3, 3.8 Hz, 1 H), 1.67 - 1.77 (m, 2 H), 1.45 - 1.60 (m, 2 H).  
TOF ES+ MS:   377.3 (M+H), 399.3 (M+Na).  HPLC (gradient A): ret. time = 4.37 min;  
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purity > 95 % 
 
 
Ethyl 1-(1-methyl-1H-indole-2-carbonyl)piperidine-4-carboxylate (199). Ethyl 1H-
indole-2-carboxylate 155 (1.00 g, 5.29 mmol) and K2CO3 (1.46 g, 10.57 mmol) were 
dissolved in DMF (10 ml). Iodomethane (0.99 ml, 16 mmol) was added and the reaction 
was stirred at 60 °C overnight. The reaction was dissolved in water and diethyl ether. The 
water layer was washed with diethyl ether twice. The organic layers were combined and 
washed with brine twice. It was then dried over magnesium sulfate, filtered, and 
concentrated. The crude product ethyl 1-methyl-1H-indole-2-carboxylate was taken 
directly into the next step. 
1
H NMR (400 MHz, DMSO- d6) δ 7.69 (d, J = 8.0 Hz, 1H), 
7.58 (d, J = 8.6 Hz, 1H), 7.35 (t, J = 7.8 Hz, 1H), 7.27 (s, 1H), 7.14 (t, J = 7.5 Hz, 1H), 
4.32 (q, J = 7.1 Hz, 2H), 4.03 (s, 3H), 1.34 (t, J = 7.1 Hz, 3H). TOF ES+ MS:  204.1 
(M+H). HPLC ret. time  = 7.85 min; purity > 95%.  
Ethyl 1-methyl-1H-indole-2-carboxylate (1.0 g, 4.92 mmol) and  lithium 
hydroxide (1.178 g, 49.2 mmol) were dissolved in 2/1 water/THF (6 ml). The reaction 
was allowed to stir overnight. The reaction was diluted with water and washed with 
diethyl ether. The water layer was then acidified with 1N HCl to pH 2. The resulting 
suspension was extracted with ethyl acetate. The organic layer was washed with saturated 
sodium chloride, dried over magnesium sulfate, filtered and concentrated to obtain pure 
1-methyl-1H-indole-2-carboxylic acid as a white solid. Yield:  560 mg (65%). 
1
H NMR 
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(400 MHz, DMSO- d6) δ 12.91 (s, 1H), 7.67 (d, J = 8.0 Hz, 1H), 7.57 (d, J = 8.5 Hz, 1H), 
7.37 – 7.29 (m, 1H), 7.22 (s, 1H), 7.16 – 7.08 (m, 1H), 4.02 (s, 3H).  TOF ES+ MS:  
176.1 (M+H).  HPLC ret. time  = 6.06 min; purity > 95%.  
1-Methyl-1H-indole-2-carboxylic acid (200 mg, 1.14 mmol), HOBt (231 mg, 
1.712 mmol), and EDCI (328 mg, 1.712 mmol) were dissolved in DCM (Volume: 4 ml). 
The reaction was allowed to stir for 10 minutes before adding DIEA (0.299 ml, 1.71 
mmol) and ethyl piperidine-4-carboxylate (0.264 ml, 1.71 mmol). The reaction was 
stirred overnight. The reaction was diluted with water and extracted with ethyl acetate. 
The organic layer was washed with saturated sodium bicarbonate and 1N HCl. This was 
followed by a wash with saturated sodium chloride. The organic phase was dried over 
magnesium sulfate, filtered and concentrated to obtain 26e as a white solid. No further 
purification was required. Yield:  214 mg, 60%. 
1
H NMR (400 MHz, DMSO- d6) δ 7.57 
(d, J = 8.0 Hz, 1H), 7.48 (d, J = 9.0 Hz, 1H), 7.21 (d, J = 15.3 Hz, 1H), 7.06 (t, J = 7.5 
Hz, 1H), 6.61 (s, 1H), 4.37 – 3.83 (m, 4H), 3.71 (s, 3H), 3.10 (bs, 2H), 2.70 – 2.59 (m, 
1H), 1.87 (bs, 2H), 1.61 – 1.46 (m, 2H), 1.16 (t, J = 7.1 Hz, 3H). TOF ES+ MS:  315.1 
(M+H), 337.1 (M+Na). HPLC ret. time  = 6.99 min; purity > 95%. 
 
1-(1-methyl-1H-indole-2-carbonyl)-N-(2-(pyridin-4-yl)ethyl)piperidine-4-
carboxamide (CCG 206484, 118). 199 (210 mg, 0.668 mmol) and lithium hydroxide, 
H2O (280 mg, 6.68 mmol) were dissolved in 2/1 water/THF (2.3 ml). The reaction was 
stirred for 6 hours before it was diluted with water and diethyl ether. The aqueous layer 
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was acidified using 2N HCl to pH ~ 2. The suspension was extracted with ethyl acetate. 
The organic phase was washed with saturated sodium chloride, dried over magnesium 
sulfate, filtered and concentrated to obtain product as a white solid. No purification was 
performed on the material. The crude acid was taken directly to the next step.  TOF ES+ 
MS: 287.1(M+H), 309.1(M+Na). HPLC ret. time  = 5.60 min; purity = 94%. 
1-(1-methyl-1H-indole-2-carbonyl)piperidine-4-carboxylic acid (100 mg, 0.349 
mmol), EDCI (100 mg, 0.524 mmol), and HOBt (70.8 mg, 0.524 mmol) were dissolved 
in DCM (Volume: 3.0 mL). The reaction was stirred for 10 minutes before 2-(pyridin-4-
yl)ethanamine (0.059 mL, 0.524 mmol) and DIEA (0.091 mL, 0.524 mmol). The reaction 
was stirred overnight at room temperature. The reaction was diluted with water and ethyl 
acetate. The organic layer was washed with saturated sodium bicarbonate solution, and 
finally saturated sodium chloride. the organic layer was then dried over magnesium 
sulfate, filtered and concentrated. The resulting solid was triturated in ethyl acetate to 
give 118. Yield:  50 mg (38%). 
1
H NMR (400 MHz, DMSO- d6) δ 8.49 – 8.42 (m, 2H), 
7.94 (t, J = 5.6 Hz, 1H), 7.60 (d, J = 7.8 Hz, 1H), 7.50 (d, J = 8.0 Hz, 1H), 7.29 – 7.19 
(m, 3H), 7.09 (t, J = 7.4 Hz, 1H), 6.62 (s, 1H), 4.40 (bs, 1H), 4.02 (bs, 1H), 3.74 (s, 3H), 
3.32 – 3.29 (m, 2H), 3.04 (bs, 2H), 2.73 (t, J = 7.0 Hz, 2H), 2.41 – 2.36 (m, 1H), 1.71 – 
1.66 (m, 2H), 1.57 – 1.46 (m, 2H). TOF ES+ MS:  391.1 (M+H). HPLC ret. time  = 4.68 
min; purity > 95%. 
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Ethyl 1-(1-(4-chlorobenzyl)-5-fluoro-1H-indole-2-carbonyl)piperidine-4-carboxylate 
(200).  Ethyl 5-fluoro-1H-indole-2-carboxylate 198 (0.500 g, 2.413 mmol) and Cs2CO3 
(1.179 g, 3.62 mmol) were dissolved in DMF (15 ml). 1-chloro-4-(chloromethyl)benzene 
(0.617 ml, 4.83 mmol) was added as a liquid. The reaction was heated at 60 °C overnight. 
The reaction was cooled and diluted with water and ethyl acetate. The aqueous layer was 
washed with another aliquot of ethyl acetate. The combined organic phases were washed 
with saturated sodium chloride solution four times. It was dried over sodium sulfate, 
filtered and concentrated. The crude oil was purified by flash chromatography using 0-
10% ethyl acetate/hexanes. The product ethyl 1-(4-chlorobenzyl)-5-fluoro-1H-indole-2-
carboxylate was isolated as a clear oil.  Yield:  600 mg (75 %). 
1
H NMR (500 MHz, 
DMSO- d6) δ 7.63 (dd, J = 9.0, 5.3 Hz, 1H), 7.51 (dd, J = 9.4, 2.4 Hz, 1H), 7.47 – 7.41 
(m, 1H), 7.37 – 7.33 (m, 2H), 7.21 (td, J = 9.3, 2.5 Hz, 1H), 7.03 (d, J = 8.5 Hz, 2H), 5.85 
(s, 2H), 4.28 (q, J = 7.1 Hz, 2H), 1.28 (t, J = 7.1 Hz, 3H). HPLC ret. time  = 9.06 min; 
purity > 95%.  
Ethyl 1-(4-chlorobenzyl)-5-fluoro-1H-indole-2-carboxylate (465 mg, 1.402 
mmol) and lithium hydroxide, H2O (588 mg, 14.0 mmol) were dissolved in 2/1 
water/THF (12 ml). The reaction was allowed to stir overnight at room temperature. The 
reaction was diluted with water and diethyl ether. The organic phase was removed and 
the aqueous phase was acidified using 2N HCl to pH ~2. The resulting suspension was 
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extracted with ethyl acetate. The aqueous phase was washed with another aliquot of ethyl 
acetate. The organic phases were combined, washed with saturated sodium chloride, 
filtered and concentrated to obtain the product 1-(4-chlorobenzyl)-5-fluoro-1H-indole-2-
carboxylic acid. No further purification was performed. Yield:  130 mg (31%).  
1
H NMR 
(500 MHz, DMSO- d6) δ 13.14 (s, 1H), 7.58 (dd, J = 9.2, 4.4 Hz, 1H), 7.49 (dd, J = 9.4, 
2.6 Hz, 1H), 7.37 – 7.28 (m, 3H), 7.18 (td, J = 9.2, 2.6 Hz, 1H), 7.06 – 7.00 (m, 2H), 5.86 
(s, 2H). HPLC ret. time  = 7.55 min; purity > 95%.  
1-(4-chlorobenzyl)-5-fluoro-1H-indole-2-carboxylic acid (130 mg, 0.428 mmol), 
EDCI (164 mg, 0.856 mmol), and DMAP (105 mg, 0.856 mmol) were dissolved in DCM 
(Volume: 5 ml). The reaction was allowed to stir for 20 minutes before adding ethyl 
piperidine-4-carboxylate (0.132 ml, 0.856 mmol) and DIEA (0.150 ml, 0.856 mmol). The 
reaction was stirred at room temperature overnight. After 18 hours, it was diluted with 
water and ethyl acetate. The organic phase was washed with 1N HCl, saturated sodium 
carbonate, and saturated sodium chloride. It was dried over sodium sulfate, filtered and 
concentrated. The crude mixture was triturated with diethyl ether and ethyl acetate. The 
product 26i was isolated as a pale yellow oil solid. Yield:  90 mg (100%). 
1
H NMR (500 
MHz, DMSO- d6) δ 7.62 (dd, J = 9.1, 4.4 Hz, 1H), 7.40 (dd, J = 9.5, 2.6 Hz, 1H), 7.35 – 
7.30 (m, 6H), 7.11 – 7.05 (m, 9H), 6.71 (s, 1H), 5.49 (s, 2H), 4.31 (bs, 1H), 4.07 (q, J = 
7.1, 7.1 Hz, 2H), 3.83 (bs, 1H), 3.08 (bs, 1H), 2.92 (bs, 1H), 2.62 – 2.53 (m, 1H), 1.86 
(bs, 1H), 1.66 (bs, 1H), 1.40 (bs, 1H), 1.18 (t, J = 7.1 Hz, 3H), 1.05 (bs, 1H). TOF ES+ 
MS:  443.0  (M+H), 465.0 (M+Na). HPLC ret. time  = 8.28 min; purity >95%.  
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1-(1-(4-chlorobenzyl)-5-fluoro-1H-indole-2-carbonyl)-N-(2-(pyridin-4-
yl)ethyl)piperidine-4-carboxamide (CCG 208919, 115).  200 (190 mg, 0.429 mmol) 
and  lithium hydroxide, H2O (180 mg, 4.29 mmol) were dissolved in 2/1 water/THF (4.5 
ml). The reaction was stirred overnight at room temperature. After 16 hours, the reaction 
was concentrated until a suspension formed. It was cooled by an ice bath and diluted with 
minimal amount of water to allow a stir bar to move freely. 2N HCl was added dropwise 
until pH 2 was reached. The resulting suspension was diluted with ethyl acetate. The 
aqueous phase was washed with another aliquot of ethyl acetate. The organic phases were 
combined and washed with saturated sodium chloride, filtered, and concentrated. No 
further purification was performed.  The product 1-(1-(4-chlorobenzyl)-5-fluoro-1H-
indole-2-carbonyl)piperidine-4-carboxylic acid was isolated as a white solid. Yield:  129 
mg, 73%.  
1
H NMR (400 MHz, DMSO- d6) δ 12.26 (s, 1H), 7.59 (dd, J = 9.0, 4.4 Hz, 
1H), 7.40 (dd, J = 9.6, 2.6 Hz, 1H), 7.35 – 7.30 (m, 2H), 7.12 – 7.05 (m, 3H), 6.71 (s, 
1H), 5.48 (s, 2H), 4.28 (bs, 1H), 3.84 (bs, 1H), 3.00 (bs, 2H), 2.48 – 2.41 (m, 1H), 1.53 
(bm, 4H). HPLC ret. time  = 5.51 min; purity > 95%.  
1-(1-(4-chlorobenzyl)-5-fluoro-1H-indole-2-carbonyl)piperidine-4-carboxylic 
acid (106 mg, 0.256 mmol), DMAP (62.4 mg, 0.51 mmol), and EDCI (98 mg, 0.51 
mmol) were dissolved in DCM (5.0 mL). The reaction was stirred for 10 minutes before 
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adding 2-(pyridin-4-yl)ethanamine (0.061 mL, 0.51 mmol) and DIEA (0.089 mL, 0.51 
mmol). The reaction was stirred overnight at room temperature. It was diluted with water 
and ethyl acetate. The organic phase was washed with water, saturated sodium carbonate, 
and saturated sodium chloride. It was filtered and concentrated. The resulting crude 
material was triturated with ethyl acetate. The resulting white solid was filtered to obtain 
the desired product. Yield:  80 mg, 60%.  
1
H NMR (500 MHz, DMSO- d6) δ 8.48 – 8.43 
(m, 2H), 7.90 (t, J = 5.7 Hz, 1H), 7.57 (dd, J = 9.1, 4.4 Hz, 1H), 7.40 (dd, J = 9.5, 2.5 Hz, 
1H), 7.36 – 7.33 (m, 2H), 7.23 – 7.20 (m, 2H), 7.13 – 7.07 (m, 3H), 6.70 (s, 1H), 5.48 (s, 
2H), 4.40 (bs, 1H), 3.90 (bs, 1H), 3.34 – 3.30 (m, 22H), 3.04 – 2.70 (m, 4H), 2.36 – 2.27 
(m, 1H), 1.67 – 1.18 (m, 4H). TOF ES+ MS:  519.1 (M+H), 541.1 (M+Na). HPLC ret. 
time  = 5.51 min; purity > 95%. 
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Photoaffinity probes 
  1-(iodomethyl)-3-(prop-2-yn-1-yloxy)benzene  (202).  To solid 3-
(hydroxymethyl)phenol (5 g, 40.3 mmol) and cesium carbonate (19.7 g, 60.4 mmol) was 
added DMF (Volume: 134 ml).  The reaction was stirred for 20 minutes at room 
temperature.  3-bromoprop-1-yne (3.66 ml, 48.3 mmol) was added and the reaction was 
stirred overnight.  The reaction was diluted with water and extracted with 50:50 ethyl 
acetate:diethyl ether.  The aqueous layer was washed again with the same organic layer 
mixture.  The organic layers were combined and washed with saturated sodium carbonate 
followed by saturated sodium chloride.  It was dried over sodium sulfate, filtered and 
concentrated.  The crude material was purified via SP1 biotage, 40g silica gel column 
with 0-45% ethyl acetate-hexanes to obtain  (3-(prop-2-yn-1-yloxy)phenyl)methanol as a 
slightly yellow oil. Yield:   2.6 g, 39.8%.  
1
H NMR (500 MHz, DMSO-d6) δ ppm 7.25 (t, 
J=7.8 Hz, 1 H), 6.88 - 6.97 (m, 2 H), 6.80 - 6.88 (m, 1 H), 5.20 (t, J=5.9 Hz, 1 H), 4.77 
(d, J=2.4 Hz, 2 H), 4.47 (d, J=5.9 Hz, 2 H), 3.55 (t, J=2.4 Hz, 1 H).  Imidazole (504 mg, 
7.40 mmol), iodine (1.88 g, 7.40mmol), and polymer bound triphenylphosphine 
(3mmol/g loading, 1.94g, 7.40 mmol) were dissolved in DCM (20 mL) and stirred for 10 
minutes at room temperature.  (3-(prop-2-yn-1-yloxy)phenyl)methanol was added as a 
DCM (10 mL) solution.  The reaction was stirred at room temperature for 3 hours at 
which time the reaction showed complete consumption of starting material by TLC.  The 
reaction was filtered and polymer was washed with DCM.  The resulting filtrate was 
washed with water followed by saturated sodium thiosulfate until organic phase was 
colorless.  The organic phase was subsequently washed with saturated sodium chloride, 
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dried over sodium sulfate, filtered and concentrated to obtain 1-(iodomethyl)-3-(prop-2-
yn-1-yloxy)benzene as a reddish oil.  Taken directly to next step without further 
purification or characterization.  Rf = 0.5 (50% EtOAc/Hex)     
   
Ethyl 1-(3-(prop-2-yn-1-yloxy)benzyl)-1H-indole-2-carboxylate (203)  Ethyl 1H-
indole-2-carboxylate (155) (200 mg, 1.05 mmol) was dissolved  in 3.0 mL of DMF.  
Cesium carbonate (448 mg, 1.37 mmol) was added to the solution.  The reaction was 
stirred for 20 minutes before 1-(iodomethyl)-3-(prop-2-yn-1-yloxy)benzene was added as 
a solution in 2.0 mL of DMF.  The reaction was stirred overnight at 60 
o
C.  The reaction 
was diluted with water and ethyl acetate.  The aqueous layer was washed with another 
portion of ethyl acetate.  The organic layers were combined and washed with brine (3x), 
dried over sodium sulfate, filtered and concentrated.  The resulting crude material was 
taken to the next step without further purification.  
1
H NMR (500 MHz, DMSO-d6) δ 
ppm 7.73 (d, J=8.1 Hz, 1 H), 7.57 (d, J=8.3 Hz, 1 H), 7.38 (s, 1 H), 7.29 - 7.34 (m, 1 H), 
7.13 - 7.21 (m, 2 H), 6.84 (dd, J=8.2, 2.3 Hz, 1 H), 6.66 (s, 1 H), 6.60 (d, J=7.8 Hz, 1 H), 
5.84 (s, 2 H), 4.71 (d, J=2.4 Hz, 2 H), 4.29 (q, J=7.2 Hz, 2 H), 3.52 (t, J=2.3 Hz, 1 H), 
1.29 (t, J=7.1 Hz, 3 H).  TOF ES+ MS:  334.3 (M+H), 356.2 (M+Na). HPLC (gradient 
A): ret. time = 8.46 min; purity 65 %.   
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1-(1-(3-(prop-2-yn-1-yloxy)benzyl)-1H-indole-2-carbonyl)-N-(2-(pyridin-4-
yl)ethyl)piperidine-4-carboxamide (CCG 212370, 120)  Compound  203  (120 mg, 
.360 mmol) was dissolved in ethanol (2.0 mL) and 2N NaOH (0.9 mL, 1.80 mmol).  The 
reaction was stirred at room temperature until TLC showed consumption of starting 
material.  The reaction was concentrated to remove ethanol.  The aqueous solution was 
acidified to pH 2 using 2N HCl.  The resulting solid was extracted using ethyl acetate 
(2x).  The combined organic phases were washed with saturated sodium chloride, dried 
over magnesium sulfate, filtered and concentrated to obtain 1-(3-(prop-2-yn-1-
yloxy)benzyl)-1H-indole-2-carboxylic acid.  The crude material was taken directily to 
next step without purification.   TOF ES+ MS:  306.2 (M+H), 328.2 (M+Na).   
1-(3-(prop-2-yn-1-yloxy)benzyl)-1H-indole-2-carboxylic acid (90 mg, .295 
mmol), EDCI (113 mg, .590 mmol), and HOBt (80 mg, .590 mmol) were suspended in 
3.0 mL of DCM.  The suspension was stirred for 20 minutes and turned into a 
homogenous solution.  Solid N-(2-(pyridin-4-yl)ethyl)piperidine-4-carboxamide 
dihydrochloride (181 mg, .590 mmol) was added followed by DIEA (0.10 mL, 0.590).  
The reaction was stirred overnight at room temperature.  The reaction was diluted with 
water and ethyl acetate:THF (10:1).  The organic phase was washed with saturated 
sodium bicarbonate, saturated sodium carbonate, and saturated sodium chloride solutions.  
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It was then dried over sodium sulfate, filtered and concentrated.  The crude material was 
purified via flash chromatography using 20% ethyl acetate-hexanes to   100% ethyl 
acetate.  The product was obtained as a white solid.  Yield:  50 mg, 33%.  
1
H NMR (500 
MHz, DMSO-d6) δ ppm 8.44 - 8.47 (m, 2 H), 7.89 (t, J=5.7 Hz, 1 H), 7.59 (dd, J=35.2, 
7.8 Hz, 2 H), 7.17 - 7.23 (m, 4 H), 7.09 (t, J=7.4 Hz, 1 H), 6.84 (dd, J=8.2, 2.3 Hz, 1 H), 
6.72 (t, J=2.2 Hz, 1 H), 6.70 (s, 1 H), 6.64 (d, J=7.8 Hz, 1 H), 5.46 (s, 2 H), 4.71 (d, 
J=2.4 Hz, 2 H), 4.42 (br. s., 1 H), 3.93 (br. s., 1 H), 3.51 (t, J=2.3 Hz, 1 H), 3.31 (q, J=7.1 
Hz, 2 H), 2.77 - 3.11 (m, 2 H), 2.73 (t, J=7.1 Hz, 2 H), 2.31 (tt, J=11.3, 3.9 Hz, 1 H), 1.20 
- 1.76 (m, 4 H).  TOF ES+ MS:  521.5 (M+H).  HPLC (gradient A): ret. time = 5.17 min; 
purity > 95 %.   
 
1-(1-(4-chlorobenzyl)-5-(prop-2-yn-1-yloxy)-1H-indole-2-carbonyl)-N-(2-(pyridin-4-
yl)ethyl)piperidine-4-carboxamide (CCG 212057, 121)  Compound 176  (42mg, 0.124 
mmol), EDCI (47.4 mg, 0.247 mmol), and HOBt (33.4 mg, 0.247 mmol) were dissolved 
in DCM and stirred for 30 minutes at room temperature. N-(2-(pyridin-4-
yl)ethyl)piperidine-4-carboxamide, 2HCl (76 mg, 0.247 mmol) was added as a solid, 
followed by Hunig'sBase (0.043 ml, 0.247 mmol).  The reaction was further stirred at 
room temperature overnight at room temperature.  The reaction was diluted with water 
and ethyl acetate/THF.  The organic phase was washed with saturated sodium carbonate, 
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sodium bicarbonate, and brine.  The organic phase was dried over sodium sulfate.  The 
drying agent was used filtered and crude material concentrated.  The crude material was 
purified via Biotage SP1 with 50% ethyl acetate/hexanes to 100% ethyl acetate.  The 
product was a white solid.  Yield: 40 mg, 58 % 
1
H NMR (500 MHz, DMSO-d6) δ ppm 
8.42 - 8.49 (m, 2 H), 7.90 (t, J=5.5 Hz, 1 H), 7.46 (d, J=9.0 Hz, 1 H), 7.30 - 7.37 (m, 2 
H), 7.19 (d, J=2.4 Hz, 1 H), 7.21 (d, J=5.6 Hz, 2 H), 7.06 - 7.12 (m, 2 H), 6.90 (dd, 
J=8.8, 2.4 Hz, 1 H), 6.64 (s, 1 H), 5.45 (s, 2 H), 4.77 (d, J=2.2 Hz, 2 H), 4.38 (br. s., 1 H), 
3.96 (br. s., 1 H), 3.55 (t, J=2.2 Hz, 1 H), 3.31 (q, J=5.9 Hz, 2 H), 2.77 - 3.08 (m, 2 H), 
2.73 (t, J=7.0 Hz, 2 H), 2.32 (tt, J=11.2, 3.4 Hz, 1 H), 1.20 - 1.77 (m, 4 H).  TOF ES+ 
MS: 555.4 (M+H); 577.4 (M+Na).  HPLC (gradient A): ret. time = 5.59 min;  purity > 95 
% 
 
1-(1-(4-chlorobenzyl)-1H-indole-2-carbonyl)-N-(prop-2-yn-1-yl)-N-(2-(pyridin-4-
yl)ethyl)piperidine-4-carboxamide (CCG 212050) Sodium hydride (9.58 mg, 0.240 
mmol) was added to an oven dried flask purged with argon and suspended in 1.5 mL of 
DMF.  The suspension was cooled to 0 
o
C.  1-(1-(4-chlorobenzyl)-1H-indole-2-
carbonyl)-N-(2-(pyridin-4-yl)ethyl)piperidine-4-carboxamide (100 mg, 0.200 mmol) 
dissolved in 1.5 mL of DMF was added dropwise and stirred for 15 minutes before 
adding 3-bromoprop-1-yne (0.018 ml, 0.240 mmol).  The reaction was allowed to warm 
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to room temperature.  After 4 hours, the reaction was diluted with water and ethyl acetate.  
The aqueous layer was washed with another portion of ethyl acetate.  The organic phases 
were combined, washed with saturated sodium chloride (3x), dried over sodium sulfate, 
filtered, and concentrated.  The crude material was purified using 0-10% methanol-ethyl 
acetate.  The product was isolated as a white solid.  Yield: 36 mg, 33% Mixture of 
rotomers.  
1
H NMR (500 MHz, DMSO-d6) δ ppm 8.47 - 8.54 (rotomer A, m, 1 H), 8.44 - 
8.47 (rotomer B, m, 1 H), 7.60 - 7.66 (m, 1 H), 7.54 (t, J=7.7 Hz, 1 H), 7.30 - 7.37 (m, 3 
H), 7.18 - 7.27 (m, 2 H), 7.07 - 7.14 (m, 3 H), 6.74 (rotomer A, s, 0.5 H), 6.71 (rotomer 
B, s, 0.5 H), 5.45 - 5.53 (m, 2 H), 3.89 - 4.58 (m, 4 H), 3.72 (rotomer A, t, J=7.0 Hz, 1 
H), 3.58 (rotomer B, t, J=7.4 Hz, 1 H), 3.36 (rotomer A, t, J=2.3 Hz, 0.5 H), 3.21 
(rotomer B, t, J=2.3 Hz, 0.5 H), 3.08 (rotomer A, br. s., 1 H), 2.90 - 2.99 (m, 2 H), 2.83 
(rotomer B, t, J=7.6 Hz, 1 H), 2.51 - 2.58 (m, 1 H), 1.16 - 1.71 (m, 4 H).  TOF ES+ MS:  
539.2 (M+H), 561.2 (M+Na). HPLC (gradient A): ret. time = 5.97min; purity 90 % 
 
Ethyl 1-(5-hydroxy-1H-indole-2-carbonyl)piperidine-4-carboxylate (206)  165 (1.0 g, 
5.23 mmol), EDCI (1.504 g, 7.85 mmol), and 1-hydroxybenzotriazole (1.060 g, 7.85 
mmol) were dissolved in DCM (Volume: 25 ml).  The reaction was stirred for 30 
minutes.  The reaction turned from a suspension to a yellow clear solution.  Hunig'sBase 
(1.370 ml, 7.85 mmol) and ethyl piperidine-4-carboxylate (1.209 ml, 7.85 mmol) were 
added.  The reaction was stirred at room temperature overnight.  It was diluted ethyl 
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acetate and water.  The phases were separated and it was sequentially washed with 1N 
HCl, saturated sodium carbonate, and saturated sodium chloride.  It was dried over 
sodium sulfate, filtered and concentrated to obtain ethyl 1-(5-methoxy-1H-indole-2-
carbonyl)piperidine-4-carboxylate  as a white solid.  The crude material did not need to 
be purified. Yield:  1.5 g, 85%   
1
H NMR (500 MHz, DMSO-d6) δ ppm 11.42 (s, 1 H), 
7.30 (d, J=8.8 Hz, 1 H), 7.06 (d, J=2.4 Hz, 1 H), 6.83 (dd, J=8.8, 2.4 Hz, 1 H), 6.68 (d, 
J=2.2 Hz, 1 H), 4.33 (dt, J=13.3, 3.2 Hz, 2 H), 4.09 (q, J=7.1 Hz, 2 H), 3.75 (s, 3 H), 3.16 
(br. s., 2 H), 2.69 (tt, J=11.0, 3.9 Hz, 1 H), 1.92 (dd, J=13.3, 3.1 Hz, 2 H), 1.50 - 1.65 (m, 
2 H), 1.20 (t, J=7.1 Hz, 3 H) 
Ethyl 1-(5-methoxy-1H-indole-2-carbonyl)piperidine-4-carboxylate (200 mg, 
0.605 mmol) was dissolved in DCM (Volume: 8 ml).  It was cooled to -78 oC and Boron 
tribromide in DCM (1.816 ml, 1.816 mmol) was added dropwise.  The reaction was 
allowed to warm to room temperature.  It was stirred until the reaction was complete by 
TLC.  It was cooled to 0 oC and water was added slowly.  The layers were separated and 
the organic phase was washed with saturated sodium carbonate.  The organic phase was 
washed with saturated sodium carbonate until the water phase from the separatory funnel 
was basic.  The ethyl acetate layer was dried over sodium sulfate, filtered, and 
concentrated.  The crude material was purified via 0 - 70 % ethyl acetate/hexanes.  The 
product was isolated as a white solid.  Yield:  153 mg, 80 %.  
1
H NMR (500 MHz, 
DMSO-d6) δ ppm 11.25 (s, 1 H), 8.79 (s, 1 H), 7.21 (d, J=8.8 Hz, 1 H), 6.88 (d, J=2.0 
Hz, 1 H), 6.71 (dd, J=8.8, 2.2 Hz, 1 H), 6.58 (d, J=2.0 Hz, 1 H), 4.33 (dt, J=13.2, 3.4 Hz, 
2 H), 4.09 (q, J=7.1 Hz, 2 H), 3.15 (br. s., 2 H), 2.68 (tt, J=11.0, 3.9 Hz, 1 H), 1.92 (dd, 
J=13.3, 3.1 Hz, 2 H), 1.51 - 1.61 (m, 2 H), 1.19 (t, J=7.1 Hz, 3 H) 
198 
 
  
Ethyl 1-(5-((tert-butyldiphenylsilyl)oxy)-1-(4-chlorobenzyl)-1H-indole-2-
carbonyl)piperidine-4-carboxylate (207)  1-(bromomethyl)-4-chlorobenzene (0.741 g, 
3.61 mmol) and sodium iodide (0.594 g, 3.97 mmol) were dissolved in Acetone (Ratio: 
1.000, Volume: 20.00 ml) and stirred overnight at room temperature.  The resulting 
suspension was filtered and the filtrate was concentrated to obtain crude 4-chlorobenzyl 
iodide.   
Ethyl 1-(5-((tert-butyldiphenylsilyl)oxy)-1H-indole-2-carbonyl)piperidine-4-
carboxylate (1.00 g, 1.803 mmol) and cesium carbonate (0.881 g, 2.70 mmol) were 
suspended in 15 mL of DMF.  4-chlorobenzyl iodide was dissolved in 5 mL of DMF and 
added to the reaction. The reaction was heated to 60 
o
C overnight.  It was diluted with 
water and ethyl acetate.  The aqueous layer was washed with another aliquot of ethyl 
acetate.  The organic phases were combined and washed with saturated sodium chloride, 
dried over sodium sulfate, filtered and concentrated.  The crude material was purified 
using 0-75% ethyl acetate/hexanes to obtain ethyl 1-(5-((tert-butyldiphenylsilyl)oxy)-1-
(4-chlorobenzyl)-1H-indole-2-carbonyl)piperidine-4-carboxylate as white solid.  The 
resulting product was taken directly to the next step.  Yield: 931 mg, 76 %.   
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Ethyl 1-(1-(4-chlorobenzyl)-5-(2-(3-methyl-3H-diazirin-3-yl)ethoxy)-1H-indole-2-
carbonyl)piperidine-4-carboxylate (208)   207 (420 mg, 0.618 mmol) was dissolved in 
THF (Volume: 10 ml) and cooled with an ice bath.  TBAF (0.927 ml, 0.927 mmol) was 
added slowly.  The reaction turned from colorless to a clear yellow solution.  It was 
stirred for an additional hour before it was diluted with water and ethyl acetate and water.  
The organic phase was washed with saturated sodium chloride, dried over sodium sulfate, 
filtered and concentrated.  The crude material was purified using 0-80% ethyl 
acetate/hexanes to obtain product as an off white solid.  Yield:  229 mg, 84%.  
1
H NMR 
(500 MHz, DMSO-d6) δ ppm 8.92 (s, 1 H), 7.36 (d, J=8.8 Hz, 1 H), 7.29 - 7.33 (m, 2 H), 
7.05 (d, J=8.3 Hz, 2 H), 6.91 (d, J=2.2 Hz, 1 H), 6.74 (dd, J=8.8, 2.2 Hz, 1 H), 6.53 (s, 1 
H), 5.41 (s, 2 H), 4.27 (br. s., 1 H), 3.82 - 4.11 (m, 3 H), 2.98 (br. s., 2 H), 2.57 (tt, 
J=11.0, 3.8 Hz, 1 H), 1.73 (br. s., 2 H), 1.14 - 1.51 (m, 5 H).  TOF ES+ MS:  441.2 
(M+H), 463.2 (M+Na).  HPLC (gradient A): ret. time = 6.84 min; purity >95% 
Cesium carbonate (238 mg, 0.731 mmol) and ethyl 1-(1-(4-chlorobenzyl)-5-
hydroxy-1H-indole-2-carbonyl)piperidine-4-carboxylate (215 mg, 0.488 mmol) were 
dissolved 3.0 mL of DMF.  2-(3-methyl-3H-diazirin-3-yl)ethyl 4-methylbenzenesulfonate 
(186 mg, 0.731 mmol) was dissolved in 2.0 mL of DMF.  The reaction was heated at 60 
o
C overnight.  The reaction was diluted with ethyl acetate and water.  The aqueous phase 
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was washed with another aliquot of ethyl acetate.  The organic phases were combined 
and washed with saturated sodium chloride, filtered and concentrated.  The crude 
material was purified via Biotage using 20-80% ethyl acetate/hexanes to obtain product 
as a white solid.  Yield:  195 mg, 76%.   
1
H NMR (500 MHz, DMSO-d6) δ ppm 7.48 (d, 
J=9.0 Hz, 1 H), 7.29 - 7.34 (m, 2 H), 7.11 (d, J=2.4 Hz, 1 H), 7.03 - 7.07 (m, 2 H), 6.89 
(dd, J=9.0, 2.4 Hz, 1 H), 6.62 (s, 1 H), 5.45 (s, 2 H), 4.31 (br. s., 1 H), 4.07 (q, J=7.1 Hz, 
2 H), 3.74 - 3.97 (m, 3 H), 2.78 - 3.19 (m, 2 H), 2.57 (tt, J=11.0, 3.9 Hz, 1 H), 1.25 - 1.96 
(m, 6 H), 1.18 (t, J=7.1 Hz, 3 H), 1.09 (s, 3 H).  TOF ES+ MS:  523.2 (M+H), 545.2 
(M+Na).  HPLC (gradient A): ret. time = 8.63 min; purity = 90 % 
 
1-(1-(4-chlorobenzyl)-5-(2-(3-methyl-3H-diazirin-3-yl)ethoxy)-1H-indole-2-
carbonyl)-N-(2-(pyridin-4-yl)ethyl)piperidine-4-carboxamide (CCG 222802, 123)   
208 (195 mg, 0.373 mmol)  was dissolved in EtOH (Ratio: 1.000, Volume: 4 ml) and 2N 
NaOH (Ratio: 1.000, Volume: 4.00 ml) and stirred at room temperature for 5 hours. At 
this point, the ethanol was removed under vacuum and the resulting solution was diluted 
with 4 mL of water and 4 mL of diethyl ether.  The organic phase was removed, and the 
aqeous layer was acidified to pH 2.  The resulting suspension was extracted with ethyl 
acetate (2x).  The organic phases were combined and washed with saturated sodium 
chloride.  It was dried over sodium sulfate, filtered and concentrated.  Taken directly to 
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the next step.  Yield:  175 mg, 95%.  
1
H NMR (500 MHz, DMSO-d6) δ ppm 12.30 (s, 1 
H), 7.46 (d, J=9.0 Hz, 1 H), 7.29 - 7.35 (m, 2 H), 7.11 (d, J=2.4 Hz, 1 H), 7.03 - 7.09 (m, 
2 H), 6.88 (dd, J=9.0, 2.4 Hz, 1 H), 6.62 (s, 1 H), 5.45 (s, 2 H), 4.27 (br. s., 1 H), 3.70 - 
4.11 (m, 3 H), 2.85 - 3.23 (m, 2 H), 2.47 (tt, J=10.7, 3.9 Hz, 1 H), 1.17 - 2.00 (m, 6 H), 
1.09 (s, 3 H).  HPLC (gradient A): ret. time = 5.95 min; purity > 95 % 
1-(1-(4-chlorobenzyl)-5-(2-(3-methyl-3H-diazirin-3-yl)ethoxy)-1H-indole-2-
carbonyl)piperidine-4-carboxylic acid (175 mg, 0.354 mmol), 1-Hydroxybenzotriazole 
(96 mg, 0.707 mmol) and EDCI (136 mg, 0.707 mmol) were dissolved in DCM (Volume: 
5 ml).  It was stirred for 10 minutes before 2-(pyridin-4-yl)ethan-1-amine (0.085 ml, 
0.707 mmol) and Hunig'sBase (0.124 ml, 0.707 mmol) were added.  The reaction was 
stirred overnight at room temperature.  It was diluted with water and ethyl acetate.  The 
organic phase was washed with saturated sodium carbonate, saturated sodium chloride, 
dried over sodium sulfate, filtered and concentrated.  The crude material was purified via 
Biotage using 20-80% ethyl acetate/hexanes to obtain product as an off-white solid.  
Yield: 40%  
1
H NMR (500 MHz, DMSO- d6) δ 8.49 – 8.41 (m, 2H), 7.89 (t, J = 5.6 Hz, 
1H), 7.44 (d, J = 9.0 Hz, 1H), 7.37 – 7.30 (m, 2H), 7.24 – 7.18 (m, 2H), 7.13 – 7.05 (m, 
3H), 6.87 (dd, J = 9.0, 2.4 Hz, 1H), 6.61 (s, 1H), 5.44 (s, 2H), 4.35 (bs, 1H), 4.09 – 3.74 
(m, 3H), 3.30 (q, J = 6.8 Hz, 2H), 3.11 – 2.62 (m, 4H), 2.32 (tt, J = 11.3, 3.8 Hz, 1H), 
1.80 (t, J = 6.1 Hz, 2H), 1.68 – 1.20 (m, 4H), 1.09 (s, 3H).  13C NMR (126 MHz, dmso) δ 
173.41, 161.77, 152.92, 149.27, 148.27, 137.19, 132.13, 132.09, 131.75, 128.62, 128.34, 
126.42, 124.15, 113.99, 111.44, 103.56, 102.99, 63.09, 46.13, 41.32, 38.68, 34.09, 33.39, 
24.59, 19.63.  TOF ES+ MS:  599.3 (M+H).  HPLC (gradient A): ret. time = 6.18 min; 
purity > 95 % 
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3-azidobenzyl 4-methylbenzenesulfonate (211)  (3-(hydroxymethyl)phenyl)boronic 
acid (500 mg, 3.29 mmol)  was converted to (3-azidophenyl)methanol according to 
literatature (Ref 150).  Yield: 95 mg, 19%  
In a flask purged with argon, (3-azidophenyl)methanol (500 mg, 3.35 mmol) and 
triethylamine (1.402 ml, 10.06 mmol) were dissolved in DCM (Volume: 15 ml).  Solid p-
toluenesulfonic anhydride (1641 mg, 5.03 mmol) was added to the reaction.  It was 
stirred at room temperature overnight.  The reaction was diluted with water and ethyl 
acetate.  The organic phase was washed with 1N NaOH (2x) and saturated sodium 
chloride.  It was dried over sodium sulfate, filtered and concentrated.    Yield:  661 mg, 
65 % 
1
H NMR (500 MHz, DMSO-d6) δ ppm 7.77 - 7.86 (m, 2 H), 7.46 - 7.52 (m, 2 H), 
7.37 - 7.43 (m, 1 H), 7.07 - 7.15 (m, 2 H), 6.97 - 7.00 (m, 1 H), 5.14 (s, 2 H), 2.43 (s, 3 
H) 
 
Ethyl 1-(3-azidobenzyl)-1H-indole-2-carboxylate (212)  ethyl 1H-indole-2-carboxylate 
(234 mg, 1.236 mmol) and cesium carbonate (537 mg, 1.648 mmol) were dissolved in 10 
mL of DMF.  211 (250 mg, 0.824 mmol) was added as a 5 mL DMF solution.  The 
reaction was stirred overnight at 60 
o
C.  It was diluted with water and ethyl acetate.  The 
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aquoues layer was washed with another portion of ethyl acetate.  The organic phases 
were combined and washed with 1N NaOH, saturated sodium chloride (2x), dried over 
sodium sulfate, filtered and concentrated.  The crude material was purified using Biotage 
0-50% ethyl acetate/hexanes.  The product was obtained as a yellow oil.  Yield:  172 mg, 
65%.  
1
H NMR (500 MHz, DMSO-d6) δ ppm 7.73 (d, J=7.8 Hz, 1 H), 7.59 (dd, J=8.5, 
0.7 Hz, 1 H), 7.39 (s, 1 H), 7.28 - 7.36 (m, 2 H), 7.13 - 7.19 (m, 1 H), 6.96 - 7.01 (m, 1 
H), 6.75 - 6.80 (m, 2 H), 5.86 (s, 2 H), 4.29 (q, J=7.1 Hz, 2 H), 1.29 (t, J=7.1 Hz, 3 H) 
 
 
1-(1-(3-azidobenzyl)-1H-indole-2-carbonyl)-N-(2-(pyridin-4-yl)ethyl)piperidine-4-
carboxamide (CCG 222881, 124)  212 (52 mg, 0.162 mmol) was dissolved in Ethanol 
(Ratio: 1.000, Volume: 2 ml) and 2N NaOH (Ratio: 1.000, Volume: 2.000 ml).  The 
reaction was stirred for 5 hours until TLC showed complete conversion.  The ethanol was 
removed under vacuum.  The resulting suspension was diluted with 1 mL of water.  The 
aqueous phase was acidified using 2N HCl to pH ~2.  The resulting solid was filtered to 
obtain 1-(3-azidobenzyl)-1H-indole-2-carboxylate as a peach solid.  Taken directly to the 
next step.  Yield:  50.9 mg, 95 % yield.   
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1-(3-azidobenzyl)-1H-indole-2-carboxylic acid (32 mg, 0.109 mmol), EDCI (42.0 
mg, 0.219 mmol), and 1-Hydroxybenzotriazole (29.6 mg, 0.219 mmol) were dissolved 
DCM (Volume: 5 ml).  The reaction was stirred for 20 minutes before solid 190 (67.1 
mg, 0.219 mmol) and Hunig'sBase (0.038 ml, 0.219 mmol) were added.  The reaction 
stirred at room temperature overnight.  The reaction was diluted with water and ethyl 
acetate.  The organic phase was washed with saturated sodium bicarbonate, saturated 
sodium carbonate and saturated sodium chloride.  It was dried over sodium sulfate, 
filtered and concentrated.  The crude material was purified via Biotage using 10 g silica 
column @ 20 mL/min with 10-80% ethyl acetate/hexanes to obtain product as a glassy 
solid.   Yield:  13 mg, 23 %.   1H NMR (500 MHz, DMSO- d6) δ ppm 8.47 - 8.56 (m, 2 
H), 7.94 (t, J=5.9 Hz, 1 H), 7.66 (dd, J=24.5, 7.8 Hz, 2 H), 7.36 (t, J=7.8 Hz, 1 H), 7.23 -
7.31 (m, 3 H), 7.16 (t, J=7.6 Hz, 1 H), 7.01 - 7.07 (m, 1 H), 6.85 - 6.95 (m, 2 H), 6.77 (s, 
1 H), 5.56 (s, 2 H), 4.45 (br. s., 1 H), 4.02 (br. s., 1 H),3.36 (q, J=6.4 Hz, 1 H), 2.73 - 3.20 
(m, 4 H), 2.37 (tt, J=10.0, 5.0 Hz, 1 H), 1.15 - 1.84 (m, 4 H)  
13
C NMR (126 MHz, dmso) 
δ 173.38, 161.75, 149.27, 148.27, 140.32, 139.44, 136.78, 131.70, 130.10, 126.00, 
124.15, 123.48, 123.04, 121.29, 120.16, 117.90, 117.45, 110.54, 103.31, 46.28, 41.31, 
38.67, 34.10.  TOF ES+ MS:  508.2 (M+H).  HPLC (gradient A): ret. time = 4.73 min; 
purity > 95 % 
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Ethyl 5-((tert-butyldiphenylsilyl)oxy)-1-(3-(prop-2-yn-1-yloxy)benzyl)-1H-indole-2-
carboxylate   ethyl 5-((tert-butyldiphenylsilyl)oxy)-1H-indole-2-carboxylate (215)  
Imidazole (1.254 g, 18.42 mmol) and ethyl 5-hydroxy-1H-indole-2-carboxylate (1.89 g, 
9.21 mmol) were dissolved in DCM (Volume: 50 ml) and stirred at room temperature for 
30 minutes.  TBDPS-Cl (4.73 ml, 18.42 mmol) was added and the reaction and stirred 
overnight.  The reaction was diluted with ethyl acetate and water.  The layers were 
separated and the organic phase was washed sequentially, 1N HCl and saturated sodium 
chloride.  It was dried over sodium sulfate filtered and concentrated.  The crude material 
was purified via flash chlormatography using 1-40% ethyl acetate/hexanes to obtain ethyl 
5-((tert-butyldiphenylsilyl)oxy)-1H-indole-2-carboxylate as a clear oil that crystallized 
over time.  Yield:  3.4 g, 82%.  
1
H NMR (500 MHz, DMSO-d6) δ ppm 11.71 (s, 1 H), 
7.62 - 7.78 (m, 4 H), 7.34 - 7.58 (m, 6 H), 7.23 (d, J=8.8 Hz, 1 H), 6.87 - 6.93 (m, 2 H), 
6.81 (dd, J=8.9, 2.3 Hz, 1 H), 4.29 (q, J=7.2 Hz, 2 H), 1.29 (t, J=7.1 Hz, 3 H), 1.05 (s, 9 
H) 
Ethyl 5-((tert-butyldiphenylsilyl)oxy)-1H-indole-2-carboxylate (215) (400 mg, 
0.902 mmol) and cesium carbonate (588 mg, 1.803 mmol) were dissolved in 20 mL of 
DMF.  1-(iodomethyl)-3-(prop-2-yn-1-yloxy)benzene (491 mg, 1.803 mmol) was 
dissolved in 10 mL of DMF and added to the reaction.  The reaction was stirred at 60 oC 
overnight.  It was diluted with water and ethyl acetate.  The aqueous phase was washed 
with ethyl acetate.  The organic phases were combined and washed with saturated sodium 
chloride, dried over sodium sulfate, filtered and concentrated.  The resulting crude 
material was purified using 0-40% ethyl acetate/hexanes to obtain product as a glassy 
solid.  Yield:  318 mg, 60 mg. TOF ES+ MS: 588.0  (M+H), 610.0 (M+Na).   
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Ethyl 5-(2-(3-methyl-3H-diazirin-3-yl)ethoxy)-1-(3-(prop-2-yn-1-yloxy)benzyl)-1H-
indole-2-carboxylate  (216)  215 (81 mg, 0.138 mmol) was dissolved in THF (Volume: 
3 ml) and cooled with an ice bath.  TBAF (0.179 ml, 0.179 mmol) was added dropwise.  
The reaction turned from colorless to yellow solution.  It was diluted with water and ethyl 
acetate.  The organic phase was washed with saturated sodium chloride, dried over 
sodium sulfate, filtered and concentrated.  The crude material was purified using 0-60% 
ethyl acetate/hexanes to obtain product.  Yield:  46 mg, 95%  
1
H NMR (500 MHz, 
DMSO-d6) δ ppm 9.06 (s, 1 H), 7.37 (d, J=9.0 Hz, 1 H), 7.14 - 7.22 (m, 2 H), 6.97 (d, 
J=2.4 Hz, 1 H), 6.80 - 6.87 (m, 2 H), 6.63 (t, J=2.1 Hz, 1 H), 6.58 (dd, J=7.8, 1.0 Hz, 1 
H), 5.75 (s, 2 H), 4.71 (d, J=2.4 Hz, 2 H), 4.27 (q, J=7.1 Hz, 2 H), 3.53 (t, J=2.4 Hz, 1 
H), 1.28 (t, J=7.1 Hz, 3 H).  HPLC (gradient A): ret. time = 7.13 min; purity > 95%  
Cesium carbonate (133 mg, 0.408 mmol) and ethyl 5-hydroxy-1-(3-(prop-2-yn-1-
yloxy)benzyl)-1H-indole-2-carboxylate (95 mg, 0.272 mmol) were dissolved in 2 mL of 
DMF and stirred at room temperature for 10 minutes before 2-(3-methyl-3H-diazirin-3-
yl)ethyl 4-methylbenzenesulfonate (104 mg, 0.408 mmol) was dissolved in 2 mL of DMF 
before it was added to the reaction and heated to 50 
o
C overnight.  The reaction was 
diluted with water and ethyl acetate.  The aqueous layer was washed with ethyl acetate 
(2x).  The organic phases were washed with saturated sodium carbonate and saturated 
sodium chloride, dried over sodium sulfate, filtered and concentrated.  The crude product 
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was taken directly to next step.  
1
H NMR (500 MHz, DMSO-d6) δ ppm 7.48 (d, J=9.3 
Hz, 1 H), 7.26 (s, 1 H), 7.16 - 7.21 (m, 2 H), 6.98 (dd, J=9.2, 2.6 Hz, 1 H), 6.83 (dd, 
J=8.3, 2.7 Hz, 1 H), 6.63 (t, J=2.2 Hz, 1 H), 6.58 (dd, J=7.6, 0.7 Hz, 1 H), 5.80 (s, 2 H), 
4.71 (d, J=2.2 Hz, 2 H), 4.28 (q, J=7.1 Hz, 2 H), 3.88 (t, J=6.1 Hz, 2 H), 3.52 (t, J=2.3 
Hz, 1 H), 1.81 (t, J=6.1 Hz, 2 H), 1.29 (t, J=7.1 Hz, 3 H), 1.09 (s, 3 H).  TOF ES+ MS: 
432.1  (M+H), 454.1  (M+Na).  HPLC (gradient A): ret. time = 8.91 min; purity > 95 %  
 
1-(5-(2-(3-methyl-3H-diazirin-3-yl)ethoxy)-1-(3-(prop-2-yn-1-yloxy)benzyl)-1H-
indole-2-carbonyl)-N-(2-(pyridin-4-yl)ethyl)piperidine-4-carboxamide  (222700, 125)  
216 (60 mg, 0.139 mmol) was dissolved in THF (Ratio: 1.000, Volume: 1 ml) and 1 N 
LiOH (Ratio: 1.000, Volume: 1.000 ml).  It was stirred at room temperature for 4 hours.  
It was diluted with water and ethyl acetate.  The aqueous phase was acidified to pH ~ 2.  
The resulting suspension was extracted with ethyl acetate.  The organic phase was 
washed with saturated sodium chloride, dried over sodium sulfate, filtered and 
concentrated. Product taken directly to the next step.  Yield:  20 mg, 36%.  TOF ES+ MS: 
404.0  (M+H), 426.0  (M+Na).   
5-(2-(3-methyl-3H-diazirin-3-yl)ethoxy)-1-(3-(prop-2-yn-1-yloxy)benzyl)-1H-
indole-2-carboxylic acid (34 mg, 0.084 mmol), EDCI (32.3 mg, 0.169 mmol), and 1-
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hydroxybenzotriazole (22.78 mg, 0.169 mmol) were dissolved in DCM (3 ml).  The 
reaction was stirred at room temperature for 10 minutes.  Solid 190 (38.7 mg, 0.126 
mmol) was added followed by Hunig'sBase (0.029 ml, 0.169 mmol).  The reaction was 
stirred at room temperature overnight.  The reaction was diluted with water and ethyl 
acetate.  The organic phase was washed with saturated sodium carbonate and saturated 
sodium chloride.  It was dried over sodium sulfate, filtered, and concentrated.  The crude 
material was purified via Biotage 20-80% ethyl acetate/hexanes to obtain product as a 
white solid.  Yield:  21 mg, 40 %.  1H NMR (500 MHz, DMSO- d6) δ ppm 8.42 - 8.49 
(m, 2 H), 7.89 (t, J=5.9 Hz, 1 H), 7.44 (d, J=9.3 Hz, 1 H), 7.16 - 7.23 (m, 3 H), 7.11 (d, 
J=2.4Hz, 1 H), 6.87 (dd, J=8.8, 2.4 Hz, 1 H), 6.84 (dd, J=8.3, 2.4 Hz, 1 H), 6.70 (t, J=2.0 
Hz, 1 H), 6.58 - 6.64 (m, 2 H), 5.41 (s, 2 H), 4.71 (d, J=2.4 Hz,2 H), 4.36 (br. s., 1 H), 
3.79 - 4.18 (m, 3 H), 3.51 (t, J=2.2 Hz, 1 H), 3.31 (q, J=5.9 Hz, 2 H), 2.68 - 3.11 (m, 4 
H), 2.31 (tt, J=11.2, 3.7 Hz, 1 H),  1.80 (t, J=6.1 Hz, 2 H), 1.19 - 1.75 (m, 4 H), 1.09 (s, 3 
H)   
13C NMR (126 MHz, dmso) δ 173.44, 161.81, 157.15, 152.86, 149.27, 148.26, 
139.77, 132.28, 132.21, 129.45, 126.37, 124.16, 119.50, 114.00, 113.89, 112.83, 111.48, 
103.51, 102.80, 79.00, 78.08, 63.10, 55.22, 46.64, 41.34, 38.66, 34.11, 33.42, 24.59, 
19.63.  TOF ES+ MS: 619.1  (M+H). HPLC (gradient A): ret. time = 6.21 min; purity > 
95 %  
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Ethyl 1-(1-(3-azidobenzyl)-5-((tert-butyldiphenylsilyl)oxy)-1H-indole-2-
carbonyl)piperidine-4-carboxylate (217)  Sodium hydride (87 mg, 2.163 mmol) was 
suspended in 5 mL of DMF and cooled to 0 
o
C.   ethyl 1-(5-((tert-
butyldiphenylsilyl)oxy)-1H-indole-2-carbonyl)piperidine-4-carboxylate (800 mg, 1.442 
mmol) was dissolved in 5 mL of DMF.  The reaction was allowed to stir at 0 oC before a 
5 mL DMF solution of 211 (656 mg, 2.163 mmol) was added.  The reaction was allowed 
to warm to room temperature over 5 hours, before it was diluted with water and ethyl 
acetate.  The aqueous phase was washed with ethyl acetate.  The organic phases were 
combined and washed with saturated sodium chloride, filtered and concentrated.  The 
crude material was purified with the biotage using 10 to 60% ethyl acetate/hexanes to 
obtain product. Yield: 841 mg, 85 %.   TOF ES+ MS:  686.3 (M+H).  
 
Ethyl 1-(1-(3-azidobenzyl)-5-(prop-2-yn-1-yloxy)-1H-indole-2-carbonyl)piperidine-
4-carboxylate (218)  217 (811 mg, 1.182 mmol) was dissolved in THF (Volume: 10 mL) 
and cooled with an ice bath.  TBAF (2.365 mL, 2.365 mmol) was added dropwise.  The 
reaction turned from colorless to yellow solution.  It was diluted with water and ethyl 
acetate.  The organic phase was washed with saturated sodium chloride, dried over 
sodium sulfate, filtered and concentrated.  The crude material was purified with the 
biotage using 0-60% ethyl acetate/hexanes to obtain ethyl 1-(1-(3-azidobenzyl)-5-
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hydroxy-1H-indole-2-carbonyl)piperidine-4-carboxylate.  Yield:  450 mg, 85% TOF ES+ 
MS:  448.3 (M+H)  
Cesium carbonate (889 mg, 2.73 mmol) and ethyl 1-(1-(3-azidobenzyl)-5-
hydroxy-1H-indole-2-carbonyl)piperidine-4-carboxylate (814 mg, 1.819 mmol) were 
dissolved in DMF and stirred for 10 minutes before adding 3-bromoprop-1-yne (0.207 
ml, 2.73 mmol).  The reaction was heated to 60 
o
C overnight.  The reaction was diluted 
with water and ethyl acetate.  The organic phase was washed with saturated sodium 
chloride, dried over sodium sulfate, filtered and concentrated.  The crude material was 
purified using 20-80% ethyl acetate/hexanes to obtain product.  Yield: 530 mg, 60 %.  
1
H 
NMR (500 MHz, DMSO-d6) δ ppm 7.53 (d, J=9.0 Hz, 1 H), 7.30 (t, J=7.9 Hz, 1 H), 7.19 
(d, J=2.4 Hz, 1 H), 6.96 - 7.01 (m, 1 H), 6.92 (dd, J=9.0, 2.7 Hz, 1 H), 6.84 (d, J=8.1 Hz, 
1 H), 6.79 (t, J=2.1 Hz, 1 H), 6.66 (s, 1 H), 5.47 (br. s., 2 H), 4.78 (d, J=2.2 Hz, 2 H), 
4.31 (br. s., 1 H), 3.79 - 4.12 (m, 3 H), 3.55 (t, J=2.3 Hz, 1 H), 2.79 - 3.22 (m, 2 H), 2.58 
(tt, J=11.0, 3.9 Hz, 1 H), 1.52 - 1.97 (m, 2 H), 0.89 - 1.52 (m, 5 H) 
 
1-(1-(3-azidobenzyl)-5-(prop-2-yn-1-yloxy)-1H-indole-2-carbonyl)-N-(2-(pyridin-4-
yl)ethyl)piperidine-4-carboxamide (CCG 223882, 126)  218 (57 mg, 0.117 mmol) was 
dissolved in THF (Volume: 3 ml).  Solid Potassium Trimethylsilanolate (16.57 mg, 0.129 
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mmol) was added and the reaction was stirred at room temperature overnight.  The 
resulting suspension was concentrated and the resulting solid was acidified using 4N HCl 
Dioxane. The suspension was concentrated to obtain product, which was taken directly to 
the next step.  Yield:  51 mg, 95%.  TOF ES+ MS:  458.0 (M+H) 
1-(1-(3-azidobenzyl)-5-(prop-2-yn-1-yloxy)-1H-indole-2-carbonyl)piperidine-4-
carboxylic acid (45 mg, 0.098 mmol), EDCI (30.5 mg, 0.197 mmol) and 1-
hydroxybenzotriazole (26.6 mg, 0.197 mmol) were dissolved in DCM (3 ml).  The 
reaction was stirred at room temperature for 15 minutes before 2-(pyridin-4-yl) ethan-1-
amine (0.024 ml, 0.197 mmol) and Hunig'sBase (0.034 ml, 0.197 mmol) were added.  
The reaction was stirred overnight at room temperature.  The reaction was diluted with 
water and ethyl acetate.  The organic phase was washed with saturated sodium 
bicarbonate, saturated sodium carbonate, and saturated sodium chloride.  It was dried 
over sodium sulfate, filtered and concentrated.  The crude material was purified using 
biotage with 25% ethyl acetate/hexanes to 100% ethyl acetate to obtain product as glassy 
solid.  Yield:  43 mg, 75 %.  
1
H NMR (500 MHz, DMSO-d6) δ ppm 8.44 - 8.48 (m, 2 H), 
7.88 (t, J=5.9 Hz, 1 H), 7.48 (d, J=9.3 Hz, 1 H), 7.30 (t, J=8.3 Hz, 1 H), 7.18 - 7.23 (m, 3 
H), 6.98 (dd, J=7.8, 2.0 Hz, 1 H), 6.91 (dd, J=8.8, 2.4 Hz, 1 H), 6.79 - 6.87 (m, 2 H), 6.64 
(s, 1 H), 5.46 (s, 2 H), 4.78 (d, J=2.4 Hz, 2 H), 4.38 (br. s., 1 H), 3.97 (br. s., 1 H), 3.54 (t, 
J=2.4 Hz, 1 H), 3.31 (q, J=6.8 Hz, 2 H), 2.70 - 3.14 (m, 4 H), 2.25 - 2.36 (m, 1 H), 1.13 - 
1.77 (m, 4 H)  
13C NMR (126 MHz, dmso) δ 173.38, 170.21, 161.70, 151.91, 149.27, 
148.27, 140.35, 139.42, 132.39, 132.29, 130.09, 126.22, 124.15, 123.45, 117.88, 117.43, 
114.02, 111.44, 104.22, 103.01, 79.65, 77.83, 59.64, 55.82, 46.41, 41.32, 34.10, 20.65, 
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13.98.  TOF ES+ MS:  562.0 (M+H).  HPLC (gradient A): ret. time = 5.68 min; purity = 
90 % 
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Biological experiments 
Mouse Liver Microsomes (courtesy of Scott Barraza) 
Experiment performed as previously described.
81
 
Passive Permeability Experiment:  
Compounds were dissolved in DMSO to generate a 10 mM compound solution. The 
experiment was performed using the Double-Sink protocol provided by pION, Inc. with 
the PAMPA Explorer® system.  A cosolvent system solution was used for the 
experiment.      
NSV, WEEV, and FMV In Vitro antiviral and viability experiment (Courtesy of Dr. 
David Miller and Craig Dobry) 
Experiment performed as previously described.
66, 81, 161
 
NSV and WEEV in vivo experiment (Courtesy of Dr. David Irani, Dr. David Miller and 
Pennelope Blakely) 
Experiment performed as previously described.
81, 161
 
Rhodamine 123 efflux experiment (Courtesy of Dr. Richard Keep and Jianming Xiang) 
Experiment performed as previously described.
161
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